# ::id 1_nonfiction_GENIA-1999;99101510,1;NE
# ::snt Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a_desArg .
( ENTITY-1 / Regulation
      :BY ( GROUP-5 / AND
             :op1 ( ENTITY-C3a / ENTITY
                    :name ( n-1 / name
                           :op1 "C3a"))
             :op2 ( ENTITY-C3a_desArg / ENTITY
                    :name ( n-2 / name
                           :op1 "C3a_desArg")))
      :OF ( ENTITY-2 / IL-6_synthesis
             :IN ( GROUP-3 / peripheral_blood_mononuclear_cells
                    :ATTRIBUTE ( ATTRIB-4 / human))))

# ::id 2_nonfiction_GENIA-1999;99101510,2;NE
# ::snt The anaphylatoxin C3a has been reported to have immunomodulatory effects on a number of different cell types .
( EVENT-3 / has_reported
      :ARG1 ( ENTITY-C3a / anaphylatoxin
             :DETERMINER ( ATTRIB-2 / the)
             :name ( n-1 / name
                    :op1 "C3a"))
      :TOCOMP ( EVENT-9 / have
             :ARG0 ENTITY-C3a
             :ARG1 ( GROUP-4 / effects
                    :ATTRIBUTE ( ATTRIB-5 / immunomodulatory)
                    :ON ( ENTITY-6 / number
                           :OF ( GROUP-7 / cell_types
                                  :ATTRIBUTE ( ATTRIB-8 / different))))))

# ::id 3_nonfiction_GENIA-1999;99101510,3;NE
# ::snt In this study we investigated the effects of C3a and C3a_desArg on gene expression and protein secretion of IL-6 in human PBMCs , either alone or in combination with LPS or IL-1beta .
( CONJ-20 / and
      :op1 ( EVENT-18 / investigated
             :MOD ( mod-21 / past)
             :ARG0 ( REF1-3 / we)
             :ARG1 ( GROUP-4 / effects
                    :DEFINITE ( ATTRIB-5 / the)
                    :IN ( GROUP-11 / PBMCs
                           :ATTRIBUTE ( ATTRIB-12 / human))
                    :ON ( ENTITY-7 / AND
                           :op1 ( ENTITY-9 / gene_expression)
                           :op2 ( ENTITY-10 / protein_secretion)
                           :OF ( ENTITY-IL-6 / ENTITY
                                  :name ( n-22 / name
                                         :op1 "IL-6")))
                    :OF ( GROUP-6 / AND
                           :op1 ( ENTITY-C3a / ENTITY
                                  :name ( n-23 / name
                                         :op1 "C3a"))
                           :op2 ( ENTITY-C3a_desArg / ENTITY
                                  :name ( n-24 / name
                                         :op1 "C3a_desArg"))))
             :IN ( ENTITY-1 / study
                    :DETERMINER ( ATTRIB-2 / this)))
      :op2 ( CONJ-19 / either_or
             :op1 ( EVENT-17 / EVENT
                    :ATTRIBUTE ( ATTRIB-13 / alone)
                    :ARG0 GROUP-4)
             :op2 ( EVENT-17 / EVENT
                    :ATTRIBUTE ( ATTRIB-14 / ATTRIB
                           :IN ( ENTITY-15 / combination
                                  :WITH ( GROUP-16 / or
                                         :op1 ( ENTITY-LPS / ENTITY
                                                :name ( n-25 / name
                                                       :op1 "LPS"))
                                         :op2 ( ENTITY-IL-1beta / ENTITY
                                                :name ( n-26 / name
                                                       :op1 "IL-1beta")))))
                    :ARG0 GROUP-4)))

# ::id 4_nonfiction_GENIA-1999;99101510,4;NE
# ::snt C3a or C3a_desArg alone exhibited no effect on the expression or secretion of IL-6 .
( EVENT-9 / exhibited
      :MOD ( mod-8 / past)
      :ARG0 ( GROUP-1 / or
             :op1 ( ENTITY-C3a / ENTITY
                    :name ( n-9 / name
                           :op1 "C3a"))
             :op2 ( ENTITY-C3a_desArg / ENTITY
                    :name ( n-10 / name
                           :op1 "C3a_desArg")))
      :ARG1 ( ENTITY-2 / effect
             :ON ( ENTITY-4 / or
                    :DEFINITE ( ATTRIB-5 / the)
                    :op1 ( ENTITY-7 / expression)
                    :op2 ( ENTITY-8 / secretion)
                    :OF ( ENTITY-IL-6 / ENTITY
                           :name ( n-11 / name
                                  :op1 "IL-6")))
             :QUANTIFIER ( ATTRIB-3 / no))
      :MOD ( mod-7 / alone))

# ::id 5_nonfiction_GENIA-1999;99101510,5;NE
# ::snt However , when PBMC were stimulated with LPS or IL-1beta , both C3a and C3a_desArg were found to enhance IL-6 release by PBMC in a dose-dependent manner .
( CND-13 / when
      :op1 ( EVENT-2 / stimulated
             :MOD ( mod-14 / past)
             :ARG1 ( ENTITY-PBMC / ENTITY
                    :name ( n-17 / name
                           :op1 "PBMC"))
             :WITH ( GROUP-1 / or
                    :op1 ( ENTITY-LPS / ENTITY
                           :name ( n-18 / name
                                  :op1 "LPS"))
                    :op2 ( ENTITY-IL-1beta / ENTITY
                           :name ( n-19 / name
                                  :op1 "IL-1beta"))))
      :op2 ( EVENT-6 / found
             :MOD ( mod-15 / past)
             :ARG1 ( group-3 / AND
                    :op1 ( ENTITY-C3a / ENTITY
                           :name ( n-20 / name
                                  :op1 "C3a"))
                    :op2 ( ENTITY-C3a_desArg / ENTITY
                           :name ( n-21 / name
                                  :op1 "C3a_desArg"))
                    :QUANTIFIER ( ATTRIB-4 / both))
             :TOCOMP ( EVENT-10 / enhance
                    :ARG0 group-3
                    :ARG1 ( ENTITY-7 / IL-6_release
                           :BY ENTITY-PBMC)
                    :IN ( ENTITY-8 / manner
                           :ATTRIBUTE ( ATTRIB-9 / dose-dependent)))
             :MOD ( mod-16 / however)))

# ::id 6_nonfiction_GENIA-1999;99101510,6;NE
# ::snt Since C3a has been shown to induce PGE2 production by monocytes , and PGE2 has been shown to influence cytokine production , we investigated the potential role of PGE2 in C3a-mediated enhancement of LPS- and IL-1beta- induced IL-6 production .
( EVENT-19 / investigated
      :MOD ( mod-22 / past)
      :ARG0 ( REF1-1 / we)
      :ARG1 ( ENTITY-10 / role
             :DEFINITE ( ATTRIB-11 / the)
             :ATTRIBUTE ( ATTRIB-12 / potential)
             :IN ( ENTITY-13 / enhancement
                    :ATTRIBUTE ( ATTRIB-14 / c3a-mediated)
                    :OF ( EVENT-18 / induced
                           :ARG0 ( GROUP-16 / AND
                                  :op1 ( ENTITY-LPS- / ENTITY
                                         :name ( n-23 / name
                                                :op1 "LPS-"))
                                  :op2 ( ENTITY-IL-1beta- / ENTITY
                                         :name ( n-24 / name
                                                :op1 "IL-1beta-")))
                           :ARG1 ( ENTITY-17 / IL-6_production)))
             :OF ( ENTITY-PGE2 / ENTITY
                    :name ( n-25 / name
                           :op1 "PGE2")))
      :SINCE ( CONJ-21 / and
             :op1 ( EVENT-4 / has_shown
                    :ARG1 ( ENTITY-C3a / ENTITY
                           :name ( n-26 / name
                                  :op1 "C3a"))
                    :BY ( GROUP-3 / monocytes)
                    :TOCOMP ( EVENT-6 / induce
                           :ARG0 ENTITY-C3a
                           :ARG1 ( ENTITY-5 / PGE2_production)))
             :op2 ( EVENT-7 / has_shown
                    :ARG1 ENTITY-PGE2
                    :TOCOMP ( EVENT-9 / influence
                           :ARG0 ENTITY-PGE2
                           :ARG1 ( ENTITY-8 / cytokine_production)))))

# ::id 7_nonfiction_GENIA-1999;99101510,7;NE
# ::snt Indomethacin blocked PGE2 release , but had no influence on the observed effects of C3a , suggesting that the effects of C3a on IL-6 production are independent of PGE2 formation by monocytes .
( CONJ-18 / and
      :op1 ( CONJ-17 / but
             :op1 ( EVENT-10 / blocked
                    :MOD ( mod-19 / past)
                    :ARG0 ( ENTITY-Indomethacin / ENTITY
                           :name ( n-21 / name
                                  :op1 "Indomethacin"))
                    :ARG1 ( ENTITY-9 / PGE2_release))
             :op2 ( EVENT-16 / had
                    :MOD ( mod-20 / past)
                    :ARG0 ENTITY-Indomethacin
                    :ARG1 ( ENTITY-11 / influence
                           :ON ( GROUP-13 / effects
                                  :DEFINITE ( ATTRIB-14 / the)
                                  :ATTRIBUTE ( ATTRIB-15 / observed)
                                  :OF ( ENTITY-C3a / ENTITY
                                         :name ( n-22 / name
                                                :op1 "C3a")))
                           :QUANTIFIER ( ATTRIB-12 / no))))
      :op2 ( EVENT-1 / suggesting
             :ARG0 ENTITY-Indomethacin
             :THAT ( EVENT-8 / copula
                    :ATTRIBUTE ( ATTRIB-5 / independent
                           :OF ( ENTITY-6 / PGE2_formation
                                  :BY ( GROUP-7 / monocytes)))
                    :ARG0 ( GROUP-2 / effects
                           :DEFINITE ( ATTRIB-3 / the)
                           :OF ENTITY-C3a
                           :ON ( ENTITY-4 / IL-6_production)))))

# ::id 8_nonfiction_GENIA-1999;99101510,8;NE
# ::snt Northern blot analysis showed that C3a as well as C3a_desArg enhanced LPS-induced mRNA levels for IL-6 .
( EVENT-2 / showed
      :MOD ( mod-8 / past)
      :ARG0 ( ENTITY-1 / Northern_blot_analysis)
      :THAT ( EVENT-6 / enhanced
             :MOD ( mod-7 / past)
             :ARG0 ( GROUP-3 / as_well
                    :op1 ( ENTITY-C3a / ENTITY
                           :name ( n-9 / name
                                  :op1 "C3a"))
                    :op2 ( ENTITY-C3a_desArg / ENTITY
                           :name ( n-10 / name
                                  :op1 "C3a_desArg")))
             :ARG1 ( GROUP-4 / mRNA_levels
                    :ATTRIBUTE ( ATTRIB-5 / lps-induced))
             :FOR ( ENTITY-IL-6 / ENTITY
                    :name ( n-11 / name
                           :op1 "IL-6"))))

# ::id 9_nonfiction_GENIA-1999;99101510,9;NE
# ::snt Pretreatment of PBMCs with pertussis toxin blocked the functions of C3a and C3a_desArg , indicating that the actions of these two molecules are mediated by a G protein-coupled pathway .
( CONJ-17 / and
      :op1 ( EVENT-16 / blocked
             :MOD ( mod-18 / past)
             :ARG0 ( ENTITY-1 / Pretreatment
                    :OF ( GROUP-2 / PBMCs
                           :WITH ( ENTITY-3 / pertussis_toxin)))
             :ARG1 ( GROUP-4 / functions
                    :DEFINITE ( ATTRIB-5 / the)
                    :OF ( GROUP-6 / AND
                           :op1 ( ENTITY-C3a / ENTITY
                                  :name ( n-19 / name
                                         :op1 "C3a"))
                           :op2 ( ENTITY-C3a_desArg / ENTITY
                                  :name ( n-20 / name
                                         :op1 "C3a_desArg")))))
      :op2 ( EVENT-7 / indicating
             :ARG0 GROUP-4
             :THAT ( EVENT-15 / mediated
                    :ARG0 ( ENTITY-13 / pathway
                           :ATTRIBUTE ( ATTRIB-14 / protein-coupled
                                  :COMP ( ENTITY-G / ENTITY
                                         :name ( n-21 / name
                                                :op1 "G"))))
                    :ARG1 ( GROUP-8 / actions
                           :DEFINITE ( ATTRIB-9 / the)
                           :OF ( GROUP-10 / molecules
                                  :DETERMINER ( ATTRIB-11 / these)
                                  :CARDINAL ( ATTRIB-12 / two))))))

# ::id 10_nonfiction_GENIA-1999;99101510,10;NE
# ::snt Furthermore , we investigated the effects of C3a and C3a_desArg on induction of NF-kappaB and activating protein-1 binding .
( EVENT-11 / investigated
      :MOD ( mod-2 / past)
      :ARG0 ( REF1-1 / we)
      :ARG1 ( GROUP-2 / effects
             :DEFINITE ( ATTRIB-3 / the)
             :ON ( GROUP-5 / AND
                    :op1 ( ENTITY-6 / induction
                           :OF ( ENTITY-NF-kappaB / ENTITY
                                  :name ( n-3 / name
                                         :op1 "NF-kappaB")))
                    :op2 ( ENTITY-7 / ENTITY
                           :ARG0-of ( EVENT-10 / activating
                                  :ARG1 ( ENTITY-9 / protein-1_binding))))
             :OF ( GROUP-4 / AND
                    :op1 ( ENTITY-C3a / ENTITY
                           :name ( n-4 / name
                                  :op1 "C3a"))
                    :op2 ( ENTITY-C3a_desArg / ENTITY
                           :name ( n-5 / name
                                  :op1 "C3a_desArg"))))
      :MOD ( mod-1 / furthermore))

# ::id 11_nonfiction_GENIA-1999;99101510,11;NE
# ::snt Both molecules enhanced LPS-induced NF-kappaB and activating protein-1 binding activity .
( EVENT-9 / enhanced
      :MOD ( mod-1 / past)
      :ARG0 ( GROUP-1 / molecules
             :QUANTIFIER ( ATTRIB-2 / both))
      :ARG1 ( GROUP-3 / AND
             :op1 ( ENTITY-NF-kappaB / ENTITY
                    :ATTRIBUTE ( ATTRIB-4 / lps-induced)
                    :name ( n-2 / name
                           :op1 "NF-kappaB"))
             :op2 ( ENTITY-5 / ENTITY
                    :ARG0-of ( EVENT-8 / activating
                           :ARG1 ( ENTITY-7 / protein-1_binding_activity)))))

# ::id 12_nonfiction_GENIA-1999;99101510,12;NE
# ::snt These results demonstrate the capacity of intact C3a and its circulating des-Arg form to exert immunmodulatory effects in vitro .
( EVENT-13 / demonstrate
      :ARG0 ( GROUP-1 / results
             :DETERMINER ( ATTRIB-2 / these))
      :ARG1 ( ENTITY-3 / capacity
             :DEFINITE ( ATTRIB-4 / the)
             :OF ( GROUP-5 / AND
                    :op1 ( ENTITY-intact_C3a / ENTITY
                           :name ( n-2 / name
                                  :op1 "intact_C3a"))
                    :op2 ( ENTITY-6 / des-Arg_form
                           :ATTRIBUTE ( ATTRIB-8 / circulating)
                           :POS ( REF1-7 / its)))
             :TOCOMP ( EVENT-11 / exert
                    :ARG1 ( GROUP-9 / effects
                           :ATTRIBUTE ( ATTRIB-10 / immunmodulatory))
                    :MOD ( mod-1 / in_vitro))))

# ::id 13_nonfiction_GENIA-1999;99101524,1;NE
# ::snt Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination .
( ENTITY-1 / Comparison
      :WITH ( GROUP-10 / responses
             :ARG0-of ( EVENT-13 / elicited
                    :BY ( ENTITY-12 / varicella_vaccination)
                    :MOD ( mod-1 / in_vivo)))
      :OF ( ENTITY-2 / sensitization
             :ATTRIBUTE ( ATTRIB-9 / in_vitro)
             :ATTRIBUTE ( ATTRIB-3 / primary)
             :BY ( GROUP-7 / cells
                    :ATTRIBUTE ( ATTRIB-8 / dendritic))
             :TO ( GROUP-6 / varicella-zoster_virus_peptides)
             :OF ( GROUP-4 / human_T_cells
                    :ATTRIBUTE ( ATTRIB-5 / naive))))

# ::id 14_nonfiction_GENIA-1999;99101524,2;NE
# ::snt Dendritic cells -LRB- DC -RRB- are potent APC during primary and secondary immune responses .
( EVENT-12 / copula
      :ARG0 ( GROUP-1 / cells
             :ATTRIBUTE ( ATTRIB-2 / dendritic)
             :NAMELY ( ENTITY-DC / ENTITY
                    :name ( n-1 / name
                           :op1 "DC")))
      :ARG1 ( ENTITY-3 / APC
             :ATTRIBUTE ( ATTRIB-4 / potent))
      :DURING ( GROUP-5 / AND
             :op1 ( GROUP-6 / responses
                    :ATTRIBUTE ( ATTRIB-8 / immune)
                    :ATTRIBUTE ( ATTRIB-7 / primary))
             :op2 ( GROUP-9 / responses
                    :ATTRIBUTE ( ATTRIB-11 / immune)
                    :ATTRIBUTE ( ATTRIB-10 / secondary))))

# ::id 15_nonfiction_GENIA-1999;99101524,3;NE
# ::snt The first objective of this study was to determine whether human DC mediate in vitro sensitization of naive CD4+ T cells to epitopes of the immediate early 62 -LRB- IE62 -RRB- protein of varicella zoster virus -LRB- VZV -RRB- .
( EVENT-6 / copula
      :MOD ( mod-23 / past)
      :ARG0 ( ENTITY-1 / objective
             :DEFINITE ( ATTRIB-2 / the)
             :ATTRIBUTE ( ATTRIB-3 / first)
             :OF ( ENTITY-4 / study
                    :DETERMINER ( ATTRIB-5 / this)))
      :TOCOMP ( EVENT-7 / determine
             :ARG0 ENTITY-1
             :THAT ( EVENT-18 / mediate
                    :domain-of ( QUEST-22 / QUEST)
                    :ARG0 ( GROUP-8 / DC
                           :ATTRIBUTE ( ATTRIB-9 / human))
                    :ARG1 ( ENTITY-10 / sensitization
                           :ATTRIBUTE ( ATTRIB-11 / in_vitro)
                           :TO ( GROUP-13 / epitopes
                                  :OF ( ENTITY-14 / 62_protein
                                         :DEFINITE ( ATTRIB-15 / the)
                                         :ATTRIBUTE ( ATTRIB-16 / immediate_early)
                                         :OF ( ENTITY-17 / varicella_zoster_virus
                                                :NAMELY ( ENTITY-VZV / ENTITY
                                                       :name ( n-24 / name
                                                              :op1 "VZV")))
                                         :NAMELY ( ENTITY-IE62 / ENTITY
                                                :name ( n-25 / name
                                                       :op1 "IE62"))))
                           :OF ( GROUP-12 / naive_CD4 + T_cells)))))

# ::id 16_nonfiction_GENIA-1999;99101524,4;NE
# ::snt The induction of CD4+ T cell proliferative responses to eight synthetic peptides representing amino acid sequences of the VZV IE62 protein was assessed using T cells and DC from VZV-susceptible donors .
( CONJ-20 / and
      :op1 ( EVENT-19 / assessed
             :MOD ( mod-21 / past)
             :ARG1 ( ENTITY-1 / induction
                    :DEFINITE ( ATTRIB-2 / the)
                    :OF ( GROUP-3 / CD4 + T_cell_proliferative_responses
                           :TO ( GROUP-4 / peptides
                                  :ATTRIBUTE ( ATTRIB-6 / synthetic)
                                  :CARDINAL ( ATTRIB-5 / eight)
                                  :ARG0-of ( EVENT-11 / representing
                                         :ARG1 ( GROUP-8 / amino_acid_sequences
                                                :OF ( ENTITY-9 / VZV_IE62_protein
                                                       :DEFINITE ( ATTRIB-10 / the))))))))
      :op2 ( EVENT-18 / using
             :ARG0 ENTITY-1
             :ARG1 ( ENTITY-12 / AND
                    :op1 ( GROUP-14 / T_cells)
                    :op2 ( GROUP-15 / DC)
                    :FROM ( GROUP-16 / donors
                           :ATTRIBUTE ( ATTRIB-17 / vzv-susceptible)))))

# ::id 17_nonfiction_GENIA-1999;99101524,5;NE
# ::snt The second objective was to compare in vitro responses of naive T cells with responses to VZV peptides induced in vivo after immunization with varicella vaccine .
( EVENT-4 / copula
      :MOD ( mod-2 / past)
      :ARG0 ( ENTITY-1 / objective
             :DEFINITE ( ATTRIB-2 / the)
             :ATTRIBUTE ( ATTRIB-3 / second))
      :TOCOMP ( EVENT-15 / compare
             :ARG0 ENTITY-1
             :ARG1 ( GROUP-5 / responses
                    :ATTRIBUTE ( ATTRIB-6 / in_vitro)
                    :OF ( GROUP-7 / naive_T_cells))
             :WITH ( GROUP-8 / responses
                    :TO ( GROUP-9 / VZV_peptides)
                    :ARG0-of ( EVENT-13 / induced
                           :AFTER ( ENTITY-11 / immunization
                                  :WITH ( ENTITY-12 / varicella_vaccine))
                           :MOD ( mod-1 / in_vivo)))))

# ::id 18_nonfiction_GENIA-1999;99101524,6;NE
# ::snt T cell proliferation was induced by three peptides , P1 , P4 , and P7 , in 71-100 % of the donors tested before and after vaccination using DC as APC .
( EVENT-21 / induced
      :MOD ( mod-101 / past)
      :ARG1 ( ENTITY-1 / T_cell_proliferation)
      :IN ( ENTITY-5 / percent
             :OF ( GROUP-7 / donors
                    :DEFINITE ( ATTRIB-8 / the)
                    :ARG1-of ( CONJ-22 / and
                           :op1 ( EVENT-20 / tested
                                  :BEFORE ( ENTITY-10 / vaccination
                                         :ARG0-of ( EVENT-14 / using
                                                :ARG1 ( ENTITY-12 / DC)
                                                :AS ( ENTITY-13 / APC))))
                           :op2 ( EVENT-20 / tested
                                  :AFTER ( ENTITY-15 / vaccination
                                         :ARG0-of ( EVENT-19 / using
                                                :ARG1 ( ENTITY-17 / DC)
                                                :AS ( ENTITY-18 / APC))))))
             :CARDINAL ( ATTRIB-6 / 71-100))
      :BY ( GROUP-3 / peptides
             :CARDINAL ( ATTRIB-4 / three)
             :NAMELY ( GROUP-2 / AND
                    :op1 ( ENTITY-P1 / ENTITY
                           :name ( n-102 / name
                                  :op1 "P1"))
                    :op2 ( ENTITY-P4 / ENTITY
                           :name ( n-103 / name
                                  :op1 "P4"))
                    :op3 ( ENTITY-P7 / ENTITY
                           :name ( n-104 / name
                                  :op1 "P7")))))

# ::id 19_nonfiction_GENIA-1999;99101524,7;NE
# ::snt Monocytes were effective APC for VZV peptides only after immunization .
( EVENT-6 / copula
      :MOD ( mod-1 / past)
      :ARG0 ( GROUP-1 / Monocytes)
      :ARG1 ( ENTITY-2 / APC
             :ATTRIBUTE ( ATTRIB-3 / effective))
      :AFTER ( ENTITY-5 / immunization)
      :FOR ( GROUP-4 / VZV_peptides))

# ::id 20_nonfiction_GENIA-1999;99101524,8;NE
# ::snt Two peptides , P2 and P8 , induced naive T cell proliferation less effectively and were also less immunogenic for T cells from vaccinated or naturally immune donors .
( CONJ-16 / and
      :op1 ( EVENT-5 / induced
             :MOD ( mod-18 / past)
             :ARG0 ( GROUP-2 / peptides
                    :CARDINAL ( ATTRIB-3 / two)
                    :NAMELY ( GROUP-1 / AND
                           :op1 ( ENTITY-P2 / ENTITY
                                  :name ( n-21 / name
                                         :op1 "P2"))
                           :op2 ( ENTITY-P8 / ENTITY
                                  :name ( n-22 / name
                                         :op1 "P8"))))
             :ARG1 ( ENTITY-4 / naive_T_cell_proliferation)
             :MOD ( mod-17 / less_effectively))
      :op2 ( EVENT-14 / copula
             :MOD ( mod-20 / past)
             :ATTRIBUTE ( ATTRIB-7 / less_immunogenic
                    :FOR ( GROUP-8 / T_cells
                           :FROM ( GROUP-9 / or
                                  :op1 ( GROUP-10 / donors
                                         :ATTRIBUTE ( ATTRIB-11 / vaccinated))
                                  :op2 ( GROUP-12 / donors
                                         :ATTRIBUTE ( ATTRIB-13 / naturally_immune)))))
             :ARG0 GROUP-2
             :MOD ( mod-19 / also)))

# ::id 21_nonfiction_GENIA-1999;99101524,9;NE
# ::snt T cell recognition of specific peptides was concordant between naive , DC-mediated responses , and postvaccine responses using monocytes as APC in 69 % of comparisons -LRB- p = 0.05 ; chi2 -RRB- ;
( CONJ-18 / and
      :op1 ( EVENT-17 / copula
             :MOD ( mod-19 / past)
             :ATTRIBUTE ( ATTRIB-4 / concordant
                    :BETWEEN ( GROUP-5 / AND
                           :op1 ( GROUP-6 / responses
                                  :ATTRIBUTE ( ATTRIB-8 / dc-mediated)
                                  :ATTRIBUTE ( ATTRIB-7 / naive))
                           :op2 ( GROUP-9 / responses
                                  :ATTRIBUTE ( ATTRIB-10 / postvaccine))))
             :ARG0 ( ENTITY-1 / T_cell_recognition
                    :OF ( GROUP-2 / peptides
                           :ATTRIBUTE ( ATTRIB-3 / specific))))
      :op2 ( EVENT-16 / using
             :ARG0 ENTITY-1
             :ARG1 ( GROUP-11 / monocytes)
             :IN ( ENTITY-13 / percent
                    :OF ( GROUP-15 / comparisons)
                    :CARDINAL ( ATTRIB-14 / 69))
             :AS ( ENTITY-12 / APC)))

# ::id 22_nonfiction_GENIA-1999;99101524,9;NE
# ::snt the predictive value of a positive response to an IE62 peptide before immunization for T cell sensitization in vivo was 82 % .
( EVENT-12 / copula
      :MOD ( mod-1 / past)
      :ARG0 ( ENTITY-1 / value
             :DEFINITE ( ATTRIB-2 / the)
             :ATTRIBUTE ( ATTRIB-3 / predictive)
             :OF ( ENTITY-4 / response
                    :ATTRIBUTE ( ATTRIB-5 / positive)
                    :FOR ( ENTITY-8 / T_cell_sensitization
                           :ATTRIBUTE ( ATTRIB-9 / in_vivo))
                    :BEFORE ( ENTITY-7 / immunization)
                    :TO ( ENTITY-6 / IE62_peptide)))
      :ARG1 ( ENTITY-10 / percent
             :CARDINAL ( ATTRIB-11 / 82)))

# ::id 23_nonfiction_GENIA-1999;99101524,10;NE
# ::snt These observations indicate that primary T cell responses detected in vitro using DC as APC may be useful to characterize the potential immunogenicity of viral protein epitopes in vivo .
( EVENT-3 / indicate
      :ARG0 ( GROUP-1 / observations
             :DETERMINER ( ATTRIB-2 / these))
      :THAT ( EVENT-18 / copula
             :domain-of ( MD-20 / may)
             :ATTRIBUTE ( ATTRIB-10 / useful
                    :TOCOMP ( EVENT-17 / characterize
                           :ARG1 ( ENTITY-11 / immunogenicity
                                  :DEFINITE ( ATTRIB-12 / the)
                                  :ATTRIBUTE ( ATTRIB-16 / in_vivo)
                                  :ATTRIBUTE ( ATTRIB-13 / potential)
                                  :OF ( GROUP-14 / protein_epitopes
                                         :ATTRIBUTE ( ATTRIB-15 / viral)))))
             :ARG0 ( GROUP-4 / primary_T_cell_responses
                    :ARG0-of ( EVENT-8 / detected_using
                           :ARG1 ( GROUP-6 / DC)
                           :AS ( ENTITY-7 / APC)
                           :MOD ( mod-21 / in_vitro)))))

# ::id 24_nonfiction_GENIA-1999;99102085,1;NE
# ::snt Mildly oxidized low-density lipoproteins decrease early production of interleukin 2 and nuclear factor kappaB binding to DNA in activated T-lymphocytes .
( EVENT-12 / decrease
      :ARG0 ( GROUP-1 / lipoproteins
             :ATTRIBUTE ( ATTRIB-3 / low-density)
             :ATTRIBUTE ( ATTRIB-2 / mildly_oxidized))
      :ARG1 ( GROUP-4 / AND
             :op1 ( ENTITY-5 / production
                    :ATTRIBUTE ( ATTRIB-6 / early)
                    :OF ( ENTITY-interleukin_2 / ENTITY
                           :name ( n-1 / name
                                  :op1 "interleukin_2")))
             :op2 ( ENTITY-7 / factor_kappaB_binding
                    :ATTRIBUTE ( ATTRIB-8 / nuclear)
                    :IN ( GROUP-10 / T-lymphocytes
                           :ATTRIBUTE ( ATTRIB-11 / activated))
                    :TO ( ENTITY-9 / DNA))))

# ::id 25_nonfiction_GENIA-1999;99102085,2;NE
# ::snt Activated T-lymphocytes are found early in atherosclerosis lesions ,
( EVENT-4 / found
      :ARG1 ( GROUP-1 / T-lymphocytes
             :ATTRIBUTE ( ATTRIB-2 / activated))
      :IN ( GROUP-3 / atherosclerosis_lesions)
      :TMP ( TIME-1 / early))

# ::id 26_nonfiction_GENIA-1999;99102085,2;NE
# ::snt but little is known about their role .
( EVENT-5 / known
      :ARG1 ( ENTITY-1 / ENTITY
             :QUANTIFIER ( ATTRIB-2 / little))
      :ABOUT ( ENTITY-3 / role
             :POS ( REF1-4 / their)))

# ::id 27_nonfiction_GENIA-1999;99102085,3;NE
# ::snt Oxidized low-density lipoproteins -LRB- oxLDLs -RRB- are considered to be involved in the pathogenesis of the lesions ,
( EVENT-5 / considered
      :ARG1 ( GROUP-2 / lipoproteins
             :ATTRIBUTE ( ATTRIB-4 / low-density)
             :ATTRIBUTE ( ATTRIB-3 / oxidized)
             :NAMELY ( ENTITY-1 / oxLDLs))
      :TOCOMP ( EVENT-10 / involved
             :ARG1 GROUP-2
             :IN ( ENTITY-6 / pathogenesis
                    :DEFINITE ( ATTRIB-7 / the)
                    :OF ( GROUP-8 / lesions
                           :DEFINITE ( ATTRIB-9 / the)))))

# ::id 28_nonfiction_GENIA-1999;99102085,3;NE
# ::snt and we have previously demonstrated that oxLDLs inhibit not only interleukin -LRB- IL -RRB- -2 -receptor expression on the surface of in vitro-activated T-lymphocytes but also their proliferation .
( EVENT-2 / have_demonstrated
      :ARG0 ( REF1-1 / we)
      :THAT ( EVENT-14 / inhibit
             :ARG0 ( GROUP-3 / oxLDLs)
             :ARG1 ( GROUP-4 / but_also
                    :op1 ( ENTITY-6 / interleukin_-2_-receptor_expression
                           :ON ( ENTITY-8 / surface
                                  :DEFINITE ( ATTRIB-9 / the)
                                  :OF ( GROUP-10 / T-lymphocytes
                                         :ATTRIBUTE ( ATTRIB-11 / in
                                                :MOD ( mod-1 / vitro-activated))))
                           :QUANTIFIER ( ATTRIB-7 / not_only)
                           :NAMELY ( ENTITY-5 / IL))
                    :op2 ( ENTITY-12 / proliferation
                           :POS ( REF2-13 / their))))
      :TMP ( TIME-2 / previously))

# ::id 29_nonfiction_GENIA-1999;99102085,4;NE
# ::snt We have now investigated the effect of oxLDLs on blast differentiation , on IL-2 synthesis and on the activation of the nuclear factor kappaB -LRB- NF-kappaB -RRB- system in activated lymphocytes .
( EVENT-14 / have_investigated
      :ARG0 ( REF1-1 / we)
      :ARG1 ( CONJ-16 / and
             :op1 ( ENTITY-2 / effect
                    :DEFINITE ( ATTRIB-3 / the)
                    :ON ( ENTITY-5 / blast_differentiation)
                    :OF ( GROUP-4 / oxLDLs))
             :op2 ( ENTITY-2 / effect
                    :DEFINITE ATTRIB-3
                    :ON ( ENTITY-6 / IL-2_synthesis)
                    :OF GROUP-4)
             :op3 ( ENTITY-2 / effect
                    :DEFINITE ATTRIB-3
                    :ON ( ENTITY-7 / activation
                           :DEFINITE ( ATTRIB-8 / the)
                           :IN ( GROUP-12 / lymphocytes
                                  :ATTRIBUTE ( ATTRIB-13 / activated))
                           :OF ( ENTITY-9 / factor_kappaB_system
                                  :DEFINITE ( ATTRIB-10 / the)
                                  :ATTRIBUTE ( ATTRIB-11 / nuclear)
                                  :NAMELY ( ENTITY-NF-kappaB / ENTITY
                                         :name ( n-18 / name
                                                :op1 "NF-kappaB"))))
                    :OF GROUP-4))
      :TMP ( TIME-17 / now))

# ::id 30_nonfiction_GENIA-1999;99102085,5;NE
# ::snt Mildly oxLDLs -LRB- 50 and 100 microgram/ml -RRB- decreased the number of lymphoblasts and the level of IL-2 concentration in the culture supernatants after activation of lymphocytes by phytohaemagglutinin and PMA+ionomycin .
( EVENT-17 / decreased
      :MOD ( mod-1 / past)
      :ARG0 ( GROUP-3 / oxLDLs
             :ATTRIBUTE ( ATTRIB-4 / mildly)
             :NAMELY ( ENTITY-1 / microgram_slash_ml
                    :CARDINAL ( ATTRIB-2 / 50_and_100)))
      :ARG1 ( GROUP-5 / AND
             :op1 ( ENTITY-6 / number
                    :DEFINITE ( ATTRIB-7 / the)
                    :OF ( GROUP-8 / lymphoblasts))
             :op2 ( ENTITY-9 / level
                    :DEFINITE ( ATTRIB-10 / the)
                    :OF ( ENTITY-11 / IL-2_concentration)))
      :AFTER ( ENTITY-14 / activation
             :BY ( GROUP-16 / AND
                    :op1 ( ENTITY-phytohaemagglutinin / ENTITY
                           :name ( n-2 / name
                                  :op1 "phytohaemagglutinin"))
                    :op2 ( ENTITY-PMA + ionomycin / ENTITY
                           :name ( n-3 / name
                                  :op1 "PMA + ionomycin")))
             :OF ( GROUP-15 / lymphocytes))
      :IN ( GROUP-12 / culture_supernatants
             :DEFINITE ( ATTRIB-13 / the)))

# ::id 31_nonfiction_GENIA-1999;99102085,6;NE
# ::snt The inhibition of IL-2 production was observed in the CD3 T-lymphocyte cytoplasm as early as 4 h after activation by PMA+ionomycin .
( EVENT-9 / observed
      :MOD ( mod-1 / past)
      :ARG1 ( ENTITY-1 / inhibition
             :DEFINITE ( ATTRIB-2 / the)
             :OF ( ENTITY-3 / IL-2_production))
      :IN ( ENTITY-4 / CD3_T-lymphocyte_cytoplasm
             :DEFINITE ( ATTRIB-5 / the))
      :TMP ( TIME-2 / as_early
             :AS ( ENTITY-6 / ENTITY
                    :AFTER ( ENTITY-8 / activation
                           :BY ( ENTITY-PMA + ionomycin / ENTITY
                                  :name ( n-3 / name
                                         :op1 "PMA + ionomycin")))
                    :CARDINAL ( ATTRIB-7 / 4))))

# ::id 32_nonfiction_GENIA-1999;99102085,7;NE
# ::snt The study of NF-kappaB showed that oxLDLs led to a decrease of activation-induced p65/p50 NF-kappaB heterodimer binding to DNA , whereas the presence of the constitutive nuclear form of p50 dimer was unchanged .
( EVENT-3 / showed
      :MOD ( mod-3 / past)
      :ARG0 ( ENTITY-1 / study
             :DEFINITE ( ATTRIB-2 / the)
             :OF ( ENTITY-NF-kappaB / ENTITY
                    :name ( n-4 / name
                           :op1 "NF-kappaB")))
      :THAT ( EVENT-18 / led
             :MOD ( mod-2 / past)
             :ARG0 ( GROUP-4 / oxLDLs)
             :WHEREAS ( EVENT-17 / copula
                    :MOD ( mod-1 / past)
                    :ATTRIBUTE ( ATTRIB-16 / unchanged)
                    :ARG0 ( ENTITY-9 / presence
                           :DEFINITE ( ATTRIB-10 / the)
                           :OF ( ENTITY-11 / form
                                  :DEFINITE ( ATTRIB-12 / the)
                                  :ATTRIBUTE ( ATTRIB-14 / nuclear)
                                  :ATTRIBUTE ( ATTRIB-13 / constitutive)
                                  :OF ( ENTITY-15 / p50_dimer))))
             :TO ( ENTITY-5 / decrease
                    :OF ( ENTITY-6 / activation-induced_p65_slash_p50_NF-kappaB_heterodimer_binding
                           :TO ( ENTITY-7 / DNA)))))

# ::id 33_nonfiction_GENIA-1999;99102085,8;NE
# ::snt This was correlated with an unchanged level of the active form of the cytosolic inhibitor protein IkappaB-alpha .
( EVENT-11 / was_correlated
      :MOD ( mod-1 / past)
      :ARG0 ( ENTITY-1 / ENTITY
             :DETERMINER ( ATTRIB-2 / this))
      :WITH ( ENTITY-3 / level
             :ATTRIBUTE ( ATTRIB-4 / unchanged)
             :OF ( ENTITY-5 / form
                    :DEFINITE ( ATTRIB-6 / the)
                    :ATTRIBUTE ( ATTRIB-7 / active)
                    :OF ( ENTITY-IkappaB-alpha / inhibitor_protein
                           :DETERMINER ( ATTRIB-9 / the)
                           :ATTRIBUTE ( ATTRIB-10 / cytosolic)
                           :name ( n-2 / name
                                  :op1 "IkappaB-alpha")))))

# ::id 34_nonfiction_GENIA-1999;99102085,9;NE
# ::snt Taken together , these observations suggest that the immunosuppressive effect of oxLDLs might operate via a dysregulation of the T-lymphocyte activation mechanisms .
( CONJ-16 / and
      :op1 ( EVENT-3 / taken
             :ARG0 ( GROUP-1 / observations
                    :DETERMINER ( ATTRIB-2 / these))
             :MOD ( mod-17 / together))
      :op2 ( EVENT-5 / suggest
             :ARG0 GROUP-1
             :THAT ( EVENT-13 / operate
                    :domain-of ( MD-15 / might)
                    :ARG0 ( ENTITY-6 / effect
                           :DEFINITE ( ATTRIB-7 / the)
                           :ATTRIBUTE ( ATTRIB-8 / immunosuppressive)
                           :OF ( GROUP-9 / oxLDLs))
                    :VIA ( ENTITY-10 / dysregulation
                           :OF ( GROUP-11 / T-lymphocyte_activation_mechanisms
                                  :DEFINITE ( ATTRIB-12 / the))))))

# ::id 35_nonfiction_GENIA-1999;99102381,1;NE
# ::snt The activity of the CCAAT -box binding factor NF-Y is modulated through the regulated expression of its A subunit during monocyte to macrophage differentiation :
( EVENT-12 / modulated
      :ARG1 ( ENTITY-1 / activity
             :DEFINITE ( ATTRIB-2 / the)
             :OF ( ENTITY-NF-Y / CCAAT_-box_binding_factor
                    :DETERMINER ( ATTRIB-4 / the)
                    :name ( n-1 / name
                           :op1 "NF-Y")))
      :TO ( ENTITY-11 / macrophage_differentiation)
      :DURING ( ENTITY-10 / monocyte)
      :THROUGH ( ENTITY-5 / expression
             :DEFINITE ( ATTRIB-6 / the)
             :ATTRIBUTE ( ATTRIB-7 / regulated)
             :OF ( ENTITY-8 / A_subunit
                    :POS ( REF1-9 / its))))

# ::id 36_nonfiction_GENIA-1999;99102381,1;NE
# ::snt regulation of tissue-specific genes through a ubiquitous transcription factor .
( ENTITY-1 / regulation
      :THROUGH ( ENTITY-4 / transcription_factor
             :ATTRIBUTE ( ATTRIB-5 / ubiquitous))
      :OF ( GROUP-2 / genes
             :ATTRIBUTE ( ATTRIB-3 / tissue-specific)))

# ::id 37_nonfiction_GENIA-1999;99102381,2;NE
# ::snt In this study , we analyzed the regulation of NF-Y expression during human monocyte to macrophage maturation .
( EVENT-10 / analyzed
      :MOD ( mod-1 / past)
      :ARG0 ( REF1-3 / we)
      :ARG1 ( ENTITY-4 / regulation
             :DEFINITE ( ATTRIB-5 / the)
             :DURING ( ENTITY-7 / monocyte
                    :ATTRIBUTE ( ATTRIB-8 / human)
                    :TO ( ENTITY-9 / macrophage_maturation))
             :OF ( ENTITY-6 / NF-Y_expression))
      :IN ( ENTITY-1 / study
             :DETERMINER ( ATTRIB-2 / this)))

# ::id 38_nonfiction_GENIA-1999;99102381,3;NE
# ::snt NF-Y is a ubiquitous and evolutionarily conserved transcription factor that binds specifically to the CCAAT motif present in the 5' promoter region of a wide variety of genes .
( EVENT-16 / copula
      :ARG0 ( ENTITY-NF-Y / ENTITY
             :name ( n-20 / name
                    :op1 "NF-Y"))
      :ARG1 ( ENTITY-1 / transcription_factor
             :ATTRIBUTE ( ATTRIB-2 / ubiquitous)
             :ARG0-of ( CONJ-17 / and
                    :op1 ( EVENT-14 / binds
                           :TO ( ENTITY-5 / CCAAT_motif
                                  :DEFINITE ( ATTRIB-6 / the)
                                  :ATTRIBUTE ( ATTRIB-7 / present
                                         :IN ( ENTITY-8 / promoter_region
                                                :DEFINITE ( ATTRIB-9 / the)
                                                :ATTRIBUTE ( ATTRIB-10 / 5 ')
                                                :OF ( ENTITY-11 / variety
                                                       :ATTRIBUTE ( ATTRIB-12 / wide)
                                                       :OF ( GROUP-13 / genes)))))
                           :MOD ( mod-18 / specifically)
                           :MOD ( mod-19 / specifically))
                    :op2 ( EVENT-14 / binds
                           :ARG0 ( ENTITY-1 / transcription_factor
                                  :ATTRIBUTE ( ATTRIB-3 / evolutionarily_conserved))
                           :TO ( ENTITY-5 / CCAAT_motif
                                  :DEFINITE ( ATTRIB-6 / the)
                                  :ATTRIBUTE ( ATTRIB-7 / present
                                         :IN ( ENTITY-8 / promoter_region
                                                :DEFINITE ( ATTRIB-9 / the)
                                                :ATTRIBUTE ( ATTRIB-10 / 5 ')
                                                :OF ( ENTITY-11 / variety
                                                       :ATTRIBUTE ( ATTRIB-12 / wide)
                                                       :OF ( GROUP-13 / genes)))))))))

# ::id 39_nonfiction_GENIA-1999;99102381,4;NE
# ::snt We show here that in circulating monocytes , NF-Y binding activity is not detected on the CCAAT motif present in the promoters of genes such as major histocompatibility complex -LRB- MHC -RRB- class II , gp91-phox , mig , and fibronectin , whereas during macrophage differentiation , a progressive increase in NF-Y binding activity is observed on these promoters .
( CONJ-35 / AND
      :op1 ( EVENT-10 / observed
             :ARG1 ( ENTITY-5 / increase
                    :ATTRIBUTE ( ATTRIB-6 / progressive)
                    :IN ( ENTITY-7 / NF-Y_binding_activity))
             :ON ( GROUP-8 / promoters
                    :DETERMINER ( ATTRIB-9 / these))
             :DURING ( ENTITY-4 / macrophage_differentiation))
      :op2 ( EVENT-2 / show
             :ARG0 ( REF1-1 / we)
             :THAT ( EVENT-25 / detected
                    :domain-of ( NEG-30 / NEG)
                    :ARG1 ( ENTITY-13 / NF-Y_binding_activity)
                    :ON ( ENTITY-14 / CCAAT_motif
                           :DEFINITE ( ATTRIB-15 / the)
                           :ATTRIBUTE ( ATTRIB-16 / present
                                  :IN ( GROUP-17 / promoters
                                         :DEFINITE ( ATTRIB-18 / the)
                                         :ATTRIBUTE ( ATTRIB-20 / such
                                                :AS ( GROUP-21 / AND
                                                       :op1 ( ENTITY-23 / histocompatibility_complex_class_II
                                                              :ATTRIBUTE ( ATTRIB-24 / major)
                                                              :NAMELY ( ENTITY-22 / MHC))
                                                       :op2 ( ENTITY-gp91-phox / ENTITY
                                                              :name ( n-32 / name
                                                                     :op1 "gp91-phox"))
                                                       :op3 ( ENTITY-mig / ENTITY
                                                              :name ( n-33 / name
                                                                     :op1 "mig"))
                                                       :op4 ( ENTITY-fibronectin / ENTITY
                                                              :name ( n-34 / name
                                                                     :op1 "fibronectin"))))
                                         :OF ( GROUP-19 / genes))))
                    :IN ( GROUP-11 / monocytes
                           :ATTRIBUTE ( ATTRIB-12 / circulating)))
             :LOC ( LOC-31 / here)))

# ::id 40_nonfiction_GENIA-1999;99102381,5;NE
# ::snt Analysis of NF-Y subunit expression indicates that the absence of NF-Y activity in circulating monocytes is caused by a lack of the A subunit .
( EVENT-3 / indicates
      :ARG0 ( ENTITY-1 / Analysis
             :OF ( ENTITY-2 / NF-Y_subunit_expression))
      :THAT ( EVENT-12 / caused
             :ARG0 ( ENTITY-9 / lack
                    :OF ( ENTITY-10 / A_subunit
                           :DEFINITE ( ATTRIB-11 / the)))
             :ARG1 ( ENTITY-4 / absence
                    :DEFINITE ( ATTRIB-5 / the)
                    :OF ( ENTITY-6 / NF-Y_activity
                           :IN ( GROUP-7 / monocytes
                                  :ATTRIBUTE ( ATTRIB-8 / circulating))))))

# ::id 41_nonfiction_GENIA-1999;99102381,6;NE
# ::snt Furthermore , addition of the recombinant NF-YA subunit restores NF-Y binding .
( EVENT-5 / restores
      :ARG0 ( ENTITY-1 / addition
             :OF ( ENTITY-2 / recombinant_NF-YA_subunit
                    :DEFINITE ( ATTRIB-3 / the)))
      :ARG1 ( ENTITY-4 / NF-Y_binding)
      :MOD ( mod-1 / furthermore))

# ::id 42_nonfiction_GENIA-1999;99102381,7;NE
# ::snt We show that the lack of NF-YA protein is due to posttranscriptional regulation and not to a specific proteolytic activity .
( EVENT-2 / show
      :ARG0 ( REF1-1 / we)
      :THAT ( EVENT-12 / copula
             :ATTRIBUTE ( CONJ-13 / and
                    :op1 ( ATTRIB-6 / due
                           :TO ( ENTITY-7 / regulation
                                  :ATTRIBUTE ( ATTRIB-8 / posttranscriptional)))
                    :op2 ( ATTRIB-6 / due
                           :TO ( ENTITY-9 / activity
                                  :ATTRIBUTE ( ATTRIB-11 / proteolytic)
                                  :ATTRIBUTE ( ATTRIB-10 / specific))))
             :ARG0 ( ENTITY-3 / lack
                    :DEFINITE ( ATTRIB-4 / the)
                    :OF ( ENTITY-5 / NF-YA_protein))))

# ::id 43_nonfiction_GENIA-1999;99102381,8;NE
# ::snt In fact , NF-YA mRNA is present at the same level at all days of monocyte cultivation , whereas the protein is absent in freshly isolated monocytes but is progressively synthesized during the maturation process .
( EVENT-22 / copula
      :ATTRIBUTE ( ATTRIB-3 / present
             :AT ( GROUP-7 / days
                    :OF ( ENTITY-9 / monocyte_cultivation)
                    :QUANTIFIER ( ATTRIB-8 / all))
             :AT ( ENTITY-4 / level
                    :DEFINITE ( ATTRIB-5 / the)
                    :ATTRIBUTE ( ATTRIB-6 / same)))
      :ARG0 ( ENTITY-2 / NF-YA_mRNA)
      :WHEREAS ( CONJ-24 / but
             :op1 ( EVENT-17 / copula
                    :ATTRIBUTE ( ATTRIB-13 / absent
                           :IN ( GROUP-14 / monocytes
                                  :ATTRIBUTE ( ATTRIB-16 / isolated)
                                  :ATTRIBUTE ( ATTRIB-15 / freshly)))
                    :ARG0 ( ENTITY-11 / protein
                           :DEFINITE ( ATTRIB-12 / the)))
             :op2 ( EVENT-20 / is_synthesized
                    :ARG0 ENTITY-11
                    :DURING ( ENTITY-18 / maturation_process
                           :DEFINITE ( ATTRIB-19 / the))
                    :MOD ( mod-25 / progressively)))
      :IN ( ENTITY-1 / fact))

# ::id 44_nonfiction_GENIA-1999;99102381,9;NE
# ::snt We thus conclude that the NF-YA subunit plays a relevant role in activating transcription of genes highly expressed in mature monocytes .
( EVENT-2 / conclude
      :ARG0 ( REF1-1 / we)
      :THAT ( EVENT-14 / plays
             :ARG0 ( ENTITY-3 / NF-YA_subunit
                    :DEFINITE ( ATTRIB-4 / the))
             :ARG1 ( ENTITY-5 / role
                    :ATTRIBUTE ( ATTRIB-6 / relevant)
                    :IN ( EVENT-13 / activating
                           :ARG1 ( ENTITY-8 / transcription
                                  :OF ( GROUP-9 / genes
                                         :ATTRIBUTE ( ATTRIB-10 / highly_expressed
                                                :IN ( GROUP-11 / monocytes
                                                       :ATTRIBUTE ( ATTRIB-12 / mature))))))))
      :MOD ( mod-1 / thus))

# ::id 45_nonfiction_GENIA-1999;99102381,10;NE
# ::snt In line with this conclusion , we show that the cut/CDP protein , a transcriptional repressor that inhibits gpc91-phox gene expression by preventing NF-Y binding to the CAAT box , is absent in monocytes .
( EVENT-5 / show
      :ARG0 ( REF1-4 / we)
      :IN ( ENTITY-1 / line
             :WITH ( ENTITY-2 / conclusion
                    :DETERMINER ( ATTRIB-3 / this)))
      :THAT ( EVENT-19 / copula
             :ATTRIBUTE ( ATTRIB-17 / absent
                    :IN ( GROUP-18 / monocytes))
             :ARG0 ( ENTITY-15 / cut_slash_CDP_protein
                    :DEFINITE ( ATTRIB-16 / the)
                    :NAMELY ( ENTITY-6 / repressor
                           :ATTRIBUTE ( ATTRIB-7 / transcriptional)
                           :ARG0-of ( CRD-20 / by
                                  :op1 ( EVENT-13 / preventing
                                         :ARG0 ENTITY-9
                                         :ARG1 ( ENTITY-10 / NF-Y_binding
                                                :TO ( ENTITY-11 / CAAT_box
                                                       :DEFINITE ( ATTRIB-12 / the))))
                                  :op2 ( EVENT-14 / inhibits
                                         :ARG1 ( ENTITY-9 / gpc91-phox_gene_expression)))))))

# ::id 46_nonfiction_GENIA-1999;99102590,1;NE
# ::snt Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells .
( EVENT-5 / accessing
      :ARG1 ( ENTITY-1 / Epstein-Barr_virus-specific_T-cell_memory)
      :WITH ( GROUP-2 / cells
             :ATTRIBUTE ( ATTRIB-4 / dendritic)
             :ATTRIBUTE ( ATTRIB-3 / peptide-loaded)))

# ::id 47_nonfiction_GENIA-1999;99102590,2;NE
# ::snt The conventional means of studying Epstein-Barr virus -LRB- EBV -RRB- -induced cytotoxic T-lymphocyte -LRB- CTL -RRB- memory , by in vitro stimulation with the latently infected autologous lymphoblastoid cell line -LRB- LCL -RRB- , has important limitations .
( EVENT-20 / has
      :ARG0 ( GROUP-1 / means
             :DEFINITE ( ATTRIB-2 / the)
             :ATTRIBUTE ( ATTRIB-3 / conventional)
             :OF ( EVENT-17 / studying
                    :ARG1 ( ENTITY-6 / T-lymphocyte_memory
                           :ATTRIBUTE ( ATTRIB-10 / cytotoxic)
                           :ATTRIBUTE ( ATTRIB-7 / -induced
                                  :COMP ( ENTITY-9 / Epstein-Barr_virus
                                         :NAMELY ( ENTITY-8 / EBV)))
                           :NAMELY ( ENTITY-5 / CTL))
                    :BY ( ENTITY-11 / stimulation
                           :ATTRIBUTE ( ATTRIB-12 / in_vitro)
                           :WITH ( ENTITY-14 / autologous_lymphoblastoid_cell_line
                                  :DEFINITE ( ATTRIB-15 / the)
                                  :ATTRIBUTE ( ATTRIB-16 / latently_infected)
                                  :NAMELY ( ENTITY-13 / LCL)))))
      :ARG1 ( GROUP-18 / limitations
             :ATTRIBUTE ( ATTRIB-19 / important)))

# ::id 48_nonfiction_GENIA-1999;99102590,3;NE
# ::snt First , it gives no information on memory to lytic cycle antigens ;
( EVENT-7 / gives
      :ARG0 ( REF1-1 / it)
      :ARG1 ( ENTITY-2 / information
             :ON ( ENTITY-4 / memory)
             :QUANTIFIER ( ATTRIB-3 / no))
      :ARG2 ( GROUP-5 / cycle_antigens
             :ATTRIBUTE ( ATTRIB-6 / lytic))
      :TMP ( TIME-1 / first))

# ::id 49_nonfiction_GENIA-1999;99102590,3;NE
# ::snt second , it preferentially amplifies the dominant components of latent antigen-specific memory at the expense of key subdominant reactivities .
( EVENT-13 / amplifies
      :ARG0 ( REF1-1 / it)
      :ARG1 ( GROUP-2 / components
             :DEFINITE ( ATTRIB-3 / the)
             :ATTRIBUTE ( ATTRIB-4 / dominant)
             :OF ( ENTITY-5 / memory
                    :ATTRIBUTE ( ATTRIB-7 / antigen-specific)
                    :ATTRIBUTE ( ATTRIB-6 / latent)))
      :AT ( ENTITY-8 / expense
             :DEFINITE ( ATTRIB-9 / the)
             :OF ( GROUP-10 / reactivities
                    :ATTRIBUTE ( ATTRIB-12 / subdominant)
                    :ATTRIBUTE ( ATTRIB-11 / key)))
      :MOD ( mod-1 / second)
      :MOD ( mod-2 / preferentially))

# ::id 50_nonfiction_GENIA-1999;99102590,4;NE
# ::snt Here we describe an alternative approach , based on in vitro stimulation with epitope peptide-loaded dendritic cells -LRB- DCs -RRB- , which allows one to probe the CTL repertoire for any individual reactivity of choice ;
( EVENT-23 / describe
      :ARG0 ( REF1-1 / we)
      :ARG1 ( ENTITY-2 / approach
             :ATTRIBUTE ( ATTRIB-3 / alternative)
             :ARG1-of ( EVENT-12 / based
                    :ON ( ENTITY-5 / stimulation
                           :ATTRIBUTE ( ATTRIB-6 / in_vitro)
                           :WITH ( GROUP-8 / cells
                                  :ATTRIBUTE ( ATTRIB-11 / dendritic)
                                  :ATTRIBUTE ( ATTRIB-10 / peptide-loaded)
                                  :ATTRIBUTE ( ATTRIB-9 / epitope)
                                  :NAMELY ( ENTITY-7 / DCs))))
             :ARG0-of ( EVENT-15 / allows
                    :ARG1 ( REF2-14 / one)
                    :TOCOMP ( EVENT-22 / probe
                           :ARG0 REF2-14
                           :ARG1 ( ENTITY-16 / CTL_repertoire
                                  :DEFINITE ( ATTRIB-17 / the))
                           :FOR ( ENTITY-18 / reactivity
                                  :ATTRIBUTE ( ATTRIB-20 / individual)
                                  :OF ( ENTITY-21 / choice)
                                  :QUANTIFIER ( ATTRIB-19 / any)))))
      :LOC ( LOC-1 / here))

# ::id 51_nonfiction_GENIA-1999;99102590,4;NE
# ::snt this method proved significantly more efficient than stimulation with peptide alone .
( EVENT-7 / proved
      :MOD ( mod-1 / past)
      :ATTRIBUTE ( ATTRIB-3 / significantly_more_efficient
             :THAN ( ENTITY-4 / stimulation
                    :WITH ( ENTITY-5 / peptide
                           :QUANTIFIER ( ATTRIB-6 / alone))))
      :ARG0 ( ENTITY-1 / method
             :DETERMINER ( ATTRIB-2 / this)))

# ::id 52_nonfiction_GENIA-1999;99102590,5;NE
# ::snt Using this approach we first show that reactivities to the immunodominant and subdominant lytic cycle epitopes identified by T cells during primary EBV infection are regularly detectable in the CTL memory of virus carriers ;
( CONJ-25 / and
      :op1 ( EVENT-4 / using
             :ARG0 ( REF1-1 / we)
             :ARG1 ( ENTITY-2 / approach
                    :DETERMINER ( ATTRIB-3 / this)))
      :op2 ( EVENT-5 / show
             :ARG0 REF1-1
             :THAT ( EVENT-23 / copula
                    :ATTRIBUTE ( ATTRIB-19 / regularly_detectable
                           :IN ( ENTITY-20 / CTL_memory
                                  :DEFINITE ( ATTRIB-21 / the)
                                  :OF ( GROUP-22 / virus_carriers)))
                    :ARG0 ( GROUP-6 / reactivities
                           :TO ( ENTITY-7 / AND
                                  :DEFINITE ( ATTRIB-8 / the)
                                  :op1 ( GROUP-10 / lytic_cycle_epitopes
                                         :ATTRIBUTE ( ATTRIB-11 / immunodominant))
                                  :op2 ( GROUP-12 / lytic_cycle_epitopes
                                         :ATTRIBUTE ( ATTRIB-13 / subdominant))
                                  :ARG1-of ( EVENT-18 / identified
                                         :ARG0 ( GROUP-15 / T_cells)
                                         :DURING ( ENTITY-16 / EBV_infection
                                                :ATTRIBUTE ( ATTRIB-17 / primary))))))
             :MOD ( mod-26 / first)))

# ::id 53_nonfiction_GENIA-1999;99102590,5;NE
# ::snt this implies that in such carriers chronic virus replication remains under direct T-cell control .
( EVENT-3 / implies
      :ARG0 ( ENTITY-1 / ENTITY
             :DETERMINER ( ATTRIB-2 / this))
      :THAT ( EVENT-10 / remains
             :ARG0 ( ENTITY-6 / virus_replication
                    :ATTRIBUTE ( ATTRIB-7 / chronic))
             :UNDER ( ENTITY-8 / T-cell_control
                    :ATTRIBUTE ( ATTRIB-9 / direct))
             :IN ( GROUP-4 / carriers
                    :ATTRIBUTE ( ATTRIB-5 / such))))

# ::id 54_nonfiction_GENIA-1999;99102590,6;NE
# ::snt We further show that subdominant latent cycle reactivities to epitopes in the latent membrane protein LMP2 , though rarely undetectable in LCL-stimulated populations , can be reactivated by DC stimulation and selectively expanded as polyclonal CTL lines ;
( EVENT-2 / show
      :ARG0 ( REF1-1 / we)
      :THAT ( CONJ-27 / and
             :domain-of ( MD-28 / can)
             :op1 ( EVENT-15 / reactivated
                    :ARG0 ( ENTITY-14 / DC_stimulation)
                    :ARG1 ( GROUP-3 / reactivities
                           :ATTRIBUTE ( ATTRIB-6 / cycle)
                           :ATTRIBUTE ( ATTRIB-5 / latent)
                           :ATTRIBUTE ( ATTRIB-4 / subdominant)
                           :TO ( GROUP-7 / epitopes
                                  :IN ( ENTITY-LMP2 / membrane_protein
                                         :DETERMINER ( ATTRIB-9 / the)
                                         :ATTRIBUTE ( ATTRIB-10 / latent)
                                         :name ( n-31 / name
                                                :op1 "LMP2"))))
                    :THOUGH ( ATTRIB-11 / rarely_undetectable
                           :IN ( GROUP-12 / populations
                                  :ATTRIBUTE ( ATTRIB-13 / lcl-stimulated))))
             :op2 ( EVENT-18 / be_expanded
                    :ARG0 GROUP-3
                    :AS ( GROUP-16 / CTL_lines
                           :ATTRIBUTE ( ATTRIB-17 / polyclonal))
                    :THOUGH ATTRIB-11
                    :MOD ( mod-29 / selectively)))
      :MOD ( mod-30 / further))

# ::id 55_nonfiction_GENIA-1999;99102590,6;NE
# ::snt the adoptive transfer of such preparations may be of value in targeting certain EBV-positive malignancies .
( EVENT-12 / copula
      :domain-of ( MD-13 / may)
      :ARG0 ( ENTITY-1 / transfer
             :DEFINITE ( ATTRIB-2 / the)
             :ATTRIBUTE ( ATTRIB-3 / adoptive)
             :OF ( GROUP-4 / preparations
                    :ATTRIBUTE ( ATTRIB-5 / such)))
      :IN ( EVENT-11 / targeting
             :ARG0 ENTITY-1
             :ARG1 ( GROUP-8 / malignancies
                    :ATTRIBUTE ( ATTRIB-10 / ebv-positive)
                    :ATTRIBUTE ( ATTRIB-9 / certain)))
      :OF ( ENTITY-6 / value))

# ::id 56_nonfiction_GENIA-1999;99103960,1;NE
# ::snt Differential monocyte adhesion and adhesion molecule expression in venous and arterial endothelial cells .
( ENTITY-1 / AND
      :op1 ( ENTITY-3 / monocyte_adhesion
             :ATTRIBUTE ( ATTRIB-4 / differential))
      :op2 ( ENTITY-5 / adhesion_molecule_expression)
      :IN ( GROUP-6 / AND
             :op1 ( GROUP-7 / cells
                    :ATTRIBUTE ( ATTRIB-9 / endothelial)
                    :ATTRIBUTE ( ATTRIB-8 / venous))
             :op2 ( GROUP-10 / cells
                    :ATTRIBUTE ( ATTRIB-12 / endothelial)
                    :ATTRIBUTE ( ATTRIB-11 / arterial))))

# ::id 57_nonfiction_GENIA-1999;99103960,2;NE
# ::snt We compared U-937 cell adhesion and adhesion molecule expression in human umbilical venous -LRB- HUVECs -RRB- and arterial -LRB- HUAECs -RRB- endothelial cells exposed to tumor necrosis factor -LRB- TNF -RRB- , interleukin-1 , and lipopolysaccharide -LRB- LPS -RRB- .
( EVENT-20 / compared
      :MOD ( mod-2 / past)
      :ARG0 ( REF1-1 / we)
      :ARG1 ( GROUP-2 / AND
             :op1 ( ENTITY-3 / U-937_cell_adhesion)
             :op2 ( ENTITY-4 / adhesion_molecule_expression))
      :IN ( GROUP-14 / cells
             :ARG1-of ( EVENT-19 / exposed
                    :TO ( GROUP-16 / AND
                           :op1 ( ENTITY-17 / tumor_necrosis_factor
                                  :NAMELY ( ENTITY-TNF / ENTITY
                                         :name ( n-3 / name
                                                :op1 "TNF")))
                           :op2 ( ENTITY-interleukin-1 / ENTITY
                                  :name ( n-4 / name
                                         :op1 "interleukin-1"))
                           :op3 ( ENTITY-18 / lipopolysaccharide
                                  :NAMELY ( ENTITY-LPS / ENTITY
                                         :name ( n-5 / name
                                                :op1 "LPS")))))
             :NAMELY ( GROUP-5 / AND
                    :op1 ( ENTITY-7 / HUVECs
                           :ATTRIBUTE ( ATTRIB-10 / venous)
                           :ATTRIBUTE ( ATTRIB-9 / umbilical)
                           :ATTRIBUTE ( ATTRIB-8 / human))
                    :op2 ( ENTITY-12 / endothelial
                           :ATTRIBUTE ( ATTRIB-13 / arterial)
                           :NAMELY ( ENTITY-11 / HUAECs)))))

# ::id 58_nonfiction_GENIA-1999;99103960,3;NE
# ::snt TNF and LPS stimulated vascular cell adhesion molecule -LRB- VCAM -RRB- -1 surface expression and adhesion of U-937 monocyte-like cells to HUVECs but not to HUAECs .
( EVENT-10 / stimulated
      :MOD ( mod-12 / past)
      :ARG0 ( GROUP-1 / AND
             :op1 ( ENTITY-TNF / ENTITY
                    :name ( n-13 / name
                           :op1 "TNF"))
             :op2 ( ENTITY-LPS / ENTITY
                    :name ( n-14 / name
                           :op1 "LPS")))
      :ARG1 ( GROUP-2 / AND
             :op1 ( ENTITY-4 / cell_adhesion_molecule_-1_surface_expression
                    :ATTRIBUTE ( ATTRIB-5 / vascular)
                    :NAMELY ( ENTITY-3 / VCAM))
             :op2 ( CONJ-11 / but
                    :op1 ( ENTITY-6 / adhesion
                           :TO ( GROUP-8 / HUVECs)
                           :OF ( GROUP-7 / U-937_monocyte-like_cells))
                    :op2 ( ENTITY-6 / adhesion
                           :TO ( GROUP-9 / HUAECs)
                           :OF GROUP-7))))

# ::id 59_nonfiction_GENIA-1999;99103960,4;NE
# ::snt Antibody studies demonstrated that in HUVECs at least 75 % of the adhesion response is VCAM-1 mediated .
( EVENT-2 / demonstrated
      :MOD ( mod-2 / past)
      :ARG0 ( GROUP-1 / Antibody_studies)
      :THAT ( EVENT-11 / copula
             :ATTRIBUTE ( ATTRIB-10 / mediated
                    :COMP ( ENTITY-VCAM-1 / ENTITY
                           :name ( n-3 / name
                                  :op1 "VCAM-1")))
             :ARG0 ( ENTITY-4 / percent
                    :OF ( ENTITY-8 / adhesion_response
                           :DEFINITE ( ATTRIB-9 / the))
                    :CARDINAL ( ATTRIB-7 / 75)
                    :AT ( ENTITY-5 / ENTITY
                           :QUANTIFIER ( ATTRIB-6 / least)))
             :IN ( GROUP-3 / HUVECs)))

# ::id 60_nonfiction_GENIA-1999;99103960,5;NE
# ::snt Interleukin-1 stimulated U-937 cell adhesion to and VCAM-1 surface expression in both HUVECs and HUAECs .
( EVENT-14 / stimulated
      :MOD ( mod-2 / past)
      :ARG0 ( ENTITY-Interleukin-1 / ENTITY
             :name ( n-3 / name
                    :op1 "Interleukin-1"))
      :ARG1 ( GROUP-1 / AND
             :op1 ( ENTITY-2 / U-937_cell_adhesion
                    :TO ( group-3 / AND
                           :op1 ( GROUP-6 / HUVECs)
                           :op2 ( GROUP-7 / HUAECs)
                           :QUANTIFIER ( ATTRIB-4 / both)))
             :op2 ( ENTITY-8 / VCAM-1_surface_expression
                    :IN ( group-9 / AND
                           :op1 ( GROUP-12 / HUVECs)
                           :op2 ( GROUP-13 / HUAECs)
                           :QUANTIFIER ( ATTRIB-10 / both)))))

# ::id 61_nonfiction_GENIA-1999;99103960,6;NE
# ::snt Pyrrolidinedithiocarbamate and the proteasome inhibitor MG-132 blocked TNF- and LPS- stimulated U-937 cell adhesion to HUVECs .
( EVENT-8 / blocked
      :MOD ( mod-133 / past)
      :ARG0 ( GROUP-1 / AND
             :op1 ( ENTITY-Pyrrolidinedithiocarbamate / ENTITY
                    :name ( n-135 / name
                           :op1 "Pyrrolidinedithiocarbamate"))
             :op2 ( ENTITY-MG-132 / proteasome_inhibitor
                    :DETERMINER ( ATTRIB-3 / the)
                    :name ( n-134 / name
                           :op1 "MG-132")))
      :ARG1 ( ENTITY-4 / U-937_cell_adhesion
             :ATTRIBUTE ( ATTRIB-5 / stimulated
                    :COMP ( GROUP-6 / AND
                           :op1 ( ENTITY-TNF- / ENTITY
                                  :name ( n-136 / name
                                         :op1 "TNF-"))
                           :op2 ( ENTITY-LPS- / ENTITY
                                  :name ( n-137 / name
                                         :op1 "LPS-"))))
             :TO ( GROUP-7 / HUVECs)))

# ::id 62_nonfiction_GENIA-1999;99103960,7;NE
# ::snt These agents also significantly decreased TNF- and LPS- stimulated increases in HUVEC surface VCAM-1 .
( EVENT-7 / decreased
      :MOD ( mod-4 / past)
      :ARG0 ( GROUP-1 / agents
             :DETERMINER ( ATTRIB-2 / these))
      :ARG1 ( GROUP-3 / increases
             :ATTRIBUTE ( ATTRIB-4 / stimulated
                    :COMP ( GROUP-5 / AND
                           :op1 ( ENTITY-TNF- / ENTITY
                                  :name ( n-6 / name
                                         :op1 "TNF-"))
                           :op2 ( ENTITY-LPS- / ENTITY
                                  :name ( n-7 / name
                                         :op1 "LPS-"))))
             :IN ( ENTITY-VCAM-1 / HUVEC_surface
                    :name ( n-5 / name
                           :op1 "VCAM-1")))
      :MOD ( mod-2 / also)
      :MOD ( mod-3 / significantly))

# ::id 63_nonfiction_GENIA-1999;99103960,8;NE
# ::snt TNF increased VCAM-1 protein and mRNA in HUVECs that was blocked by pyrrolidinedithiocarbamate .
( EVENT-6 / increased
      :MOD ( mod-2 / past)
      :ARG0 ( ENTITY-TNF / ENTITY
             :name ( n-3 / name
                    :op1 "TNF"))
      :ARG1 ( GROUP-1 / AND
             :op1 ( ENTITY-2 / VCAM-1_protein)
             :op2 ( ENTITY-mRNA / ENTITY
                    :name ( n-4 / name
                           :op1 "mRNA")))
      :IN ( GROUP-3 / HUVECs
             :ARG1-of ( EVENT-5 / blocked
                    :MOD ( mod-1 / past)
                    :ARG0 ( ENTITY-pyrrolidinedithiocarbamate / ENTITY
                           :name ( n-5 / name
                                  :op1 "pyrrolidinedithiocarbamate")))))

# ::id 64_nonfiction_GENIA-1999;99103960,9;NE
# ::snt However , neither TNF or LPS stimulated VCAM-1 expression in HUAECs .
( EVENT-4 / stimulated
      :MOD ( mod-2 / past)
      :ARG0 ( GROUP-1 / neither_or
             :op1 ( ENTITY-TNF / ENTITY
                    :name ( n-3 / name
                           :op1 "TNF"))
             :op2 ( ENTITY-LPS / ENTITY
                    :name ( n-4 / name
                           :op1 "LPS")))
      :ARG1 ( ENTITY-2 / VCAM-1_expression
             :IN ( GROUP-3 / HUAECs))
      :MOD ( mod-1 / however))

# ::id 65_nonfiction_GENIA-1999;99103960,10;NE
# ::snt TNF stimulated expression of both intercellular adhesion molecule-1 and E-selectin in HUVECs ,
( EVENT-8 / stimulated
      :MOD ( mod-2 / past)
      :ARG0 ( ENTITY-TNF / ENTITY
             :name ( n-3 / name
                    :op1 "TNF"))
      :ARG1 ( ENTITY-1 / expression
             :IN ( GROUP-7 / HUVECs)
             :OF ( group-2 / AND
                    :op1 ( ENTITY-5 / adhesion_molecule-1
                           :ATTRIBUTE ( ATTRIB-6 / intercellular))
                    :op2 ( ENTITY-E-selectin / ENTITY
                           :name ( n-4 / name
                                  :op1 "E-selectin"))
                    :QUANTIFIER ( ATTRIB-3 / both))))

# ::id 66_nonfiction_GENIA-1999;99103960,10;NE
# ::snt but in HUAECs , only intercellular adhesion molecule-1 was increased .
( EVENT-5 / increased
      :MOD ( mod-2 / past)
      :ARG1 ( ENTITY-2 / adhesion_molecule-1
             :ATTRIBUTE ( ATTRIB-4 / intercellular)
             :QUANTIFIER ( ATTRIB-3 / only))
      :IN ( GROUP-1 / HUAECs))

# ::id 67_nonfiction_GENIA-1999;99103960,11;NE
# ::snt Electrophoretic mobility shift assays demonstrated no difference in the pattern of TNF- stimulated nuclear factor -kappaB activation between HUVECs and HUAECs .
( EVENT-13 / demonstrated
      :MOD ( mod-1 / past)
      :ARG0 ( GROUP-1 / mobility_shift_assays
             :ATTRIBUTE ( ATTRIB-2 / electrophoretic))
      :ARG1 ( ENTITY-3 / difference
             :BETWEEN ( GROUP-10 / AND
                    :op1 ( GROUP-11 / HUVECs)
                    :op2 ( GROUP-12 / HUAECs))
             :IN ( ENTITY-5 / pattern
                    :DEFINITE ( ATTRIB-6 / the)
                    :OF ( ENTITY-7 / factor_-kappaB_activation
                           :ATTRIBUTE ( ATTRIB-9 / nuclear)
                           :ATTRIBUTE ( ATTRIB-8 / stimulated
                                  :COMP ( ENTITY-TNF- / ENTITY
                                         :name ( n-2 / name
                                                :op1 "TNF-")))))
             :QUANTIFIER ( ATTRIB-4 / no)))

# ::id 68_nonfiction_GENIA-1999;99103960,12;NE
# ::snt These studies demonstrate a novel and striking insensitivity of arterial endothelium to the effects of TNF and LPS and indicate a dissociation between the ability of HUAECs to upregulate nuclear factor -kappaB and VCAM-1 .
( CONJ-22 / and
      :op1 ( EVENT-11 / demonstrate
             :ARG0 ( GROUP-1 / studies
                    :DETERMINER ( ATTRIB-2 / these))
             :ARG1 ( CONJ-21 / and
                    :op1 ( ENTITY-3 / insensitivity
                           :ATTRIBUTE ( ATTRIB-4 / novel)
                           :TO ( GROUP-8 / effects
                                  :DEFINITE ( ATTRIB-9 / the)
                                  :OF ( GROUP-10 / AND
                                         :op1 ( ENTITY-TNF / ENTITY
                                                :name ( n-23 / name
                                                       :op1 "TNF"))
                                         :op2 ( ENTITY-LPS / ENTITY
                                                :name ( n-24 / name
                                                       :op1 "LPS"))))
                           :OF ( ENTITY-6 / endothelium
                                  :ATTRIBUTE ( ATTRIB-7 / arterial)))
                    :op2 ( ENTITY-3 / insensitivity
                           :ATTRIBUTE ( ATTRIB-5 / striking)
                           :TO ( GROUP-8 / effects
                                  :DEFINITE ( ATTRIB-9 / the)
                                  :OF ( GROUP-10 / AND
                                         :op1 ENTITY-TNF
                                         :op2 ENTITY-LPS))
                           :OF ( ENTITY-6 / endothelium
                                  :ATTRIBUTE ( ATTRIB-7 / arterial)))))
      :op2 ( EVENT-20 / indicate
             :ARG0 GROUP-1
             :ARG1 ( ENTITY-12 / dissociation
                    :BETWEEN ( ENTITY-13 / ability
                           :DEFINITE ( ATTRIB-14 / the)
                           :OF ( GROUP-15 / HUAECs)
                           :TOCOMP ( EVENT-19 / upregulate
                                  :ARG1 ( GROUP-16 / AND
                                         :op1 ( ENTITY-17 / factor_-kappaB
                                                :ATTRIBUTE ( ATTRIB-18 / nuclear))
                                         :op2 ( ENTITY-VCAM-1 / ENTITY
                                                :name ( n-25 / name
                                                       :op1 "VCAM-1"))))))))

# ::id 69_nonfiction_GENIA-1999;99106021,1;NE
# ::snt Tissue factor expression of human monocytes is suppressed by lysophosphatidylcholine .
( EVENT-4 / suppressed
      :ARG0 ( ENTITY-lysophosphatidylcholine / ENTITY
             :name ( n-1 / name
                    :op1 "lysophosphatidylcholine"))
      :ARG1 ( ENTITY-1 / Tissue_factor_expression
             :OF ( GROUP-2 / monocytes
                    :ATTRIBUTE ( ATTRIB-3 / human))))

# ::id 70_nonfiction_GENIA-1999;99106021,2;NE
# ::snt The expression of tissue factor -LRB- TF -RRB- , the principal initiator of coagulation , is increased during inflammation and atherosclerosis .
( EVENT-11 / increased
      :ARG1 ( ENTITY-1 / expression
             :DEFINITE ( ATTRIB-2 / the)
             :OF ( ENTITY-7 / tissue_factor
                    :NAMELY ( ENTITY-TF / ENTITY
                           :name ( n-1 / name
                                  :op1 "TF"))
                    :NAMELY ( ENTITY-3 / initiator
                           :DETERMINER ( ATTRIB-4 / the)
                           :ATTRIBUTE ( ATTRIB-5 / principal)
                           :OF ( ENTITY-6 / coagulation))))
      :DURING ( GROUP-8 / AND
             :op1 ( ENTITY-9 / inflammation)
             :op2 ( ENTITY-10 / atherosclerosis)))

# ::id 71_nonfiction_GENIA-1999;99106021,3;NE
# ::snt Both conditions are promoted by lysophosphatidylcholine -LRB- lysoPC -RRB- .
( EVENT-3 / promoted
      :ARG0 ( ENTITY-lysophosphatidylcholine / ENTITY
             :name ( n-2 / name
                    :op1 "lysoPC")
             :name ( n-1 / name
                    :op1 "lysophosphatidylcholine"))
      :ARG1 ( GROUP-1 / conditions
             :QUANTIFIER ( ATTRIB-2 / both)))

# ::id 72_nonfiction_GENIA-1999;99106021,4;NE
# ::snt We observed in the present study that lysoPC -LRB- 1 to 10 micromol/L -RRB- dose-dependently reduced TF activity in human monocytes , as elicited by lipopolysaccharide -LRB- LPS -RRB- .
( EVENT-5 / observed
      :MOD ( mod-3 / past)
      :ARG0 ( REF1-1 / we)
      :IN ( ENTITY-2 / study
             :DEFINITE ( ATTRIB-3 / the)
             :ATTRIBUTE ( ATTRIB-4 / present))
      :THAT ( EVENT-13 / reduced
             :MOD ( mod-1 / past)
             :ARG0 ( ENTITY-lysoPC / ENTITY
                    :name ( n-5 / name
                           :op1 "lysoPC"))
             :ARG1 ( ENTITY-8 / TF_activity
                    :IN ( GROUP-9 / monocytes
                           :ATTRIBUTE ( ATTRIB-10 / human)))
             :AS ( EVENT-12 / elicited
                    :ARG0 ( ENTITY-lipopolysaccharide / ENTITY
                           :name ( n-6 / name
                                  :op1 "LPS")
                           :name ( n-4 / name
                                  :op1 "lipopolysaccharide"))
                    :ARG1 ENTITY-8)
             :MSR ( DEGREE-6 / micromol_slash_L
                    :CARDINAL ( ATTRIB-7 / 1_to_10))
             :MOD ( mod-2 / dose-dependently)))

# ::id 73_nonfiction_GENIA-1999;99106021,5;NE
# ::snt Lysophosphatidylethanolamine -LRB- lysoPE -RRB- and other lysophospholipids did not affect LPS-induced TF activity of human monocytes .
( EVENT-9 / did_affect
      :domain-of ( NEG-10 / NEG)
      :MOD ( mod-11 / past)
      :ARG0 ( GROUP-1 / AND
             :op1 ( ENTITY-Lysophosphatidylethanolamine / lysoPE
                    :name ( n-12 / name
                           :op1 "Lysophosphatidylethanolamine"))
             :op2 ( GROUP-3 / lysophospholipids
                    :ATTRIBUTE ( ATTRIB-4 / other)))
      :ARG1 ( ENTITY-5 / TF_activity
             :ATTRIBUTE ( ATTRIB-6 / lps-induced)
             :OF ( GROUP-7 / monocytes
                    :ATTRIBUTE ( ATTRIB-8 / human))))

# ::id 74_nonfiction_GENIA-1999;99106021,6;NE
# ::snt TF antigen expression as elicited by LPS was also lowered by lysoPC .
( EVENT-4 / lowered
      :MOD ( mod-2 / past)
      :ARG0 ( ENTITY-lysoPC / ENTITY
             :name ( n-3 / name
                    :op1 "lysoPC"))
      :ARG1 ( ENTITY-1 / TF_antigen_expression)
      :AS ( EVENT-3 / elicited
             :ARG0 ( ENTITY-LPS / ENTITY
                    :name ( n-4 / name
                           :op1 "LPS"))
             :ARG1 ENTITY-1)
      :MOD ( mod-1 / also))

# ::id 75_nonfiction_GENIA-1999;99106021,7;NE
# ::snt Phospholipid analyses indicated a selective increase in the lysoPC content of the monocytes after preincubation with the lysophospholipid .
( EVENT-11 / indicated
      :MOD ( mod-1 / past)
      :ARG0 ( GROUP-1 / Phospholipid_analyses)
      :ARG1 ( ENTITY-2 / increase
             :ATTRIBUTE ( ATTRIB-3 / selective)
             :AFTER ( ENTITY-8 / preincubation
                    :WITH ( ENTITY-9 / lysophospholipid
                           :DEFINITE ( ATTRIB-10 / the)))
             :IN ( ENTITY-4 / lysoPC_content
                    :DEFINITE ( ATTRIB-5 / the)
                    :OF ( GROUP-6 / monocytes
                           :DEFINITE ( ATTRIB-7 / the)))))

# ::id 76_nonfiction_GENIA-1999;99106021,8;NE
# ::snt LysoPC inhibited the TF activity of Mono Mac-6 cells to a similar extent as in the monocytes .
( EVENT-8 / inhibited
      :MOD ( mod-1 / past)
      :ARG0 ( ENTITY-LysoPC / ENTITY
             :name ( n-2 / name
                    :op1 "LysoPC"))
      :ARG1 ( ENTITY-1 / TF_activity
             :DEFINITE ( ATTRIB-2 / the)
             :AS_IN ( GROUP-6 / monocytes
                    :DEFINITE ( ATTRIB-7 / the))
             :TO ( ENTITY-4 / extent
                    :ATTRIBUTE ( ATTRIB-5 / similar))
             :OF ( GROUP-3 / Mono_Mac-6_cells)))

# ::id 77_nonfiction_GENIA-1999;99106021,9;NE
# ::snt LPS binding to plasma membrane receptors and internalization of LPS into monocytes were not affected by lysoPC .
( EVENT-6 / affected
      :domain-of ( NEG-7 / NEG)
      :MOD ( mod-8 / past)
      :ARG0 ( ENTITY-lysoPC / ENTITY
             :name ( n-9 / name
                    :op1 "lysoPC"))
      :ARG1 ( GROUP-1 / AND
             :op1 ( ENTITY-2 / LPS_binding
                    :TO ( GROUP-3 / plasma_membrane_receptors))
             :op2 ( ENTITY-4 / internalization
                    :INTO ( GROUP-5 / monocytes)
                    :OF ( ENTITY-LPS / ENTITY
                           :name ( n-10 / name
                                  :op1 "LPS")))))

# ::id 78_nonfiction_GENIA-1999;99106021,10;NE
# ::snt In contrast , LPS-mediated nuclear binding of nuclear factor -kappaB/Rel to a TF-specific kappaB site was inhibited by lysoPC .
( EVENT-9 / inhibited
      :MOD ( mod-1 / past)
      :ARG0 ( ENTITY-lysoPC / ENTITY
             :name ( n-2 / name
                    :op1 "lysoPC"))
      :ARG1 ( ENTITY-2 / binding
             :ATTRIBUTE ( ATTRIB-4 / nuclear)
             :ATTRIBUTE ( ATTRIB-3 / lps-mediated)
             :TO ( ENTITY-7 / kappaB_site
                    :ATTRIBUTE ( ATTRIB-8 / tf-specific))
             :OF ( ENTITY-5 / factor_-kappaB_slash_Rel
                    :ATTRIBUTE ( ATTRIB-6 / nuclear)))
      :IN ( ENTITY-1 / contrast))

# ::id 79_nonfiction_GENIA-1999;99106021,11;NE
# ::snt Induction of TF mRNA expression by LPS tended to be partially reduced by the lysophospholipid .
( EVENT-3 / tended
      :MOD ( mod-2 / past)
      :ARG0 ( ENTITY-1 / Induction
             :BY ( ENTITY-LPS / ENTITY
                    :name ( n-3 / name
                           :op1 "LPS"))
             :OF ( ENTITY-2 / TF_mRNA_expression))
      :TOCOMP ( EVENT-4 / reduced
             :ARG0 ( ENTITY-lysophospholipid / ENTITY
                    :name ( n-4 / name
                           :op1 "lysophospholipid"))
             :ARG1 ENTITY-1
             :MOD ( mod-1 / partially)))

# ::id 80_nonfiction_GENIA-1999;99106021,12;NE
# ::snt Preincubation with lysoPC increased monocytic cAMP levels .
( EVENT-4 / increased
      :MOD ( mod-1 / past)
      :ARG0 ( ENTITY-1 / Preincubation
             :WITH ( ENTITY-lysoPC / ENTITY
                    :name ( n-2 / name
                           :op1 "lysoPC")))
      :ARG1 ( GROUP-2 / cAMP_levels
             :ATTRIBUTE ( ATTRIB-3 / monocytic)))

# ::id 81_nonfiction_GENIA-1999;99106021,13;NE
# ::snt Inhibition of adenylyl cyclase by pretreatment with 2'-deoxy-3'-adenosine monophosphate partially reversed the inhibition of TF activity promoted by lysoPC .
( EVENT-12 / reversed
      :MOD ( mod-2 / past)
      :ARG0 ( ENTITY-1 / Inhibition
             :OF ( ENTITY-2 / cyclase
                    :ATTRIBUTE ( ATTRIB-3 / adenylyl))
             :BY ( ENTITY-4 / pretreatment
                    :WITH ( ENTITY-5 / monophosphate
                           :ATTRIBUTE ( ATTRIB-6 / 2 ' -deoxy-3 ' -adenosine))))
      :ARG1 ( ENTITY-7 / inhibition
             :DEFINITE ( ATTRIB-8 / the)
             :OF ( ENTITY-9 / TF_activity
                    :ARG1-of ( EVENT-11 / promoted
                           :ARG0 ( ENTITY-lysoPC / ENTITY
                                  :name ( n-3 / name
                                         :op1 "lysoPC")))))
      :MOD ( mod-1 / partially))

# ::id 82_nonfiction_GENIA-1999;99106021,14;NE
# ::snt In conclusion , lysoPC markedly decreases LPS-mediated TF expression of human monocytes , the effect probably being mediated by both transcriptional and posttranscriptional mechanisms .
( CONJ-18 / and
      :op1 ( EVENT-15 / decreases
             :ARG0 ( ENTITY-lysoPC / ENTITY
                    :name ( n-21 / name
                           :op1 "lysoPC"))
             :ARG1 ( ENTITY-2 / TF_expression
                    :ATTRIBUTE ( ATTRIB-3 / lps-mediated)
                    :OF ( GROUP-4 / monocytes
                           :ATTRIBUTE ( ATTRIB-5 / human)))
             :IN ( ENTITY-1 / conclusion))
      :op2 ( EVENT-13 / being_mediated
             :ARG0 ( ENTITY-6 / effect
                    :DEFINITE ( ATTRIB-7 / the))
             :BY ( GROUP-8 / AND
                    :op1 ( GROUP-9 / mechanisms
                           :ATTRIBUTE ( ATTRIB-10 / transcriptional))
                    :op2 ( GROUP-11 / mechanisms
                           :ATTRIBUTE ( ATTRIB-12 / posttranscriptional)))
             :MOD ( mod-19 / probably))
      :MOD ( mod-20 / markedly))

# ::id 83_nonfiction_GENIA-1999;99106021,15;NE
# ::snt LysoPC may thus attenuate activation of coagulation during inflammation and atherosclerosis .
( EVENT-7 / attenuate
      :domain-of ( MD-9 / may)
      :ARG0 ( ENTITY-1 / LysoPC)
      :ARG1 ( ENTITY-2 / activation
             :OF ( ENTITY-3 / coagulation))
      :DURING ( GROUP-4 / AND
             :op1 ( ENTITY-5 / inflammation)
             :op2 ( ENTITY-6 / atherosclerosis))
      :MOD ( mod-10 / thus))

# ::id 84_nonfiction_GENIA-1999;99107757,1;NE
# ::snt Intranuclear targeted delivery of functional NF-kappaB by 70 kDa heat shock protein .
( ENTITY-1 / delivery
      :ATTRIBUTE ( ATTRIB-3 / targeted)
      :ATTRIBUTE ( ATTRIB-2 / intranuclear)
      :BY ( ENTITY-6 / 70_kDa_heat_shock_protein)
      :OF ( ENTITY-4 / NF-kappaB
             :ATTRIBUTE ( ATTRIB-5 / functional)))

# ::id 85_nonfiction_GENIA-1999;99107757,2;NE
# ::snt The 70 kDa heat shock protein -LRB- Hsp70 -RRB- is a highly conserved , ubiquitous protein involved in chaperoning proteins to various cellular organelles .
( EVENT-14 / copula
      :ARG0 ( ENTITY-1 / 70_kDa_heat_shock_protein
             :DEFINITE ( ATTRIB-2 / the)
             :NAMELY ( ENTITY-Hsp70 / ENTITY
                    :name ( n-2 / name
                           :op1 "Hsp70")))
      :ARG1 ( ENTITY-3 / protein
             :ATTRIBUTE ( ATTRIB-5 / ubiquitous)
             :ATTRIBUTE ( ATTRIB-4 / highly_conserved)
             :ARG0-of ( EVENT-13 / involved
                    :MOD ( mod-1 / past)
                    :IN ( EVENT-12 / chaperoning
                           :ARG0 ENTITY-3
                           :ARG1 ( GROUP-8 / proteins)
                           :TO ( GROUP-9 / organelles
                                  :ATTRIBUTE ( ATTRIB-11 / cellular)
                                  :ATTRIBUTE ( ATTRIB-10 / various))))))

# ::id 86_nonfiction_GENIA-1999;99107757,3;NE
# ::snt Here we show that when added exogenously to cells , Hsp70 is readily imported into both cytoplasmic and nuclear compartments in a cell-type-specific fashion .
( EVENT-2 / show
      :ARG0 ( REF1-1 / we)
      :THAT ( CND-19 / when
             :op1 ( EVENT-4 / added
                    :ARG0 ENTITY-Hsp70
                    :TO ( GROUP-3 / cells)
                    :MOD ( mod-20 / exogenously))
             :op2 ( EVENT-13 / is_imported
                    :ARG0 ( ENTITY-Hsp70 / ENTITY
                           :name ( n-23 / name
                                  :op1 "Hsp70"))
                    :IN ( ENTITY-11 / fashion
                           :ATTRIBUTE ( ATTRIB-12 / cell-type-specific))
                    :INTO ( GROUP-6 / AND
                           :op1 ( GROUP-7 / compartments
                                  :ATTRIBUTE ( ATTRIB-8 / cytoplasmic))
                           :op2 ( GROUP-9 / compartments
                                  :ATTRIBUTE ( ATTRIB-10 / nuclear)))
                    :MOD ( mod-21 / readily)))
      :LOC ( LOC-22 / here))

# ::id 87_nonfiction_GENIA-1999;99107757,4;NE
# ::snt We exploited this ability of Hsp70 to deliver NF-kappaB , a key transcriptional regulator of inflammatory responses .
( EVENT-10 / exploited
      :MOD ( mod-1 / past)
      :ARG0 ( REF1-1 / we)
      :ARG1 ( ENTITY-2 / ability
             :DETERMINER ( ATTRIB-3 / this)
             :OF ( ENTITY-Hsp70 / ENTITY
                    :name ( n-3 / name
                           :op1 "Hsp70"))
             :TOCOMP ( EVENT-9 / deliver
                    :ARG1 ( ENTITY-NF-kappaB / regulator
                           :ATTRIBUTE ( ATTRIB-6 / transcriptional)
                           :ATTRIBUTE ( ATTRIB-5 / key)
                           :OF ( GROUP-7 / responses
                                  :ATTRIBUTE ( ATTRIB-8 / inflammatory))
                           :name ( n-2 / name
                                  :op1 "NF-kappaB")))))

# ::id 88_nonfiction_GENIA-1999;99107757,5;NE
# ::snt We demonstrate that a fusion protein composed of a C-terminal Hsp70 peptide and the p50 subunit of NF-kappaB was directed into the nucleus of cells , could bind DNA specifically , and activated Igkappa expression and TNFalpha production .
( EVENT-2 / demonstrate
      :ARG0 ( REF1-1 / we)
      :THAT ( CONJ-24 / and
             :op1 ( EVENT-13 / directed
                    :MOD ( mod-25 / past)
                    :ARG1 ( ENTITY-3 / fusion_protein
                           :ARG1-of ( EVENT-9 / composed
                                  :OF ( GROUP-5 / AND
                                         :op1 ( ENTITY-6 / C-terminal_Hsp70_peptide)
                                         :op2 ( ENTITY-7 / p50_subunit
                                                :DEFINITE ( ATTRIB-8 / the)
                                                :OF ( ENTITY-NF-kappaB / ENTITY
                                                       :name ( n-28 / name
                                                              :op1 "NF-kappaB"))))))
                    :INTO ( ENTITY-10 / nucleus
                           :DEFINITE ( ATTRIB-11 / the)
                           :OF ( GROUP-12 / cells)))
             :op2 ( EVENT-15 / bind
                    :domain-of ( MD-23 / could)
                    :ARG0 ENTITY-3
                    :ARG1 ( ENTITY-14 / DNA)
                    :MOD ( mod-26 / specifically))
             :op3 ( EVENT-20 / activated
                    :MOD ( mod-27 / past)
                    :ARG0 ENTITY-3
                    :ARG1 ( GROUP-17 / AND
                           :op1 ( ENTITY-18 / Igkappa_expression)
                           :op2 ( ENTITY-19 / TNFalpha_production)))))

# ::id 89_nonfiction_GENIA-1999;99107757,6;NE
# ::snt We therefore propose that Hsp70 can be used as a vehicle for intracytoplasmic and intranuclear delivery of proteins or DNA to modulate gene expression and thereby control immune responses .
( EVENT-2 / propose
      :ARG0 ( REF1-1 / we)
      :THAT ( EVENT-13 / used
             :domain-of ( MD-32 / can)
             :ARG1 ( ENTITY-Hsp70 / ENTITY
                    :name ( n-35 / name
                           :op1 "Hsp70"))
             :AS ( ENTITY-3 / vehicle
                    :FOR ( ENTITY-4 / AND
                           :op1 ( ENTITY-6 / delivery
                                  :ATTRIBUTE ( ATTRIB-7 / intracytoplasmic))
                           :op2 ( ENTITY-8 / delivery
                                  :ATTRIBUTE ( ATTRIB-9 / intranuclear))
                           :OF ( GROUP-10 / or
                                  :op1 ( GROUP-11 / proteins)
                                  :op2 ( ENTITY-12 / DNA))))
             :TOCOMP ( CONJ-31 / and
                    :op1 ( EVENT-15 / modulate
                           :ARG0 ENTITY-Hsp70
                           :ARG1 ( ENTITY-14 / gene_expression))
                    :op2 ( EVENT-18 / control
                           :ARG0 ENTITY-Hsp70
                           :ARG1 ( GROUP-16 / responses
                                  :ATTRIBUTE ( ATTRIB-17 / immune))
                           :MOD ( mod-33 / thereby))))
      :MOD ( mod-34 / therefore))

# ::id 90_nonfiction_GENIA-1999;99107758,1;NE
# ::snt Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation .
( ENTITY-1 / Regulation
      :DURING ( ENTITY-5 / T_helper_cell_differentiation)
      :BY ( ENTITY-JunB / transcription_factor
             :DETERMINER ( ATTRIB-4 / the)
             :name ( n-1 / name
                    :op1 "JunB"))
      :OF ( ENTITY-2 / IL-4_expression))

# ::id 91_nonfiction_GENIA-1999;99107758,2;NE
# ::snt The molecular basis for restricted cytokine expression by T helper 1 -LRB- Th1 -RRB- and T helper 2 -LRB- Th2 -RRB- cells is unclear .
( EVENT-9 / copula
      :ATTRIBUTE ( ATTRIB-8 / unclear)
      :ARG0 ( ENTITY-1 / basis
             :DEFINITE ( ATTRIB-2 / the)
             :ATTRIBUTE ( ATTRIB-3 / molecular)
             :FOR ( ENTITY-4 / cytokine_expression
                    :ATTRIBUTE ( ATTRIB-5 / restricted)
                    :BY ( GROUP-7 / cells
                           :NAMELY ( GROUP-6 / AND
                                  :op1 ( ENTITY-T_helper_1 / ENTITY
                                         :name ( n-3 / name
                                                :op1 "Th1")
                                         :name ( n-1 / name
                                                :op1 "T_helper_1"))
                                  :op2 ( ENTITY-T_helper_2 / ENTITY
                                         :name ( n-4 / name
                                                :op1 "Th2")
                                         :name ( n-2 / name
                                                :op1 "T_helper_2")))))))

# ::id 92_nonfiction_GENIA-1999;99107758,3;NE
# ::snt Previous studies found that P1 , an element of the interleukin 4 -LRB- IL-4 -RRB- promoter that binds AP-1 , is important for Th2-restricted IL-4 expression .
( EVENT-3 / found
      :MOD ( mod-5 / past)
      :ARG0 ( GROUP-1 / studies
             :ATTRIBUTE ( ATTRIB-2 / previous))
      :THAT ( EVENT-12 / copula
             :ATTRIBUTE ( ATTRIB-9 / important
                    :FOR ( ENTITY-10 / IL-4_expression
                           :ATTRIBUTE ( ATTRIB-11 / th2-restricted)))
             :ARG0 ( ENTITY-P1 / element
                    :OF ( ENTITY-5 / interleukin_4_promoter
                           :DEFINITE ( ATTRIB-6 / the)
                           :ARG0-of ( EVENT-8 / binds
                                  :ARG1 ( ENTITY-AP-1 / ENTITY
                                         :name ( n-7 / name
                                                :op1 "AP-1")))
                           :NAMELY ( ENTITY-IL-4 / ENTITY
                                  :name ( n-8 / name
                                         :op1 "IL-4")))
                    :name ( n-6 / name
                           :op1 "P1"))))

# ::id 93_nonfiction_GENIA-1999;99107758,4;NE
# ::snt Here we show that JunB , but not the other Jun family members , was selectively induced in Th2 cells and not in Th1 cells during differentiation .
( EVENT-2 / show
      :ARG0 ( REF1-1 / we)
      :THAT ( CONJ-20 / and
             :op1 ( EVENT-10 / induced
                    :MOD ( mod-21 / past)
                    :ARG1 ( GROUP-3 / but
                           :op1 ( ENTITY-JunB / ENTITY
                                  :name ( n-24 / name
                                         :op1 "JunB"))
                           :op2 ( GROUP-4 / other_Jun_family_members
                                  :DEFINITE ( ATTRIB-6 / the)
                                  :QUANTIFIER ( ATTRIB-5 / not)))
                    :DURING ( ENTITY-9 / differentiation)
                    :IN ( GROUP-7 / Th2_cells))
             :op2 ( EVENT-10 / induced
                    :ARG1 GROUP-3
                    :DURING ( ENTITY-9 / differentiation)
                    :IN ( GROUP-8 / Th1_cells))
             :MOD ( mod-22 / selectively))
      :LOC ( LOC-23 / here))

# ::id 94_nonfiction_GENIA-1999;99107758,5;NE
# ::snt JunB has previously been considered to be a negative regulator of transcription .
( EVENT-1 / has_considered
      :ARG1 ( ENTITY-JunB / ENTITY
             :name ( n-2 / name
                    :op1 "JunB"))
      :TOCOMP ( EVENT-5 / copula
             :ARG0 ENTITY-JunB
             :ARG1 ( ENTITY-2 / regulator
                    :ATTRIBUTE ( ATTRIB-3 / negative)
                    :OF ( ENTITY-4 / transcription)))
      :TMP ( TIME-1 / previously))

# ::id 95_nonfiction_GENIA-1999;99107758,6;NE
# ::snt However , we show that JunB binds directly to the P1 site and synergizes with c-Maf to activate an IL-4 luciferase reporter gene .
( EVENT-2 / show
      :ARG0 ( REF1-1 / we)
      :THAT ( CONJ-15 / and
             :op1 ( EVENT-5 / binds
                    :ARG0 ( ENTITY-JunB / ENTITY
                           :name ( n-18 / name
                                  :op1 "JunB"))
                    :TO ( ENTITY-3 / P1_site
                           :DEFINITE ( ATTRIB-4 / the))
                    :MOD ( mod-16 / directly))
             :op2 ( EVENT-10 / synergizes
                    :ARG0 ENTITY-JunB
                    :PRP ( EVENT-9 / activate
                           :ARG0 ENTITY-JunB
                           :ARG1 ( ENTITY-8 / IL-4_luciferase_reporter_gene))
                    :WITH ( ENTITY-c-Maf / ENTITY
                           :name ( n-19 / name
                                  :op1 "c-Maf"))))
      :MOD ( mod-17 / however))

# ::id 96_nonfiction_GENIA-1999;99107758,7;NE
# ::snt JunB -control of IL-4 expression is mediated by the phosphorylation of JunB at Thr102 and -104 by JNK MAP kinase .
( EVENT-7 / is_mediated
      :ARG0 ( ENTITY-1 / JunB_-control
             :OF ( ENTITY-2 / IL-4_expression))
      :BY ( ENTITY-3 / phosphorylation
             :DEFINITE ( ATTRIB-4 / the)
             :BY ( ENTITY-6 / JNK_MAP_kinase)
             :AT ( GROUP-5 / AND
                    :op1 ( ENTITY-Thr102 / ENTITY
                           :name ( n-105 / name
                                  :op1 "Thr102"))
                    :op2 ( ENTITY--104 / ENTITY
                           :name ( n-106 / name
                                  :op1 "-104")))
             :OF ( ENTITY-JunB / ENTITY
                    :name ( n-107 / name
                           :op1 "JunB"))))

# ::id 97_nonfiction_GENIA-1999;99107758,8;NE
# ::snt The synergy between c-Maf and JunB can be attributed to cooperative DNA binding , which is facilitated by JunB phosphorylation .
( EVENT-9 / attributed
      :domain-of ( MD-10 / can)
      :ARG1 ( ENTITY-1 / synergy
             :DEFINITE ( ATTRIB-2 / the)
             :BETWEEN ( GROUP-3 / AND
                    :op1 ( ENTITY-c-Maf / ENTITY
                           :name ( n-11 / name
                                  :op1 "c-Maf"))
                    :op2 ( ENTITY-JunB / ENTITY
                           :name ( n-12 / name
                                  :op1 "JunB"))))
      :TO ( ENTITY-4 / DNA_binding
             :ATTRIBUTE ( ATTRIB-5 / cooperative)
             :ARG0-of ( EVENT-8 / is_facilitated
                    :BY ( ENTITY-7 / JunB_phosphorylation))))

# ::id 98_nonfiction_GENIA-1999;99107758,9;NE
# ::snt In transgenic mice , elevated JunB levels caused increased expression of several Th2 cytokines in developing Th1 cells .
( EVENT-9 / caused
      :MOD ( mod-1 / past)
      :ARG0 ( GROUP-3 / elevated_JunB_levels)
      :ARG1 ( ENTITY-4 / expression
             :ATTRIBUTE ( ATTRIB-5 / increased)
             :IN ( GROUP-8 / developing_Th1_cells)
             :OF ( GROUP-6 / Th2_cytokines
                    :QUANTIFIER ( ATTRIB-7 / several)))
      :IN ( GROUP-1 / mice
             :ATTRIBUTE ( ATTRIB-2 / transgenic)))

# ::id 99_nonfiction_GENIA-1999;99107758,10;NE
# ::snt JunB also upregulated IL-4 expression in response to immunization .
( EVENT-4 / upregulated
      :MOD ( mod-2 / past)
      :ARG0 ( ENTITY-JunB / ENTITY
             :name ( n-3 / name
                    :op1 "JunB"))
      :ARG1 ( ENTITY-1 / IL-4_expression
             :IN ( ENTITY-2 / response
                    :TO ( ENTITY-3 / immunization)))
      :MOD ( mod-1 / also))

# ::id 100_nonfiction_GENIA-1999;99107758,11;NE
# ::snt Thus , the early increase of JunB protein in Th2 cells can provide the specificity for c-Maf in IL-4 expression during T cell development and directs thereby Th2 differentiation .
( CONJ-18 / and
      :op1 ( EVENT-10 / provide
             :domain-of ( MD-17 / can)
             :ARG0 ( ENTITY-1 / increase
                    :DEFINITE ( ATTRIB-2 / the)
                    :ATTRIBUTE ( ATTRIB-3 / early)
                    :IN ( GROUP-5 / Th2_cells)
                    :OF ( ENTITY-4 / JunB_protein))
             :ARG1 ( ENTITY-6 / specificity
                    :DEFINITE ( ATTRIB-7 / the)
                    :IN ( ENTITY-8 / IL-4_expression)
                    :FOR ( ENTITY-c-Maf / ENTITY
                           :name ( n-21 / name
                                  :op1 "c-Maf")))
             :DURING ( ENTITY-9 / T_cell_development))
      :op2 ( EVENT-12 / directs
             :ARG0 ENTITY-1
             :ARG1 ( ENTITY-11 / Th2_differentiation)
             :MOD ( mod-19 / thereby))
      :MOD ( mod-20 / thus))

# ::id 101_nonfiction_GENIA-1999;99111186,1;NE
# ::snt Immunohistochemical study of c-fos-positive lymphocytes infiltrated into human squamous cell carcinomas of the head and neck during radiation therapy and its clinical significance .
( GROUP-1 / AND
      :op1 ( ENTITY-2 / study
             :ATTRIBUTE ( ATTRIB-3 / immunohistochemical)
             :OF ( GROUP-4 / lymphocytes
                    :ATTRIBUTE ( ATTRIB-5 / c-fos-positive)
                    :ARG0-of ( EVENT-16 / infiltrated
                           :DURING ( ENTITY-15 / radiation_therapy)
                           :INTO ( GROUP-7 / cell_carcinomas
                                  :ATTRIBUTE ( ATTRIB-9 / squamous)
                                  :ATTRIBUTE ( ATTRIB-8 / human)
                                  :OF ( ENTITY-10 / AND
                                         :DEFINITE ( ATTRIB-11 / the)
                                         :op1 ( ENTITY-13 / head)
                                         :op2 ( ENTITY-14 / neck))))))
      :op2 ( ENTITY-17 / significance
             :ATTRIBUTE ( ATTRIB-19 / clinical)
             :POS ( REF1-18 / its)))

# ::id 102_nonfiction_GENIA-1999;99111186,2;NE
# ::snt C-fos has been reported to be one of the immediate early genes in signal transduction systems after many kinds of stresses , including ionizing radiation .
( EVENT-1 / has_reported
      :ARG1 ( ENTITY-C-fos / ENTITY
             :name ( n-1 / name
                    :op1 "C-fos"))
      :TOCOMP ( EVENT-16 / copula
             :ARG0 ENTITY-C-fos
             :ARG1 ( ENTITY-2 / ENTITY
                    :OF ( GROUP-4 / genes
                           :DEFINITE ( ATTRIB-5 / the)
                           :ATTRIBUTE ( ATTRIB-7 / early)
                           :ATTRIBUTE ( ATTRIB-6 / immediate)
                           :IN ( GROUP-8 / signal_transduction_systems))
                    :CARDINAL ( ATTRIB-3 / one))
             :AFTER ( GROUP-9 / kinds
                    :OF ( GROUP-11 / stresses)
                    :QUANTIFIER ( ATTRIB-10 / many)
                    :ARG0-of ( EVENT-15 / including
                           :ARG1 ( ENTITY-13 / radiation
                                  :ATTRIBUTE ( ATTRIB-14 / ionizing))))))

# ::id 103_nonfiction_GENIA-1999;99111186,3;NE
# ::snt Changes in c-fos expression induced by radiation therapy in tumor tissues have not yet been reported .
( EVENT-7 / have_reported
      :domain-of ( NEG-9 / NEG)
      :ARG1 ( GROUP-1 / Changes
             :IN ( ENTITY-2 / c-fos_expression
                    :ARG0-of ( EVENT-6 / induced
                           :IN ( GROUP-5 / tumor_tissues)
                           :BY ( ENTITY-4 / radiation_therapy))))
      :TMP ( TIME-10 / yet))

# ::id 104_nonfiction_GENIA-1999;99111186,4;NE
# ::snt In this study , we have attempted to determine whether c-fos expression is induced by radiotherapy in human squamous cell carcinomas of the head and neck and to establish a possible correlation between c-fos expression and the therapeutic effects of radiation therapy .
( EVENT-4 / have_attempted
      :ARG0 ( REF1-3 / we)
      :IN ( ENTITY-1 / study
             :DETERMINER ( ATTRIB-2 / this))
      :TOCOMP ( CONJ-31 / and
             :op1 ( EVENT-5 / determine
                    :ARG0 REF1-3
                    :THAT ( EVENT-16 / is_induced
                           :domain-of ( QUEST-30 / QUEST)
                           :ARG0 ( ENTITY-6 / c-fos_expression)
                           :IN ( GROUP-8 / cell_carcinomas
                                  :ATTRIBUTE ( ATTRIB-10 / squamous)
                                  :ATTRIBUTE ( ATTRIB-9 / human)
                                  :OF ( ENTITY-11 / AND
                                         :DEFINITE ( ATTRIB-12 / the)
                                         :op1 ( ENTITY-14 / head)
                                         :op2 ( ENTITY-15 / neck)))
                           :BY ( ENTITY-7 / radiotherapy)))
             :op2 ( EVENT-25 / establish
                    :ARG0 REF1-3
                    :ARG1 ( ENTITY-17 / correlation
                           :ATTRIBUTE ( ATTRIB-18 / possible)
                           :BETWEEN ( GROUP-19 / AND
                                  :op1 ( ENTITY-20 / c-fos_expression)
                                  :op2 ( GROUP-21 / effects
                                         :DEFINITE ( ATTRIB-22 / the)
                                         :ATTRIBUTE ( ATTRIB-23 / therapeutic)
                                         :OF ( ENTITY-24 / radiation_therapy)))))))

# ::id 105_nonfiction_GENIA-1999;99111186,5;NE
# ::snt Twenty-seven patients with tumors of the oral cavity , oropharynx , and maxillary sinus were examined , all of which were confirmed as squamous cell carcinomas .
( EVENT-18 / examined
      :MOD ( mod-2 / past)
      :ARG1 ( GROUP-1 / patients
             :WITH ( GROUP-3 / tumors
                    :OF ( ENTITY-4 / AND
                           :DEFINITE ( ATTRIB-5 / the)
                           :op1 ( ENTITY-7 / cavity
                                  :ATTRIBUTE ( ATTRIB-8 / oral))
                           :op2 ( ENTITY-9 / oropharynx)
                           :op3 ( ENTITY-10 / sinus
                                  :ATTRIBUTE ( ATTRIB-11 / maxillary)))
                    :OF-of ( ENTITY-12 / ENTITY
                           :QUANTIFIER ( ATTRIB-13 / all)
                           :ARG1-of ( EVENT-17 / confirmed
                                  :MOD ( mod-1 / past)
                                  :AS ( GROUP-15 / cell_carcinomas
                                         :ATTRIBUTE ( ATTRIB-16 / squamous)))))
             :CARDINAL ( ATTRIB-2 / twenty-seven)))

# ::id 106_nonfiction_GENIA-1999;99111186,6;NE
# ::snt After obtaining the patients ' informed consent , biopsies were performed before treatment and at doses of 4 , 10 , and 20 Gy of radiotherapy .
( CRD-14 / After
      :op1 ( EVENT-6 / obtaining
             :ARG0 ( GROUP-1 / biopsies)
             :ARG1 ( ENTITY-2 / consent
                    :ATTRIBUTE ( ATTRIB-5 / informed)
                    :POS ( GROUP-3 / patients
                           :DEFINITE ( ATTRIB-4 / the))))
      :op2 ( CONJ-13 / and
             :op1 ( EVENT-12 / performed
                    :MOD ( mod-15 / past)
                    :ARG1 GROUP-1
                    :BEFORE ( ENTITY-7 / treatment))
             :op2 ( EVENT-12 / performed
                    :ARG1 GROUP-1
                    :AT ( GROUP-8 / doses
                           :OF ( ENTITY-9 / Gy
                                  :OF ( ENTITY-11 / radiotherapy)
                                  :CARDINAL ( ATTRIB-10 / 4,10,and_20))))))

# ::id 107_nonfiction_GENIA-1999;99111186,6;NE
# ::snt and the specimens were preserved in liquid nitrogen for further examination ,
( EVENT-7 / preserved
      :MOD ( mod-1 / past)
      :ARG1 ( GROUP-1 / specimens
             :DEFINITE ( ATTRIB-2 / the))
      :FOR ( ENTITY-5 / examination
             :ATTRIBUTE ( ATTRIB-6 / further))
      :IN ( ENTITY-3 / nitrogen
             :ATTRIBUTE ( ATTRIB-4 / liquid)))

# ::id 108_nonfiction_GENIA-1999;99111186,7;NE
# ::snt Serial sectioning of 6 micrometer was performed using a cryostat ,
( CONJ-8 / and
      :op1 ( EVENT-7 / performed
             :MOD ( mod-9 / past)
             :ARG1 ( ENTITY-1 / sectioning
                    :ATTRIBUTE ( ATTRIB-2 / serial)
                    :OF ( ENTITY-3 / micrometer
                           :CARDINAL ( ATTRIB-4 / 6))))
      :op2 ( EVENT-6 / using
             :ARG0 ENTITY-1
             :ARG1 ( ENTITY-5 / cryostat)))

# ::id 109_nonfiction_GENIA-1999;99111186,7;NE
# ::snt and samples were immunohistochemically stained using the streptoavidin-biotin peroxidase method and a monoclonal antibody against c-fos .
( CONJ-12 / and
      :op1 ( EVENT-9 / stained
             :MOD ( mod-13 / past)
             :ARG1 ( GROUP-1 / samples))
      :op2 ( EVENT-8 / using
             :ARG0 GROUP-1
             :ARG1 ( GROUP-2 / AND
                    :op1 ( ENTITY-3 / peroxidase_method
                           :DEFINITE ( ATTRIB-4 / the)
                           :ATTRIBUTE ( ATTRIB-5 / streptoavidin-biotin))
                    :op2 ( ENTITY-6 / antibody
                           :ATTRIBUTE ( ATTRIB-7 / monoclonal)
                           :AGAINST ( ENTITY-c-fos / ENTITY
                                  :name ( n-15 / name
                                         :op1 "c-fos")))))
      :MOD ( mod-14 / immunohistochemically))

# ::id 110_nonfiction_GENIA-1999;99111186,8;NE
# ::snt Three of the 27 patients with squamous cell carcinoma showed slight expression of c-fos in their tumor cells before and/or at 4 or 10 Gy of radiotherapy .
( CONJ-17 / and_slash_or
      :op1 ( EVENT-16 / showed
             :MOD ( mod-18 / past)
             :ARG0 ( ENTITY-1 / ENTITY
                    :OF ( GROUP-3 / patients
                           :DEFINITE ( ATTRIB-4 / the)
                           :CARDINAL ( ATTRIB-5 / 27))
                    :WITH ( ENTITY-squamous_cell_carcinoma / ENTITY
                           :name ( n-19 / name
                                  :op1 "squamous_cell_carcinoma"))
                    :CARDINAL ( ATTRIB-2 / three))
             :ARG1 ( ENTITY-6 / expression
                    :ATTRIBUTE ( ATTRIB-7 / slight)
                    :OF ( ENTITY-c-fos / ENTITY
                           :name ( n-20 / name
                                  :op1 "c-fos")))
             :BEFORE ( ENTITY-10 / Gy
                    :OF ( ENTITY-12 / radiotherapy)
                    :CARDINAL ( ATTRIB-11 / 4_or_10))
             :IN ( GROUP-8 / tumor_cells
                    :POS ( REF1-9 / their)))
      :op2 ( EVENT-16 / showed
             :ARG0 ENTITY-1
             :ARG1 ENTITY-6
             :AT ( ENTITY-13 / Gy
                    :OF ( ENTITY-15 / radiotherapy)
                    :CARDINAL ( ATTRIB-14 / 4_or_10))
             :IN GROUP-8))

# ::id 111_nonfiction_GENIA-1999;99111186,9;NE
# ::snt The tumors showed high radiosensitivity .
( EVENT-5 / showed
      :MOD ( mod-1 / past)
      :ARG0 ( GROUP-1 / tumors
             :DEFINITE ( ATTRIB-2 / the))
      :ARG1 ( ENTITY-3 / radiosensitivity
             :ATTRIBUTE ( ATTRIB-4 / high)))

# ::id 112_nonfiction_GENIA-1999;99111186,10;NE
# ::snt Concerning tumor-infiltrating lymphocytes , the rate of moderate or remarkable grades of c-fos-positive lymphocytes before radiotherapy and at radiation doses of 4 , 10 , and 20 Gy was 8.0 , 29.2 , 4.8 , and 0 % , respectively .
( CONJ-35 / and
      :op1 ( EVENT-22 / concerning
             :ARG0 ( CONJ-34 / and
                    :op1 ( ENTITY-1 / rate
                           :DEFINITE ( ATTRIB-2 / the)
                           :BEFORE ( ENTITY-11 / radiotherapy)
                           :OF ( ENTITY-3 / or
                                  :op1 ( GROUP-5 / grades
                                         :ATTRIBUTE ( ATTRIB-6 / moderate))
                                  :op2 ( GROUP-7 / grades
                                         :ATTRIBUTE ( ATTRIB-8 / remarkable))
                                  :OF ( GROUP-9 / lymphocytes
                                         :ATTRIBUTE ( ATTRIB-10 / c-fos-positive))))
                    :op2 ( ENTITY-1 / rate
                           :DEFINITE ATTRIB-2
                           :AT ( GROUP-12 / radiation_doses
                                  :OF ( GROUP-13 / AND
                                         :op1 ( ENTITY-14 / Gy
                                                :CARDINAL ( ATTRIB-15 / 4))
                                         :op2 ( ENTITY-16 / Gy
                                                :CARDINAL ( ATTRIB-17 / 10))
                                         :op3 ( ENTITY-18 / Gy
                                                :CARDINAL ( ATTRIB-19 / 20))))
                           :OF ENTITY-3))
             :ARG1 ( GROUP-20 / lymphocytes
                    :ATTRIBUTE ( ATTRIB-21 / tumor-infiltrating)))
      :op2 ( EVENT-32 / copula
             :MOD ( mod-37 / past)
             :ARG0 ENTITY-1
             :ARG1 ( GROUP-23 / AND
                    :op1 ( ENTITY-24 / percent
                           :CARDINAL ( ATTRIB-25 / 8.0))
                    :op2 ( ENTITY-26 / percent
                           :CARDINAL ( ATTRIB-27 / 29.2))
                    :op3 ( ENTITY-28 / percent
                           :CARDINAL ( ATTRIB-29 / 4.8))
                    :op4 ( ENTITY-30 / percent
                           :CARDINAL ( ATTRIB-31 / 0)))
             :MOD ( mod-36 / respectively)))

# ::id 113_nonfiction_GENIA-1999;99111186,11;NE
# ::snt The relationship between the immunohistochemical findings and the antitumor effect at a radiation dose of 20 Gy was examined on the corresponding H & E -stained sections .
( EVENT-17 / examined
      :MOD ( mod-1 / past)
      :ARG1 ( ENTITY-1 / relationship
             :DEFINITE ( ATTRIB-2 / the)
             :BETWEEN ( GROUP-3 / AND
                    :op1 ( GROUP-4 / findings
                           :DEFINITE ( ATTRIB-5 / the)
                           :ATTRIBUTE ( ATTRIB-6 / immunohistochemical))
                    :op2 ( ENTITY-7 / antitumor_effect
                           :DEFINITE ( ATTRIB-8 / the)
                           :AT ( ENTITY-9 / radiation_dose
                                  :OF ( ENTITY-10 / Gy
                                         :CARDINAL ( ATTRIB-11 / 20))))))
      :ON ( GROUP-12 / sections
             :DEFINITE ( ATTRIB-13 / the)
             :ATTRIBUTE ( ATTRIB-15 / -stained
                    :COMP ( GROUP-16 / AND
                           :op1 ( ENTITY-H / ENTITY
                                  :name ( n-2 / name
                                         :op1 "H"))
                           :op2 ( ENTITY-E / ENTITY
                                  :name ( n-3 / name
                                         :op1 "E"))))
             :ATTRIBUTE ( ATTRIB-14 / corresponding)))

# ::id 114_nonfiction_GENIA-1999;99111186,12;NE
# ::snt In patients whose infiltration of c-fos-positive lymphocytes into tumor tissues were moderate or remarkable at 4 Gy of radiotherapy , the tumors responded significantly well to radiation therapy -LRB- P < 0.025 , chi2 test -RRB- ,
( CONJ-22 / AND
      :op1 ( CONJ-18 / or
             :op1 ( EVENT-12 / copula
                    :MOD ( mod-19 / past)
                    :ATTRIBUTE ( ATTRIB-7 / moderate)
                    :ARG0 ( ENTITY-2 / infiltration
                           :INTO ( GROUP-6 / tumor_tissues)
                           :OF ( GROUP-4 / lymphocytes
                                  :ATTRIBUTE ( ATTRIB-5 / c-fos-positive))
                           :POS ( GROUP-1 / patients))
                    :AT ( ENTITY-9 / Gy
                           :OF ( ENTITY-11 / radiotherapy)
                           :CARDINAL ( ATTRIB-10 / 4)))
             :op2 ( EVENT-12 / copula
                    :ATTRIBUTE ( ATTRIB-8 / remarkable)
                    :ARG0 ENTITY-2
                    :AT ( ENTITY-9 / Gy
                           :OF ( ENTITY-11 / radiotherapy)
                           :CARDINAL ( ATTRIB-10 / 4))))
      :op2 ( EVENT-16 / responded
             :MOD ( mod-21 / past)
             :ARG0 ( GROUP-13 / tumors
                    :DEFINITE ( ATTRIB-14 / the))
             :TO ( ENTITY-15 / radiation_therapy)
             :IN GROUP-1
             :MOD ( mod-20 / significantly_well)))

# ::id 115_nonfiction_GENIA-1999;99111186,12;NE
# ::snt and the patients took a significantly favorable clinical course -LRB- P < 0.05 , chi2 test -RRB- .
( EVENT-6 / took
      :MOD ( mod-1 / past)
      :ARG0 ( GROUP-1 / patients
             :DEFINITE ( ATTRIB-2 / the))
      :ARG1 ( ENTITY-3 / course
             :ATTRIBUTE ( ATTRIB-5 / clinical)
             :ATTRIBUTE ( ATTRIB-4 / significantly_favorable)))

# ::id 116_nonfiction_GENIA-1999;99111186,13;NE
# ::snt In a sample from one of the patients , c-fos-positive lymphocytes were identified as CD4 positive and CD8 negative .
( EVENT-9 / identified
      :MOD ( mod-1 / past)
      :ARG1 ( GROUP-6 / lymphocytes
             :ATTRIBUTE ( ATTRIB-7 / c-fos-positive))
      :AS ( GROUP-8 / AND
             :op1 ( ENTITY-CD4_positive / ENTITY
                    :name ( n-2 / name
                           :op1 "CD4_positive"))
             :op2 ( ENTITY-CD8_negative / ENTITY
                    :name ( n-3 / name
                           :op1 "CD8_negative")))
      :IN ( ENTITY-1 / sample
             :FROM ( ENTITY-2 / ENTITY
                    :OF ( GROUP-4 / patients
                           :DEFINITE ( ATTRIB-5 / the))
                    :CARDINAL ( ATTRIB-3 / one))))

# ::id 117_nonfiction_GENIA-1999;99111186,14;NE
# ::snt Therefore , the high radiosensitivity of squamous cell carcinomas in our samples could be explained by an overexpression of c-fos in the tumor-infiltrating lymphocytes induced by small doses of radiation therapy ,
( EVENT-17 / explained
      :domain-of ( MD-20 / could)
      :ARG0 ( ENTITY-8 / overexpression
             :IN ( GROUP-9 / lymphocytes
                    :DEFINITE ( ATTRIB-10 / the)
                    :ATTRIBUTE ( ATTRIB-11 / tumor-infiltrating))
             :OF ( ENTITY-c-fos / ENTITY
                    :name ( n-22 / name
                           :op1 "c-fos"))
             :ARG0-of ( EVENT-16 / induced
                    :BY ( GROUP-13 / doses
                           :ATTRIBUTE ( ATTRIB-14 / small)
                           :OF ( ENTITY-15 / radiation_therapy))))
      :ARG1 ( ENTITY-1 / radiosensitivity
             :DEFINITE ( ATTRIB-2 / the)
             :ATTRIBUTE ( ATTRIB-3 / high)
             :OF ( GROUP-4 / cell_carcinomas
                    :ATTRIBUTE ( ATTRIB-5 / squamous)
                    :IN ( GROUP-6 / samples
                           :POS ( REF1-7 / our))))
      :MOD ( mod-21 / therefore))

# ::id 118_nonfiction_GENIA-1999;99111186,14;NE
# ::snt and these activated lymphocytes exerted a cytotoxic effect against the cancer cells .
( EVENT-8 / exerted
      :MOD ( mod-1 / past)
      :ARG0 ( GROUP-1 / lymphocytes
             :DETERMINER ( ATTRIB-2 / these)
             :ATTRIBUTE ( ATTRIB-3 / activated))
      :ARG1 ( ENTITY-4 / effect
             :ATTRIBUTE ( ATTRIB-5 / cytotoxic))
      :AGAINST ( GROUP-6 / cancer_cells
             :DEFINITE ( ATTRIB-7 / the)))

# ::id 119_nonfiction_GENIA-1999;99111421,1;NE
# ::snt CD2 signalling induces phosphorylation of CREB in primary lymphocytes .
( EVENT-5 / induces
      :ARG0 ( ENTITY-1 / CD2_signalling)
      :ARG1 ( ENTITY-2 / phosphorylation
             :OF ( ENTITY-CREB / ENTITY
                    :name ( n-1 / name
                           :op1 "CREB")))
      :IN ( GROUP-3 / lymphocytes
             :ATTRIBUTE ( ATTRIB-4 / primary)))

# ::id 120_nonfiction_GENIA-1999;99111421,2;NE
# ::snt Promoter sequences responsive to cyclic AMP -LRB- cAMP -RRB- are found in a number of cellular genes , and bind transcription factors of the cAMP response element binding protein -LRB- CREB -RRB- / activating transcription factor-1 -LRB- ATF-1 -RRB- family .
( CONJ-18 / and
      :op1 ( EVENT-9 / are_found
             :ARG0 ( GROUP-1 / Promoter_sequences
                    :ATTRIBUTE ( ATTRIB-2 / responsive
                           :TO ( ENTITY-4 / AMP
                                  :ATTRIBUTE ( ATTRIB-5 / cyclic)
                                  :NAMELY ( ENTITY-3 / cAMP))))
             :IN ( ENTITY-6 / number
                    :OF ( GROUP-7 / genes
                           :ATTRIBUTE ( ATTRIB-8 / cellular))))
      :op2 ( EVENT-17 / bind
             :ARG0 GROUP-1
             :ARG1 ( GROUP-10 / transcription_factors
                    :OF ( ENTITY-15 / cAMP_response_element_binding_protein
                           :DEFINITE ( ATTRIB-16 / the)
                           :NAMELY ( ENTITY-CREB / ENTITY
                                  :name ( n-19 / name
                                         :op1 "CREB"))
                           :NAMELY ( ENTITY-13 / transcription_factor-1
                                  :ATTRIBUTE ( ATTRIB-14 / activating))
                           :NAMELY ( ENTITY-12 / family)
                           :NAMELY ( ENTITY-11 / ATF-1)))))

# ::id 121_nonfiction_GENIA-1999;99111421,3;NE
# ::snt We have used a human T-lymphotropic virus type 1 -LRB- HTLV-1 -RRB- model of cAMP response element -LRB- CRE -RRB- transcription to investigate the influence of lymphocyte activation on transcription from homologous regions in the viral promoter .
( EVENT-8 / have_used
      :ARG0 ( REF1-1 / we)
      :ARG1 ( ENTITY-3 / virus_type_1_model
             :ATTRIBUTE ( ATTRIB-5 / t-lymphotropic)
             :ATTRIBUTE ( ATTRIB-4 / human)
             :OF ( ENTITY-7 / cAMP_response_element_transcription
                    :NAMELY ( ENTITY-6 / CRE))
             :NAMELY ( ENTITY-2 / HTLV-1))
      :TOCOMP ( EVENT-18 / investigate
             :ARG0 ENTITY-3
             :ARG1 ( ENTITY-9 / influence
                    :DEFINITE ( ATTRIB-10 / the)
                    :ON ( ENTITY-12 / transcription
                           :FROM ( GROUP-13 / regions
                                  :ATTRIBUTE ( ATTRIB-14 / homologous)
                                  :IN ( ENTITY-15 / promoter
                                         :DEFINITE ( ATTRIB-16 / the)
                                         :ATTRIBUTE ( ATTRIB-17 / viral))))
                    :OF ( ENTITY-11 / lymphocyte_activation))))

# ::id 122_nonfiction_GENIA-1999;99111421,4;NE
# ::snt We previously demonstrated increased HTLV-1 transcription following CD2 but not CD3 receptor cross-linking .
( EVENT-8 / demonstrated
      :MOD ( mod-1 / past)
      :ARG0 ( REF1-1 / we)
      :ARG1 ( ENTITY-2 / increased_HTLV-1_transcription
             :ARG0-of ( EVENT-7 / following
                    :ARG1 ( ENTITY-6 / receptor_cross-linking
                           :NAMELY ( GROUP-4 / but
                                  :op1 ( ENTITY-CD2 / ENTITY
                                         :name ( n-4 / name
                                                :op1 "CD2"))
                                  :op2 ( ENTITY-CD3 / ENTITY
                                         :name ( n-3 / name
                                                :op1 "CD3")
                                         :QUANTIFIER ( ATTRIB-5 / not))))))
      :TMP ( TIME-2 / previously))

# ::id 123_nonfiction_GENIA-1999;99111421,5;NE
# ::snt We hypothesized that this increased viral transcription was mediated , in part , through the phosphorylation of CREB .
( EVENT-2 / hypothesized
      :MOD ( mod-2 / past)
      :ARG0 ( REF1-1 / we)
      :THAT ( EVENT-10 / was_mediated
             :MOD ( mod-1 / past)
             :ARG0 ( ENTITY-3 / transcription
                    :DETERMINER ( ATTRIB-4 / this)
                    :ATTRIBUTE ( ATTRIB-6 / viral)
                    :ATTRIBUTE ( ATTRIB-5 / increased))
             :THROUGH ( ENTITY-8 / phosphorylation
                    :DEFINITE ( ATTRIB-9 / the)
                    :OF ( ENTITY-CREB / ENTITY
                           :name ( n-3 / name
                                  :op1 "CREB")))
             :IN ( ENTITY-7 / part)))

# ::id 124_nonfiction_GENIA-1999;99111421,6;NE
# ::snt Therefore , we investigated CD2 and CD3 receptor-mediated signalling in primary human peripheral blood mononuclear cells -LRB- PBMC -RRB- .
( EVENT-8 / investigated
      :MOD ( mod-2 / past)
      :ARG0 ( REF1-1 / we)
      :ARG1 ( ENTITY-3 / signalling
             :ATTRIBUTE ( ATTRIB-4 / receptor-mediated)
             :NAMELY ( GROUP-2 / AND
                    :op1 ( ENTITY-CD2 / ENTITY
                           :name ( n-3 / name
                                  :op1 "CD2"))
                    :op2 ( ENTITY-CD3 / ENTITY
                           :name ( n-4 / name
                                  :op1 "CD3"))))
      :IN ( GROUP-5 / peripheral_blood_mononuclear_cells
             :ATTRIBUTE ( ATTRIB-7 / human)
             :ATTRIBUTE ( ATTRIB-6 / primary)
             :NAMELY ( ENTITY-PBMC / ENTITY
                    :name ( n-5 / name
                           :op1 "PBMC")))
      :MOD ( mod-1 / therefore))

# ::id 125_nonfiction_GENIA-1999;99111421,7;NE
# ::snt CD2 , but not CD3 , cross-linking increased cAMP detected by competitive enzyme-linked immunosorbent assay -LRB- ELISA -RRB- approximately fourfold .
( EVENT-9 / increased
      :MOD ( mod-2 / past)
      :ARG0 ( ENTITY-3 / cross-linking
             :NAMELY ( GROUP-1 / but
                    :op1 ( ENTITY-CD2 / ENTITY
                           :name ( n-5 / name
                                  :op1 "CD2"))
                    :op2 ( ENTITY-CD3 / ENTITY
                           :name ( n-3 / name
                                  :op1 "CD3")
                           :QUANTIFIER ( ATTRIB-2 / not))))
      :ARG1 ( ENTITY-cAMP / ENTITY
             :name ( n-4 / name
                    :op1 "cAMP")
             :ARG1-of ( EVENT-8 / detected
                    :ARG0 ( ENTITY-5 / immunosorbent_assay
                           :ATTRIBUTE ( ATTRIB-7 / enzyme-linked)
                           :ATTRIBUTE ( ATTRIB-6 / competitive)
                           :NAMELY ( ENTITY-ELISA / ENTITY
                                  :name ( n-6 / name
                                         :op1 "ELISA")))))
      :MOD ( mod-1 / approximately_fourfold))

# ::id 126_nonfiction_GENIA-1999;99111421,8;NE
# ::snt CD2 cross-linking concurrently increased phosphorylation of CREB detected by immunoblot assay eightfold .
( EVENT-6 / increased
      :MOD ( mod-2 / past)
      :ARG0 ( ENTITY-1 / CD2_cross-linking)
      :ARG1 ( ENTITY-2 / phosphorylation
             :OF ( ENTITY-CREB / ENTITY
                    :name ( n-4 / name
                           :op1 "CREB"))
             :ARG1-of ( EVENT-5 / detected
                    :ARG0 ( ENTITY-4 / immunoblot_assay)))
      :MOD ( mod-1 / eightfold)
      :MOD ( mod-3 / concurrently))

# ::id 127_nonfiction_GENIA-1999;99111421,9;NE
# ::snt Consistent with post-translational regulation , no change in total level of CREB protein was observed .
( CONJ-11 / and
      :op1 ( EVENT-10 / observed
             :MOD ( mod-12 / past)
             :ARG1 ( ENTITY-1 / change
                    :IN ( ENTITY-3 / level
                           :ATTRIBUTE ( ATTRIB-4 / total)
                           :OF ( ENTITY-5 / CREB_protein))
                    :QUANTIFIER ( ATTRIB-2 / no)))
      :op2 ( EVENT-9 / EVENT
             :ATTRIBUTE ( ATTRIB-6 / consistent
                    :WITH ( ENTITY-7 / regulation
                           :ATTRIBUTE ( ATTRIB-8 / post-translational)))
             :ARG0 ENTITY-1))

# ::id 128_nonfiction_GENIA-1999;99111421,10;NE
# ::snt Phosphorylation of CREB occurred through a herbimycin A and Rp-cAMP -sensitive pathway , suggesting phosphorylation required antecedent activation of both protein tyrosine kinases -LRB- PTK -RRB- and protein kinase A -LRB- PKA -RRB- .
( CONJ-16 / and
      :op1 ( EVENT-15 / occurred
             :MOD ( mod-17 / past)
             :ARG0 ( ENTITY-1 / Phosphorylation
                    :OF ( ENTITY-CREB / ENTITY
                           :name ( n-20 / name
                                  :op1 "CREB")))
             :THROUGH ( ENTITY-2 / pathway
                    :ATTRIBUTE ( ATTRIB-3 / -sensitive
                           :COMP ( GROUP-4 / AND
                                  :op1 ( ENTITY-herbimycin_A / ENTITY
                                         :name ( n-21 / name
                                                :op1 "herbimycin_A"))
                                  :op2 ( ENTITY-Rp-cAMP / ENTITY
                                         :name ( n-22 / name
                                                :op1 "Rp-cAMP"))))))
      :op2 ( EVENT-5 / suggesting
             :ARG0 ENTITY-1
             :THAT ( EVENT-14 / required
                    :MOD ( mod-18 / past)
                    :ARG0 ( ENTITY-6 / phosphorylation)
                    :ARG1 ( ENTITY-7 / activation
                           :ATTRIBUTE ( ATTRIB-8 / antecedent)
                           :OF ( group-9 / AND
                                  :op1 ( GROUP-13 / protein_tyrosine_kinases
                                         :NAMELY ( ENTITY-12 / PTK))
                                  :op2 ( ENTITY-protein_kinase_A / ENTITY
                                         :name ( n-23 / name
                                                :op1 "PKA")
                                         :name ( n-19 / name
                                                :op1 "protein_kinase_A"))
                                  :QUANTIFIER ( ATTRIB-10 / both))))))

# ::id 129_nonfiction_GENIA-1999;99111421,11;NE
# ::snt Both CD2 and CD3 cross-linking increased binding of nuclear proteins to a radiolabelled CRE oligonucleotide probe in electrophoretic mobility shift assays suggesting that lymphocyte activation enhances binding independently of phosphorylation of CREB at serine 133 .
( CONJ-17 / and
      :op1 ( EVENT-16 / increased
             :MOD ( mod-18 / past)
             :ARG0 ( ENTITY-2 / cross-linking
                    :NAMELY ( GROUP-1 / AND
                           :op1 ( ENTITY-CD2 / ENTITY
                                  :name ( n-20 / name
                                         :op1 "CD2"))
                           :op2 ( ENTITY-CD3 / ENTITY
                                  :name ( n-21 / name
                                         :op1 "CD3"))))
             :ARG1 ( ENTITY-3 / binding
                    :IN ( GROUP-8 / mobility_shift_assays
                           :ATTRIBUTE ( ATTRIB-9 / electrophoretic))
                    :TO ( ENTITY-6 / CRE_oligonucleotide_probe
                           :ATTRIBUTE ( ATTRIB-7 / radiolabelled))
                    :OF ( GROUP-4 / proteins
                           :ATTRIBUTE ( ATTRIB-5 / nuclear))))
      :op2 ( EVENT-10 / suggesting
             :ARG0 ENTITY-3
             :THAT ( EVENT-14 / enhances
                    :ARG0 ( ENTITY-11 / lymphocyte_activation)
                    :ARG1 ( ENTITY-12 / binding)
                    :MOD ( mod-19 / independently
                           :OF ( ENTITY-13 / phosphorylation
                                  :AT ( ENTITY-serine_133 / ENTITY
                                         :name ( n-22 / name
                                                :op1 "serine_133"))
                                  :OF ( ENTITY-CREB / ENTITY
                                         :name ( n-23 / name
                                                :op1 "CREB")))))))

# ::id 130_nonfiction_GENIA-1999;99111421,12;NE
# ::snt These data indicate specific modulation of the CREB/ATF-1 family of transcription factors by the CD2 signalling pathway and suggest CD2 receptor modulation of CRE-mediated transcription following ligand engagement -LRB- e.g. cell-to-cell contact -RRB- .
( CONJ-20 / and
      :op1 ( EVENT-10 / indicate
             :ARG0 ( GROUP-1 / data
                    :DETERMINER ( ATTRIB-2 / these))
             :ARG1 ( ENTITY-3 / modulation
                    :ATTRIBUTE ( ATTRIB-4 / specific)
                    :BY ( ENTITY-8 / CD2_signalling_pathway
                           :DEFINITE ( ATTRIB-9 / the))
                    :OF ( ENTITY-5 / CREB_slash_ATF-1_family
                           :DEFINITE ( ATTRIB-6 / the)
                           :OF ( GROUP-7 / transcription_factors))))
      :op2 ( EVENT-19 / suggest
             :ARG0 GROUP-1
             :ARG1 ( ENTITY-11 / CD2_receptor_modulation
                    :OF ( ENTITY-12 / transcription
                           :ATTRIBUTE ( ATTRIB-13 / cre-mediated))
                    :E_DOT_G_DOT ( ENTITY-14 / contact
                           :ATTRIBUTE ( ATTRIB-15 / cell-to-cell))
                    :ARG0-of ( EVENT-18 / following
                           :ARG1 ( ENTITY-17 / ligand_engagement)))))

# ::id 131_nonfiction_GENIA-1999;99113717,1;NE
# ::snt Protective effects of notch-1 on TCR-induced apoptosis .
( GROUP-1 / effects
      :ATTRIBUTE ( ATTRIB-2 / protective)
      :ON ( ENTITY-3 / apoptosis
             :ATTRIBUTE ( ATTRIB-4 / tcr-induced))
      :OF ( ENTITY-notch-1 / ENTITY
             :name ( n-2 / name
                    :op1 "notch-1")))

# ::id 132_nonfiction_GENIA-1999;99113717,2;NE
# ::snt The Notch receptor protein was originally identified in Drosophila and is known to mediate cell to cell communication and influence cell fate decisions .
( CONJ-13 / and
      :op1 ( EVENT-3 / identified
             :MOD ( mod-15 / past)
             :ARG1 ( ENTITY-1 / Notch_receptor_protein
                    :DEFINITE ( ATTRIB-2 / the))
             :IN ( ENTITY-Drosophila / ENTITY
                    :name ( n-17 / name
                           :op1 "Drosophila"))
             :MOD ( mod-14 / originally))
      :op2 ( EVENT-5 / is_known
             :ARG0 ENTITY-1
             :TOCOMP ( CONJ-12 / and
                    :op1 ( EVENT-8 / mediate
                           :ARG0 ENTITY-1
                           :ARG1 ( ENTITY-6 / communication
                                  :ATTRIBUTE ( ATTRIB-7 / to
                                         :MOD ( mod-16 / cell_cell))))
                    :op2 ( EVENT-10 / influence
                           :ARG0 ENTITY-1
                           :ARG1 ( GROUP-9 / cell_fate_decisions)))))

# ::id 133_nonfiction_GENIA-1999;99113717,3;NE
# ::snt Members of this family have been isolated from invertebrates as well as vertebrates .
( EVENT-6 / have_isolated
      :ARG1 ( GROUP-1 / Members
             :OF ( ENTITY-2 / family
                    :DETERMINER ( ATTRIB-3 / this)))
      :FROM ( GROUP-4 / invertebrates)
      :MOD ( mod-1 / as_well
             :AS ( GROUP-5 / vertebrates)))

# ::id 134_nonfiction_GENIA-1999;99113717,4;NE
# ::snt We isolated mouse Notch-1 in a yeast two-hybrid screen with Nur77 , which is a protein that has been shown previously to be required for apoptosis in T cell lines .
( EVENT-12 / isolated
      :MOD ( mod-3 / past)
      :ARG0 ( REF1-1 / we)
      :ARG1 ( ENTITY-mouse_Notch-1 / ENTITY
             :name ( n-5 / name
                    :op1 "mouse_Notch-1"))
      :WITH ( ENTITY-Nur77 / ENTITY
             :name ( n-4 / name
                    :op1 "Nur77")
             :ARG0-of ( EVENT-11 / copula
                    :ARG1 ( ENTITY-4 / protein
                           :ARG1-of ( EVENT-6 / has_shown
                                  :TOCOMP ( EVENT-9 / required
                                         :ARG1 ENTITY-4
                                         :FOR ( ENTITY-7 / apoptosis
                                                :IN ( GROUP-8 / T_cell_lines)))
                                  :TMP ( TIME-2 / previously)))))
      :IN ( ENTITY-2 / yeast_two-hybrid_screen))

# ::id 135_nonfiction_GENIA-1999;99113717,5;NE
# ::snt The data presented below indicate that Notch-1 expression provides significant protection to T cell lines from TCR-mediated apoptosis .
( EVENT-5 / indicate
      :ARG0 ( GROUP-1 / data
             :DEFINITE ( ATTRIB-2 / the)
             :ARG1-of ( EVENT-4 / presented))
      :THAT ( EVENT-12 / provides
             :ARG0 ( ENTITY-6 / Notch-1_expression)
             :ARG1 ( ENTITY-7 / protection
                    :ATTRIBUTE ( ATTRIB-8 / significant))
             :FROM ( ENTITY-10 / apoptosis
                    :ATTRIBUTE ( ATTRIB-11 / tcr-mediated))
             :TO ( GROUP-9 / T_cell_lines)))

# ::id 136_nonfiction_GENIA-1999;99113717,6;NE
# ::snt These data demonstrate a new antiapoptotic role for Notch-1 , providing evidence that , in addition to regulating cell fate decisions , Notch-1 can play a critical role in controlling levels of cell death in T cells .
( CONJ-23 / and
      :op1 ( EVENT-20 / demonstrate
             :ARG0 ( GROUP-1 / data
                    :DETERMINER ( ATTRIB-2 / these))
             :ARG1 ( ENTITY-3 / role
                    :ATTRIBUTE ( ATTRIB-5 / antiapoptotic)
                    :ATTRIBUTE ( ATTRIB-4 / new)
                    :FOR ( ENTITY-Notch-1 / ENTITY
                           :name ( n-24 / name
                                  :op1 "Notch-1"))))
      :op2 ( EVENT-19 / providing
             :ARG0 ENTITY-3
             :ARG1 ( ENTITY-6 / evidence
                    :THAT ( EVENT-18 / play
                           :domain-of ( MD-22 / can)
                           :ARG0 ENTITY-Notch-1
                           :ARG1 ( ENTITY-11 / role
                                  :ATTRIBUTE ( ATTRIB-12 / critical)
                                  :IN ( EVENT-17 / controlling
                                         :ARG1 ( GROUP-14 / levels
                                                :IN ( GROUP-16 / T_cells)
                                                :OF ( ENTITY-15 / cell_death))))
                           :IN ( ENTITY-7 / addition
                                  :TO ( EVENT-10 / regulating
                                         :ARG1 ( GROUP-9 / cell_fate_decisions)))))))

# ::id 137_nonfiction_GENIA-1999;99113747,1;NE
# ::snt T cell priming enhances IL-4 gene expression by increasing nuclear factor of activated T cells .
( CRD-8 / by
      :op1 ( EVENT-6 / increasing
             :ARG0 ENTITY-2
             :ARG1 ( ENTITY-3 / factor
                    :ATTRIBUTE ( ATTRIB-4 / nuclear)
                    :OF ( GROUP-5 / activated_T_cells)))
      :op2 ( EVENT-7 / enhances
             :ARG0 ( ENTITY-1 / T_cell_priming)
             :ARG1 ( ENTITY-2 / IL-4_gene_expression)))

# ::id 138_nonfiction_GENIA-1999;99113747,2;NE
# ::snt The repetitive activation of T cells -LRB- priming -RRB- enhances the expression of many cytokines , such as IL-4 , but not others , such as IL-2 .
( EVENT-15 / enhances
      :ARG0 ( ENTITY-2 / activation
             :DEFINITE ( ATTRIB-3 / the)
             :ATTRIBUTE ( ATTRIB-4 / repetitive)
             :OF ( GROUP-5 / T_cells)
             :NAMELY ( ENTITY-1 / priming))
      :ARG1 ( ENTITY-6 / expression
             :DEFINITE ( ATTRIB-7 / the)
             :OF ( GROUP-8 / but
                    :op1 ( GROUP-9 / cytokines
                           :ATTRIBUTE ( ATTRIB-11 / such
                                  :AS ( ENTITY-IL-4 / ENTITY
                                         :name ( n-5 / name
                                                :op1 "IL-4")))
                           :QUANTIFIER ( ATTRIB-10 / many))
                    :op2 ( GROUP-12 / others
                           :ATTRIBUTE ( ATTRIB-14 / such
                                  :AS ( ENTITY-IL-2 / ENTITY
                                         :name ( n-6 / name
                                                :op1 "IL-2")))
                           :QUANTIFIER ( ATTRIB-13 / not)))))

# ::id 139_nonfiction_GENIA-1999;99113747,3;NE
# ::snt Molecular mechanisms underlying selective expression of cytokines by T cells remain poorly understood .
( EVENT-10 / remain
      :ATTRIBUTE ( ATTRIB-9 / poorly_understood)
      :ARG0 ( GROUP-1 / mechanisms
             :ATTRIBUTE ( ATTRIB-2 / molecular)
             :ARG0-of ( EVENT-8 / underlying
                    :ARG1 ( ENTITY-4 / expression
                           :ATTRIBUTE ( ATTRIB-5 / selective)
                           :BY ( GROUP-7 / T_cells)
                           :OF ( GROUP-6 / cytokines)))))

# ::id 140_nonfiction_GENIA-1999;99113747,4;NE
# ::snt Here we show that priming of CD4 T cells selectively enhances IL-4 expression relative to IL-2 expression by a transcriptional mechanism involving nuclear factor of activated T cells -LRB- NFAT -RRB- proteins .
( EVENT-2 / show
      :ARG0 ( REF1-1 / we)
      :THAT ( EVENT-16 / enhances
             :ARG0 ( ENTITY-3 / priming
                    :OF ( GROUP-4 / CD4_T_cells))
             :ARG1 ( ENTITY-5 / IL-4_expression
                    :ATTRIBUTE ( ATTRIB-6 / relative
                           :TO ( ENTITY-7 / IL-2_expression)))
             :BY ( ENTITY-8 / mechanism
                    :ATTRIBUTE ( ATTRIB-9 / transcriptional)
                    :ARG0-of ( EVENT-15 / involving
                           :ARG1 ( GROUP-12 / factor_proteins
                                  :ATTRIBUTE ( ATTRIB-13 / nuclear)
                                  :OF ( GROUP-14 / activated_T_cells)
                                  :NAMELY ( ENTITY-11 / NFAT))))
             :MOD ( mod-1 / selectively))
      :LOC ( LOC-2 / here))

# ::id 141_nonfiction_GENIA-1999;99113747,5;NE
# ::snt As detected by in vivo footprinting , priming markedly increases the activation-dependent engagement of the P0 and P1 NFAT -binding elements of the IL-4 promoter .
( CRD-17 / As
      :op1 ( EVENT-4 / detected
             :ARG0 ( ENTITY-2 / footprinting
                    :ATTRIBUTE ( ATTRIB-3 / in_vivo))
             :ARG1 ( ENTITY-1 / priming))
      :op2 ( EVENT-15 / increases
             :ARG0 ENTITY-1
             :ARG1 ( ENTITY-5 / engagement
                    :DEFINITE ( ATTRIB-6 / the)
                    :ATTRIBUTE ( ATTRIB-7 / activation-dependent)
                    :OF ( GROUP-8 / elements
                           :DEFINITE ( ATTRIB-9 / the)
                           :ATTRIBUTE ( ATTRIB-10 / -binding
                                  :COMP ( ENTITY-12 / NFAT
                                         :NAMELY ( GROUP-11 / AND
                                                :op1 ( ENTITY-P0 / ENTITY
                                                       :name ( n-19 / name
                                                              :op1 "P0"))
                                                :op2 ( ENTITY-P1 / ENTITY
                                                       :name ( n-20 / name
                                                              :op1 "P1")))))
                           :OF ( ENTITY-13 / IL-4_promoter
                                  :DEFINITE ( ATTRIB-14 / the))))
             :MOD ( mod-18 / markedly)))

# ::id 142_nonfiction_GENIA-1999;99113747,6;NE
# ::snt Moreover , each proximal P element is essential for optimal IL-4 promoter activity .
( EVENT-5 / copula
      :ATTRIBUTE ( ATTRIB-3 / essential
             :FOR ( ENTITY-4 / optimal_IL-4_promoter_activity))
      :ARG0 ( ENTITY-1 / proximal_P_element
             :QUANTIFIER ( ATTRIB-2 / each))
      :MOD ( mod-1 / moreover))

# ::id 143_nonfiction_GENIA-1999;99113747,7;NE
# ::snt Activated primed CD4 T cells contain more NFAT1 and support greater NFAT-directed transcription than unprimed CD4 T cells , while activator protein 1 binding and activator protein 1-mediated transcription by both cell types is similar .
( CRD-21 / while
      :op1 ( EVENT-11 / copula
             :ATTRIBUTE ( ATTRIB-10 / similar)
             :ARG0 ( GROUP-3 / AND
                    :op1 ( ENTITY-4 / activator_protein_1_binding
                           :BY ( GROUP-5 / cell_types
                                  :QUANTIFIER ( ATTRIB-6 / both)))
                    :op2 ( ENTITY-7 / activator_protein_1-mediated_transcription
                           :BY ( GROUP-8 / cell_types
                                  :QUANTIFIER ( ATTRIB-9 / both)))))
      :op2 ( CONJ-20 / and
             :op1 ( EVENT-15 / contain
                    :ARG0 ( GROUP-1 / CD4_T_cells
                           :ATTRIBUTE ( ATTRIB-2 / activated_primed))
                    :ARG1 ( ENTITY-12 / NFAT1
                           :THAN ( GROUP-14 / unprimed_CD4_T_cells)
                           :QUANTIFIER ( ATTRIB-13 / more)))
             :op2 ( EVENT-19 / support
                    :ATTRIBUTE ( ATTRIB-16 / greater
                           :COMP ( ENTITY-17 / transcription
                                  :ATTRIBUTE ( ATTRIB-18 / nfat-directed)))
                    :ARG0 GROUP-1)))

# ::id 144_nonfiction_GENIA-1999;99113747,8;NE
# ::snt Increased expression of wild-type NFAT1 substantially increases IL-4 promoter activity in unprimed CD4 T cells , suggesting NFAT1 may be limiting for IL-4 gene expression in this cell type .
( CONJ-20 / and
      :op1 ( EVENT-13 / increases
             :ARG0 ( ENTITY-1 / expression
                    :ATTRIBUTE ( ATTRIB-2 / increased)
                    :OF ( ENTITY-3 / NFAT1
                           :ATTRIBUTE ( ATTRIB-4 / wild-type)))
             :ARG1 ( ENTITY-5 / IL-4_promoter_activity)
             :IN ( GROUP-6 / unprimed_CD4_T_cells))
      :op2 ( EVENT-7 / suggesting
             :ARG0 ENTITY-5
             :THAT ( EVENT-12 / be_limiting
                    :domain-of ( MD-19 / may)
                    :ARG0 ( ENTITY-8 / NFAT1)
                    :FOR ( ENTITY-9 / IL-4_gene_expression
                           :IN ( ENTITY-10 / cell_type
                                  :DETERMINER ( ATTRIB-11 / this)))))
      :MOD ( mod-21 / substantially))

# ::id 145_nonfiction_GENIA-1999;99113747,9;NE
# ::snt Furthermore , a truncated form of NFAT1 acts as a dominant-negative , reducing IL-4 promoter activity in primed CD4 T cells and confirming the importance of endogenous NFAT to increased IL-4 gene expression by effector T cells .
( CONJ-21 / and
      :op1 ( EVENT-16 / acts
             :ARG0 ( ENTITY-1 / form
                    :ATTRIBUTE ( ATTRIB-2 / truncated)
                    :OF ( ENTITY-3 / NFAT1))
             :AS ( ENTITY-4 / ENTITY
                    :ATTRIBUTE ( ATTRIB-5 / dominant-negative)))
      :op2 ( CONJ-20 / and
             :op1 ( EVENT-8 / reducing
                    :ARG0 ENTITY-1
                    :ARG1 ( ENTITY-6 / IL-4_promoter_activity)
                    :IN ( GROUP-7 / primed_CD4_T_cells))
             :op2 ( EVENT-15 / confirming
                    :ARG0 ENTITY-1
                    :ARG1 ( ENTITY-9 / importance
                           :DEFINITE ( ATTRIB-10 / the)
                           :TO ( ENTITY-13 / increased_IL-4_gene_expression
                                  :BY ( GROUP-14 / effector_T_cells))
                           :OF ( ENTITY-11 / NFAT
                                  :ATTRIBUTE ( ATTRIB-12 / endogenous)))))
      :MOD ( mod-22 / furthermore))

# ::id 146_nonfiction_GENIA-1999;99113747,10;NE
# ::snt NFAT1 appears to be the major NFAT family member responsible for the initial increased expression of IL-4 by primed CD4 T cells .
( EVENT-2 / appears
      :TOCOMP ( EVENT-11 / copula
             :ARG0 ( ENTITY-1 / NFAT1)
             :ARG1 ( ENTITY-3 / major_NFAT_family_member
                    :DEFINITE ( ATTRIB-4 / the)
                    :ATTRIBUTE ( ATTRIB-5 / responsible
                           :FOR ( ENTITY-6 / expression
                                  :DEFINITE ( ATTRIB-7 / the)
                                  :ATTRIBUTE ( ATTRIB-9 / increased)
                                  :ATTRIBUTE ( ATTRIB-8 / initial)
                                  :BY ( GROUP-10 / primed_CD4_T_cells)
                                  :OF ( ENTITY-IL-4 / ENTITY
                                         :name ( n-5 / name
                                                :op1 "IL-4")))))))

# ::id 147_nonfiction_GENIA-1999;99115412,1;NE
# ::snt Anoxia/reoxygenation-induced tolerance with respect to polymorphonuclear leukocyte adhesion to cultured endothelial cells .
( ENTITY-1 / tolerance
      :ATTRIBUTE ( ATTRIB-2 / anoxia_slash_reoxygenation-induced)
      :WITH ( ENTITY-3 / respect
             :TO ( ENTITY-4 / leukocyte_adhesion
                    :ATTRIBUTE ( ATTRIB-5 / polymorphonuclear)
                    :TO ( GROUP-6 / cells
                           :ATTRIBUTE ( ATTRIB-8 / endothelial)
                           :ATTRIBUTE ( ATTRIB-7 / cultured)))))

# ::id 148_nonfiction_GENIA-1999;99115412,2;NE
# ::snt A nuclear factor -kappaB -mediated phenomenon .
( ENTITY-1 / phenomenon
      :ATTRIBUTE ( ATTRIB-2 / -mediated
             :COMP ( ENTITY-3 / factor_-kappaB
                    :ATTRIBUTE ( ATTRIB-4 / nuclear))))

# ::id 149_nonfiction_GENIA-1999;99115412,3;NE
# ::snt Exposing human umbilical vein endothelial cells -LRB- HUVECs -RRB- to anoxia/reoxygenation -LRB- A/R -RRB- results in an increase in polymorphonuclear leukocyte -LRB- PMN -RRB- adhesion to HUVECs .
( EVENT-12 / results
      :ARG0 ( EVENT-6 / exposing
             :ARG1 ( GROUP-3 / vein_endothelial_cells
                    :ATTRIBUTE ( ATTRIB-5 / umbilical)
                    :ATTRIBUTE ( ATTRIB-4 / human)
                    :NAMELY ( ENTITY-2 / HUVECs))
             :TO ( ENTITY-anoxia_slash_reoxygenation / ENTITY
                    :name ( n-2 / name
                           :op1 "A_slash_R")
                    :name ( n-1 / name
                           :op1 "anoxia_slash_reoxygenation")))
      :IN ( ENTITY-7 / increase
             :IN ( ENTITY-9 / leukocyte_adhesion
                    :ATTRIBUTE ( ATTRIB-10 / polymorphonuclear)
                    :TO ( GROUP-11 / HUVECs)
                    :NAMELY ( ENTITY-8 / PMN))))

# ::id 150_nonfiction_GENIA-1999;99115412,4;NE
# ::snt This A/R-induced hyperadhesion is completely prevented by a previous -LRB- 24 hours earlier -RRB- exposure of HUVECs to A/R .
( EVENT-9 / prevented
      :ARG0 ( ENTITY-4 / TMP_earlier
             :TMP ( GROUP-6 / hours
                    :CARDINAL ( ATTRIB-7 / 24))
             :MOD ( mod-1 / exposure
                    :ATTRIBUTE ( ATTRIB-5 / previous)
                    :TO ( ENTITY-A_slash_R / ENTITY
                           :name ( n-3 / name
                                  :op1 "A_slash_R"))
                    :OF ( GROUP-8 / HUVECs)))
      :ARG1 ( ENTITY-1 / hyperadhesion
             :DETERMINER ( ATTRIB-2 / this)
             :ATTRIBUTE ( ATTRIB-3 / a_slash_r-induced))
      :MOD ( mod-2 / completely))

# ::id 151_nonfiction_GENIA-1999;99115412,5;NE
# ::snt This phenomenon has been termed " A/R tolerance . "
( EVENT-4 / has_termed
      :ARG1 ( ENTITY-3 / A_slash_R_tolerance)
      :ARG2 ( ENTITY-1 / phenomenon
             :DETERMINER ( ATTRIB-2 / this)))

# ::id 152_nonfiction_GENIA-1999;99115412,6;NE
# ::snt Exposing HUVECs to A/R induces an increase in nuclear factor kappaB -LRB- NF-kappaB -RRB- in HUVEC nuclei within 4 hours .
( EVENT-10 / induces
      :ARG0 ( EVENT-3 / exposing
             :ARG1 ( GROUP-2 / HUVECs)
             :TO ( ENTITY-A_slash_R / ENTITY
                    :name ( n-1 / name
                           :op1 "A_slash_R")))
      :ARG1 ( ENTITY-4 / increase
             :IN ( GROUP-7 / HUVEC_nuclei)
             :IN ( ENTITY-5 / factor_kappaB
                    :ATTRIBUTE ( ATTRIB-6 / nuclear)
                    :NAMELY ( ENTITY-NF-kappaB / ENTITY
                           :name ( n-2 / name
                                  :op1 "NF-kappaB"))))
      :WITHIN ( GROUP-8 / hours
             :CARDINAL ( ATTRIB-9 / 4)))

# ::id 153_nonfiction_GENIA-1999;99115412,7;NE
# ::snt Interfering with either NF-kappaB activation -LRB- proteasome inhibitor -RRB- or translocation -LRB- double-stranded oligonucleotides containing NF-kappaB binding sequence -RRB- prevents the development of A/R tolerance
( EVENT-15 / prevents
      :ARG0 ( EVENT-11 / interfering
             :WITH ( GROUP-2 / either_or
                    :op1 ( ENTITY-4 / NF-kappaB_activation
                           :NAMELY ( ENTITY-3 / proteasome_inhibitor))
                    :op2 ( ENTITY-10 / translocation
                           :NAMELY ( ENTITY-5 / oligonucleotides
                                  :ATTRIBUTE ( ATTRIB-6 / double-stranded)
                                  :ARG0-of ( EVENT-9 / containing
                                         :ARG1 ( ENTITY-8 / NF-kappaB_binding_sequence))))))
      :ARG1 ( ENTITY-12 / development
             :DEFINITE ( ATTRIB-13 / the)
             :OF ( ENTITY-14 / A_slash_R_tolerance)))

# ::id 154_nonfiction_GENIA-1999;99115412,7;NE
# ::snt -LRB- ie , the increase in A/R-induced PMN adhesion to HUVECs is the same after the first and second A/R challenges -RRB- .
( EVENT-14 / copula
      :ARG0 ( ENTITY-1 / increase
             :DEFINITE ( ATTRIB-2 / the)
             :IN ( ENTITY-3 / PMN_adhesion
                    :ATTRIBUTE ( ATTRIB-4 / a_slash_r-induced)
                    :TO ( GROUP-5 / HUVECs)))
      :ARG1 ( ENTITY-6 / ENTITY
             :DEFINITE ( ATTRIB-7 / the)
             :ATTRIBUTE ( ATTRIB-8 / same)
             :AFTER ( ENTITY-9 / AND
                    :DEFINITE ( ATTRIB-10 / the)
                    :op1 ( GROUP-12 / first_A_slash_R_challenges)
                    :op2 ( GROUP-13 / second_A_slash_R_challenges))))

# ::id 155_nonfiction_GENIA-1999;99115412,8;NE
# ::snt NO production by HUVECs is increased after the second A/R challenge , but not after the first A/R challenge .
( CONJ-8 / but
      :op1 ( EVENT-7 / is_increased
             :ARG0 ( ENTITY-1 / NO_production
                    :BY ( GROUP-2 / HUVECs))
             :AFTER ( ENTITY-3 / second_A_slash_R_challenge
                    :DEFINITE ( ATTRIB-4 / the)))
      :op2 ( EVENT-7 / is_increased
             :ARG0 ENTITY-1
             :AFTER ( ENTITY-5 / first_A_slash_R_challenge
                    :DEFINITE ( ATTRIB-6 / the))))

# ::id 156_nonfiction_GENIA-1999;99115412,9;NE
# ::snt Inhibition of NO synthase -LRB- NOS -RRB- during the second A/R challenge prevents the development of A/R tolerance with respect to PMN adhesion .
( EVENT-11 / prevents
      :ARG0 ( ENTITY-1 / Inhibition
             :OF ( ENTITY-3 / NO_synthase
                    :NAMELY ( ENTITY-2 / NOS))
             :DURING ( ENTITY-4 / second_A_slash_R_challenge
                    :DEFINITE ( ATTRIB-5 / the)))
      :ARG1 ( ENTITY-6 / development
             :DEFINITE ( ATTRIB-7 / the)
             :OF ( ENTITY-8 / A_slash_R_tolerance))
      :WITH ( ENTITY-9 / respect
             :TO ( ENTITY-10 / PMN_adhesion)))

# ::id 157_nonfiction_GENIA-1999;99115412,10;NE
# ::snt However , while HUVECs contained endothelial NOS protein , no inducible NOS was detected in either tolerant or nontolerant cells .
( CRD-16 / while
      :op1 ( EVENT-4 / contained
             :MOD ( mod-17 / past)
             :ARG0 ( GROUP-1 / HUVECs)
             :ARG1 ( ENTITY-2 / NOS_protein
                    :ATTRIBUTE ( ATTRIB-3 / endothelial)))
      :op2 ( EVENT-13 / detected
             :MOD ( mod-18 / past)
             :ARG1 ( ENTITY-5 / NOS
                    :ATTRIBUTE ( ATTRIB-7 / inducible)
                    :QUANTIFIER ( ATTRIB-6 / no))
             :IN ( GROUP-8 / either_or
                    :op1 ( GROUP-9 / cells
                           :ATTRIBUTE ( ATTRIB-10 / tolerant))
                    :op2 ( GROUP-11 / cells
                           :ATTRIBUTE ( ATTRIB-12 / nontolerant))))
      :MOD ( mod-19 / however))

# ::id 158_nonfiction_GENIA-1999;99115412,11;NE
# ::snt Further studies indicated that inhibition of GTP-cyclohydrolase I -LRB- an enzyme involved in de novo synthesis of an important cofactor for NOS activity , tetrahydrobiopterin -RRB- prevented the generation of NO in A/R-tolerant cells .
( EVENT-3 / indicated
      :MOD ( mod-2 / past)
      :ARG0 ( GROUP-1 / studies
             :ATTRIBUTE ( ATTRIB-2 / further))
      :THAT ( EVENT-18 / prevented
             :MOD ( mod-1 / past)
             :ARG0 ( ENTITY-4 / inhibition
                    :OF ( ENTITY-GTP-cyclohydrolase_I / enzyme
                           :ARG1-of ( EVENT-12 / involved
                                  :IN ( ENTITY-7 / synthesis
                                         :ATTRIBUTE ( ATTRIB-8 / de_novo)
                                         :OF ( ENTITY-tetrahydrobiopterin / cofactor
                                                :ATTRIBUTE ( ATTRIB-10 / important)
                                                :FOR ( ENTITY-11 / NOS_activity)
                                                :name ( n-4 / name
                                                       :op1 "tetrahydrobiopterin"))))
                           :name ( n-3 / name
                                  :op1 "GTP-cyclohydrolase_I")))
             :ARG1 ( ENTITY-13 / generation
                    :DEFINITE ( ATTRIB-14 / the)
                    :IN ( GROUP-16 / cells
                           :ATTRIBUTE ( ATTRIB-17 / a_slash_r-tolerant))
                    :OF ( ENTITY-15 / NO))))

# ::id 159_nonfiction_GENIA-1999;99115412,12;NE
# ::snt Extracellular generation of NO -LRB- NO donor -RRB- did not effect the hyperadhesion response induced by the initial A/R challenge .
( EVENT-11 / did_effect
      :domain-of ( NEG-12 / NEG)
      :MOD ( mod-13 / past)
      :ARG0 ( ENTITY-1 / generation
             :ATTRIBUTE ( ATTRIB-2 / extracellular)
             :OF ( ENTITY-4 / NO
                    :NAMELY ( ENTITY-3 / NO_donor)))
      :ARG1 ( ENTITY-5 / hyperadhesion_response
             :DEFINITE ( ATTRIB-6 / the)
             :ARG0-of ( EVENT-10 / induced
                    :BY ( ENTITY-8 / initial_A_slash_R_challenge
                           :DEFINITE ( ATTRIB-9 / the)))))

# ::id 160_nonfiction_GENIA-1999;99115412,13;NE
# ::snt A/R also induced an oxidant stress in naive HUVECs , but not in A/R-tolerant HUVECs .
( CONJ-10 / but
      :op1 ( EVENT-7 / induced
             :MOD ( mod-11 / past)
             :ARG0 ( ENTITY-A_slash_R / ENTITY
                    :name ( n-13 / name
                           :op1 "A_slash_R"))
             :ARG1 ( ENTITY-1 / stress
                    :ATTRIBUTE ( ATTRIB-2 / oxidant))
             :IN ( GROUP-3 / HUVECs
                    :ATTRIBUTE ( ATTRIB-4 / naive)))
      :op2 ( EVENT-7 / induced
             :ARG0 ENTITY-A_slash_R
             :ARG1 ENTITY-1
             :IN ( GROUP-5 / HUVECs
                    :ATTRIBUTE ( ATTRIB-6 / a_slash_r-tolerant)))
      :MOD ( mod-12 / also))

# ::id 161_nonfiction_GENIA-1999;99115412,14;NE
# ::snt Inhibition of NOS during the second A/R insult results in the generation of an oxidant stress similar to that observed after the first A/R challenge .
( EVENT-16 / results
      :ARG0 ( ENTITY-1 / Inhibition
             :OF ( ENTITY-2 / NOS)
             :DURING ( ENTITY-3 / second_A_slash_R_insult
                    :DEFINITE ( ATTRIB-4 / the)))
      :IN ( ENTITY-5 / generation
             :DEFINITE ( ATTRIB-6 / the)
             :OF ( ENTITY-7 / stress
                    :ATTRIBUTE ( ATTRIB-9 / similar
                           :TO ( ENTITY-10 / ENTITY
                                  :DETERMINER ( ATTRIB-11 / that)
                                  :ARG0-of ( EVENT-15 / observed
                                         :AFTER ( ENTITY-13 / first_A_slash_R_challenge
                                                :DEFINITE ( ATTRIB-14 / the)))))
                    :ATTRIBUTE ( ATTRIB-8 / oxidant))))

# ::id 162_nonfiction_GENIA-1999;99115412,15;NE
# ::snt Taken together , the findings of the present study are consistent with a role for NF-kappaB in the development of A/R tolerance -LRB- with respect to PMN adhesion -RRB- , perhaps by transcriptional regulation of GTP-cyclohydrolase .
( CONJ-18 / and
      :op1 ( EVENT-6 / taken
             :ARG0 ( GROUP-1 / findings
                    :DEFINITE ( ATTRIB-2 / the)
                    :OF ( ENTITY-3 / study
                           :DEFINITE ( ATTRIB-4 / the)
                           :ATTRIBUTE ( ATTRIB-5 / present)))
             :MOD ( mod-19 / together))
      :op2 ( EVENT-17 / copula
             :ATTRIBUTE ( ATTRIB-8 / consistent
                    :WITH ( ENTITY-9 / role
                           :IN ( ENTITY-10 / development
                                  :DEFINITE ( ATTRIB-11 / the)
                                  :OF ( ENTITY-12 / A_slash_R_tolerance
                                         :PERHAPS_BY ( ENTITY-15 / regulation
                                                :ATTRIBUTE ( ATTRIB-16 / transcriptional)
                                                :OF ( ENTITY-GTP-cyclohydrolase / ENTITY
                                                       :name ( n-20 / name
                                                              :op1 "GTP-cyclohydrolase")))
                                         :WITH ( ENTITY-13 / respect
                                                :TO ( ENTITY-14 / PMN_adhesion))))
                           :FOR ( ENTITY-NF-kappaB / ENTITY
                                  :name ( n-21 / name
                                         :op1 "NF-kappaB"))))
             :ARG0 GROUP-1))

# ::id 163_nonfiction_GENIA-1999;99115412,16;NE
# ::snt The increased NO production during the second A/R insult reduces PMN adhesion most likely by reducing the intracellular oxidant stress induced by A/R .
( EVENT-15 / reduces
      :ARG0 ( ENTITY-1 / NO_production
             :DEFINITE ( ATTRIB-2 / the)
             :ATTRIBUTE ( ATTRIB-3 / increased)
             :DURING ( ENTITY-4 / second_A_slash_R_insult
                    :DEFINITE ( ATTRIB-5 / the)))
      :ARG1 ( ENTITY-6 / PMN_adhesion)
      :MOD ( mod-1 / most_likely
             :BY ( EVENT-14 / reducing
                    :ARG1 ( ENTITY-8 / stress
                           :DEFINITE ( ATTRIB-9 / the)
                           :ATTRIBUTE ( ATTRIB-11 / oxidant)
                           :ATTRIBUTE ( ATTRIB-10 / intracellular)
                           :ARG0-of ( EVENT-13 / induced
                                  :BY ( ENTITY-A_slash_R / ENTITY
                                         :name ( n-2 / name
                                                :op1 "A_slash_R")))))))

# ::id 164_nonfiction_GENIA-1999;99115544,1;NE
# ::snt Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins .
( ENTITY-1 / Involvement
      :IN ( ENTITY-4 / interleukin-8_production
             :BY ( GROUP-5 / AND
                    :op1 ( GROUP-6 / monocytes
                           :ATTRIBUTE ( ATTRIB-7 / human))
                    :op2 ( GROUP-8 / cells
                           :ATTRIBUTE ( ATTRIB-9 / polymorphonuclear)
                           :ARG1-of ( EVENT-14 / stimulated
                                  :WITH ( GROUP-11 / or
                                         :op1 ( ENTITY-12 / lipopolysaccharide)
                                         :op2 ( GROUP-13 / Mycoplasma_fermentans_membrane_lipoproteins))))))
      :OF ( GROUP-2 / protein_kinase_pathways
             :ATTRIBUTE ( ATTRIB-3 / mitogen-activated)))

# ::id 165_nonfiction_GENIA-1999;99115544,2;NE
# ::snt Interleukin-8 -LRB- IL-8 -RRB- is a chemokine that belongs to the alpha-chemokine or CXC subfamily and is produced by a wide variety of human cells , including monocytes and polymorphonuclear cells -LRB- PMN -RRB- .
( CONJ-22 / and
      :op1 ( EVENT-9 / copula
             :ARG0 ( ENTITY-Interleukin-8 / ENTITY
                    :name ( n-24 / name
                           :op1 "IL-8")
                    :name ( n-23 / name
                           :op1 "Interleukin-8"))
             :ARG1 ( ENTITY-1 / chemokine
                    :ARG0-of ( EVENT-8 / belongs
                           :TO ( ENTITY-3 / or
                                  :DEFINITE ( ATTRIB-4 / the)
                                  :op1 ( ENTITY-6 / alpha-chemokine_subfamily)
                                  :op2 ( ENTITY-7 / CXC_subfamily)))))
      :op2 ( EVENT-21 / produced
             :ARG0 ( ENTITY-10 / variety
                    :ATTRIBUTE ( ATTRIB-11 / wide)
                    :OF ( GROUP-12 / cells
                           :ATTRIBUTE ( ATTRIB-13 / human)
                           :ARG0-of ( EVENT-20 / including
                                  :ARG1 ( GROUP-15 / AND
                                         :op1 ( GROUP-16 / monocytes)
                                         :op2 ( GROUP-18 / cells
                                                :ATTRIBUTE ( ATTRIB-19 / polymorphonuclear)
                                                :NAMELY ( ENTITY-17 / PMN))))))
             :ARG1 ENTITY-Interleukin-8))

# ::id 166_nonfiction_GENIA-1999;99115544,3;NE
# ::snt IL-8 is secreted in response to inflammatory stimuli , notably bacterial products such as lipopolysaccharide -LRB- LPS -RRB- ,
( EVENT-7 / is_secreted
      :ARG0 ( ENTITY-IL-8 / ENTITY
             :name ( n-11 / name
                    :op1 "IL-8"))
      :IN ( ENTITY-1 / response
             :TO ( GROUP-5 / stimuli
                    :ATTRIBUTE ( ATTRIB-6 / inflammatory)
                    :NAMELY ( ENTITY-2 / notably
                           :MOD ( mod-9 / products
                                  :ATTRIBUTE ( ATTRIB-4 / such
                                         :AS ( ENTITY-lipopolysaccharide / ENTITY
                                                :name ( n-12 / name
                                                       :op1 "LPS")
                                                :name ( n-10 / name
                                                       :op1 "lipopolysaccharide")))
                                  :ATTRIBUTE ( ATTRIB-3 / bacterial))))))

# ::id 167_nonfiction_GENIA-1999;99115544,3;NE
# ::snt but little is known about the mechanisms by which these agents mediate IL-8 induction .
( EVENT-10 / known
      :ARG1 ( ENTITY-1 / ENTITY
             :QUANTIFIER ( ATTRIB-2 / little))
      :ABOUT ( GROUP-3 / mechanisms
             :DEFINITE ( ATTRIB-4 / the)
             :BY-of ( EVENT-9 / mediate
                    :ARG0 ( GROUP-6 / agents
                           :DETERMINER ( ATTRIB-7 / these))
                    :ARG1 ( ENTITY-8 / IL-8_induction))))

# ::id 168_nonfiction_GENIA-1999;99115544,4;NE
# ::snt In this report , we show that Mycoplasma fermentans lipid-associated membrane proteins -LRB- LAMPf -RRB- induce the production of high levels of IL-8 by THP-1 -LRB- human monocyte -RRB- cells and PMN at the same extent as LPS .
( EVENT-4 / show
      :ARG0 ( REF1-3 / we)
      :IN ( ENTITY-1 / report
             :DETERMINER ( ATTRIB-2 / this))
      :THAT ( EVENT-18 / induce
             :ARG0 ( GROUP-5 / Mycoplasma_fermentans_lipid-associated_membrane_proteins
                    :NAMELY ( ENTITY-LAMPf / ENTITY
                           :name ( n-9 / name
                                  :op1 "LAMPf")))
             :ARG1 ( ENTITY-6 / production
                    :DEFINITE ( ATTRIB-7 / the)
                    :BY ( GROUP-10 / AND
                           :op1 ( GROUP-13 / THP-1_cells
                                  :NAMELY ( ENTITY-11 / monocyte
                                         :ATTRIBUTE ( ATTRIB-12 / human)))
                           :op2 ( GROUP-14 / PMN))
                    :OF ( GROUP-8 / levels
                           :ATTRIBUTE ( ATTRIB-9 / high)
                           :OF ( ENTITY-IL-8 / ENTITY
                                  :name ( n-10 / name
                                         :op1 "IL-8"))))
             :AT ( ENTITY-15 / extent
                    :DEFINITE ( ATTRIB-16 / the)
                    :ATTRIBUTE ( ATTRIB-17 / same)
                    :AS ( ENTITY-LPS / ENTITY
                           :name ( n-11 / name
                                  :op1 "LPS")))))

# ::id 169_nonfiction_GENIA-1999;99115544,5;NE
# ::snt It was previously demonstrated that stimulation of monocytic cells with either LPS or LAMPf led to a series of common downstream signaling events , including the activation of protein tyrosine kinase and of mitogen-activated protein kinase cascades .
( EVENT-19 / demonstrated
      :MOD ( mod-24 / past)
      :ARG1 ( EVENT-18 / led
             :MOD ( mod-22 / past)
             :ARG0 ( ENTITY-2 / stimulation
                    :OF ( GROUP-3 / cells
                           :ATTRIBUTE ( ATTRIB-4 / monocytic))
                    :WITH ( GROUP-5 / either_or
                           :op1 ( ENTITY-LPS / ENTITY
                                  :name ( n-25 / name
                                         :op1 "LPS"))
                           :op2 ( ENTITY-LAMPf / ENTITY
                                  :name ( n-26 / name
                                         :op1 "LAMPf"))))
             :TO ( ENTITY-6 / series
                    :OF ( GROUP-7 / events
                           :ATTRIBUTE ( ATTRIB-10 / signaling)
                           :ATTRIBUTE ( ATTRIB-9 / downstream)
                           :ATTRIBUTE ( ATTRIB-8 / common)
                           :ARG0-of ( EVENT-17 / including
                                  :ARG1 ( CONJ-21 / and
                                         :op1 ( ENTITY-12 / activation
                                                :DEFINITE ( ATTRIB-13 / the)
                                                :OF ( ENTITY-14 / protein_tyrosine_kinase))
                                         :op2 ( ENTITY-12 / activation
                                                :DEFINITE ATTRIB-13
                                                :OF ( GROUP-15 / protein_kinase_cascades
                                                       :ATTRIBUTE ( ATTRIB-16 / mitogen-activated))))))))
      :TMP ( TIME-23 / previously))

# ::id 170_nonfiction_GENIA-1999;99115544,6;NE
# ::snt By using PD-98059 and SB203580 , two potent and selective inhibitors of MEK1 -LRB- a kinase upstream of ERK1/2 -RRB- and p38 , respectively , we have demonstrated that both ERK1/2 and p38 cascades play a key role in the production of IL-8 by monocytes and PMN stimulated with bacterial fractions .
( EVENT-13 / have_demonstrated
      :ARG0 ( REF1-1 / we)
      :BY ( EVENT-11 / using
             :ARG0 REF1-1
             :ARG1 ( ENTITY-9 / AND
                    :op1 ( ENTITY-PD-98059 / ENTITY
                           :name ( n-98064 / name
                                  :op1 "PD-98059"))
                    :op2 ( ENTITY-SB203580 / ENTITY
                           :name ( n-98065 / name
                                  :op1 "SB203580"))
                    :NAMELY ( CONJ-30 / and
                           :op1 ( ENTITY-3 / inhibitors
                                  :ATTRIBUTE ( ATTRIB-5 / potent)
                                  :OF ( GROUP-7 / AND
                                         :op1 ( ENTITY-MEK1 / ENTITY
                                                :NAMELY ( ENTITY-8 / kinase
                                                       :name ( n-98062 / name
                                                              :op1 "MEK1")))
                                         :op2 ( ENTITY-p38 / ENTITY
                                                :name ( n-98066 / name
                                                       :op1 "p38")))
                                  :CARDINAL ( ATTRIB-4 / two))
                           :op2 ( ENTITY-3 / inhibitors
                                  :ATTRIBUTE ( ATTRIB-6 / selective)
                                  :OF ( GROUP-7 / AND
                                         :op1 ENTITY-MEK1
                                         :op2 ENTITY-p38)
                                  :CARDINAL ATTRIB-4)))
             :MOD ( mod-98060 / respectively))
      :THAT ( EVENT-29 / play
             :ARG0 ( group-14 / cascades
                    :EQUALS ( GROUP-16 / AND
                           :op1 ( ENTITY-ERK1_slash_2 / ENTITY
                                  :name ( n-98063 / name
                                         :op1 "ERK1_slash_2")
                                  :OF-of ( ENTITY-8 / LOC_upstream)
                                  :OF-of ( ENTITY-8 / LOC_upstream
                                         :MOD ( mod-98061 / kinase
                                                :NAMELY-of ENTITY-MEK1)))
                           :op2 ENTITY-p38
                           :QUANTIFIER ( ATTRIB-15 / both)))
             :ARG1 ( ENTITY-17 / role
                    :ATTRIBUTE ( ATTRIB-18 / key)
                    :IN ( ENTITY-19 / production
                           :DEFINITE ( ATTRIB-20 / the)
                           :BY ( ENTITY-21 / AND
                                  :op1 ( GROUP-23 / monocytes)
                                  :op2 ( GROUP-24 / PMN)
                                  :ARG1-of ( EVENT-28 / stimulated
                                         :WITH ( GROUP-26 / fractions
                                                :ATTRIBUTE ( ATTRIB-27 / bacterial))))
                           :OF ( ENTITY-IL-8 / ENTITY
                                  :name ( n-98067 / name
                                         :op1 "IL-8"))))))

# ::id 171_nonfiction_GENIA-1999;99115659,1;NE
# ::snt CD80 and CD86 are not equivalent in their ability to induce the tyrosine phosphorylation of CD28 .
( EVENT-8 / copula
      :domain-of ( NEG-9 / NEG)
      :ATTRIBUTE ( ATTRIB-2 / equivalent
             :IN ( ENTITY-3 / ability
                    :POS ( REF1-4 / their)
                    :TOCOMP ( EVENT-7 / induce
                           :ARG1 ( ENTITY-5 / tyrosine_phosphorylation
                                  :DEFINITE ( ATTRIB-6 / the)
                                  :OF ( ENTITY-CD28 / ENTITY
                                         :name ( n-12 / name
                                                :op1 "CD28"))))))
      :ARG0 ( GROUP-1 / AND
             :op1 ( ENTITY-CD80 / ENTITY
                    :name ( n-10 / name
                           :op1 "CD80"))
             :op2 ( ENTITY-CD86 / ENTITY
                    :name ( n-11 / name
                           :op1 "CD86"))))

# ::id 172_nonfiction_GENIA-1999;99115659,2;NE
# ::snt Ligation of either CD80 -LRB- B7-1 -RRB- or CD86 -LRB- B7-2 -RRB- , two principal ligands for CD28 , is thought to skew the immune response toward Th1 or Th2 differentiation .
( EVENT-7 / thought
      :ARG1 ( ENTITY-1 / Ligation
             :OF ( ENTITY-5 / either_or
                    :op1 ( ENTITY-CD80 / ENTITY
                           :name ( n-5 / name
                                  :op1 "B7-1")
                           :name ( n-3 / name
                                  :op1 "CD80"))
                    :op2 ( ENTITY-CD86 / ENTITY
                           :name ( n-6 / name
                                  :op1 "B7-2")
                           :name ( n-4 / name
                                  :op1 "CD86"))
                    :NAMELY ( ENTITY-2 / ligands
                           :ATTRIBUTE ( ATTRIB-4 / principal)
                           :FOR ( ENTITY-CD28 / ENTITY
                                  :name ( n-7 / name
                                         :op1 "CD28"))
                           :CARDINAL ( ATTRIB-3 / two))))
      :TOCOMP ( EVENT-13 / skew
             :ARG0 ENTITY-1
             :ARG1 ( ENTITY-8 / response
                    :DEFINITE ( ATTRIB-9 / the)
                    :ATTRIBUTE ( ATTRIB-10 / immune)
                    :TOWARD ( ENTITY-12 / differentiation
                           :NAMELY ( GROUP-11 / or
                                  :op1 ( ENTITY-Th1 / ENTITY
                                         :name ( n-8 / name
                                                :op1 "Th1"))
                                  :op2 ( ENTITY-Th2 / ENTITY
                                         :name ( n-9 / name
                                                :op1 "Th2")))))))

# ::id 173_nonfiction_GENIA-1999;99115659,3;NE
# ::snt We have examined early signal transduction pathways recruited following T cell stimulation with either CD80 or CD86 .
( EVENT-10 / have_examined
      :ARG0 ( REF1-1 / we)
      :ARG1 ( GROUP-2 / signal_transduction_pathways
             :ATTRIBUTE ( ATTRIB-3 / early)
             :ARG1-of ( EVENT-5 / recruited)
             :ARG0-of ( EVENT-9 / following
                    :ARG1 ( ENTITY-7 / T_cell_stimulation
                           :WITH ( GROUP-8 / either_or
                                  :op1 ( ENTITY-CD80 / ENTITY
                                         :name ( n-1 / name
                                                :op1 "CD80"))
                                  :op2 ( ENTITY-CD86 / ENTITY
                                         :name ( n-2 / name
                                                :op1 "CD86")))))))

# ::id 174_nonfiction_GENIA-1999;99115659,4;NE
# ::snt Purified human peripheral T cells or Jurkat T cells were stimulated with Chinese hamster ovary -LRB- CHO -RRB- cells expressing either human CD80 -LRB- CHO-CD80 -RRB- or human CD86 -LRB- CHO-CD86 -RRB- or with anti-CD28 monoclonal antibody -LRB- mAb -RRB- .
( CONJ-16 / or
      :op1 ( EVENT-15 / stimulated
             :MOD ( mod-17 / past)
             :ARG1 ( GROUP-1 / or
                    :op1 ( GROUP-2 / Purified_T_cells
                           :ATTRIBUTE ( ATTRIB-3 / human_peripheral))
                    :op2 ( GROUP-4 / Jurkat_T_cells))
             :WITH ( GROUP-6 / hamster_ovary_cells
                    :ATTRIBUTE ( ATTRIB-7 / chinese)
                    :ARG0-of ( EVENT-10 / expressing
                           :ARG1 ( GROUP-9 / either_or
                                  :op1 ( ENTITY-human_CD80 / ENTITY
                                         :name ( n-20 / name
                                                :op1 "CHO-CD80")
                                         :name ( n-18 / name
                                                :op1 "human_CD80"))
                                  :op2 ( ENTITY-human_CD86 / ENTITY
                                         :name ( n-21 / name
                                                :op1 "CHO-CD86")
                                         :name ( n-19 / name
                                                :op1 "human_CD86"))))
                    :NAMELY ( ENTITY-5 / CHO)))
      :op2 ( EVENT-15 / stimulated
             :ARG1 GROUP-1
             :WITH ( ENTITY-12 / antibody
                    :ATTRIBUTE ( ATTRIB-14 / monoclonal)
                    :ATTRIBUTE ( ATTRIB-13 / anti-cd28)
                    :NAMELY ( ENTITY-11 / mAb))))

# ::id 175_nonfiction_GENIA-1999;99115659,5;NE
# ::snt In the presence of phorbol 12-myristate 13-acetate , both CHO-CD80 and CHO-CD86 , like anti-CD28 mAb , were capable of stimulating cytokine production from both human peripheral T cells and Jurkat T cells .
( CONJ-21 / and
      :op1 ( EVENT-20 / copula
             :MOD ( mod-22 / past)
             :ATTRIBUTE ( ATTRIB-11 / capable
                    :OF ( EVENT-19 / stimulating
                           :ARG1 ( ENTITY-13 / cytokine_production)
                           :FROM ( group-14 / AND
                                  :op1 ( GROUP-17 / human_peripheral_T_cells)
                                  :op2 ( GROUP-18 / Jurkat_T_cells)
                                  :QUANTIFIER ( ATTRIB-15 / both))))
             :ARG0 ( group-4 / AND
                    :op1 ( ENTITY-CHO-CD80 / ENTITY
                           :name ( n-23 / name
                                  :op1 "CHO-CD80"))
                    :op2 ( ENTITY-CHO-CD86 / ENTITY
                           :name ( n-24 / name
                                  :op1 "CHO-CD86"))
                    :QUANTIFIER ( ATTRIB-5 / both))
             :IN ( ENTITY-1 / presence
                    :DEFINITE ( ATTRIB-2 / the)
                    :OF ( ENTITY-3 / phorbol_12-myristate_13-acetate)))
      :op2 ( EVENT-10 / EVENT
             :ATTRIBUTE ( ATTRIB-7 / like
                    :COMP ( ENTITY-8 / mAb
                           :ATTRIBUTE ( ATTRIB-9 / anti-cd28)))
             :ARG0 group-4))

# ::id 176_nonfiction_GENIA-1999;99115659,6;NE
# ::snt Both CHO-CD80 and CHO-CD86 , in the presence of anti-CD3 mAb , costimulated NFAT-dependent transcriptional activation .
( EVENT-10 / costimulated
      :MOD ( mod-1 / past)
      :ARG0 ( GROUP-1 / AND
             :op1 ( ENTITY-CHO-CD80 / ENTITY
                    :name ( n-2 / name
                           :op1 "CHO-CD80"))
             :op2 ( ENTITY-2 / CHO-CD86))
      :ARG1 ( ENTITY-7 / activation
             :ATTRIBUTE ( ATTRIB-9 / transcriptional)
             :ATTRIBUTE ( ATTRIB-8 / nfat-dependent))
      :IN ( ENTITY-3 / presence
             :DEFINITE ( ATTRIB-4 / the)
             :OF ( ENTITY-5 / mAb
                    :ATTRIBUTE ( ATTRIB-6 / anti-cd3))))

# ::id 177_nonfiction_GENIA-1999;99115659,7;NE
# ::snt Several intracellular signaling proteins , such as CBL and VAV , were phosphorylated on tyrosine in response to CD80 , CD86 , and anti-CD28 mAb .
( EVENT-12 / were_phosphorylated
      :MOD ( mod-1 / past)
      :ARG0 ( GROUP-1 / proteins
             :ATTRIBUTE ( ATTRIB-5 / such
                    :AS ( GROUP-6 / AND
                           :op1 ( ENTITY-CBL / ENTITY
                                  :name ( n-2 / name
                                         :op1 "CBL"))
                           :op2 ( ENTITY-VAV / ENTITY
                                  :name ( n-3 / name
                                         :op1 "VAV"))))
             :ATTRIBUTE ( ATTRIB-4 / signaling)
             :ATTRIBUTE ( ATTRIB-3 / intracellular)
             :QUANTIFIER ( ATTRIB-2 / several))
      :IN ( ENTITY-8 / response
             :TO ( GROUP-9 / AND
                    :op1 ( ENTITY-CD80 / ENTITY
                           :name ( n-4 / name
                                  :op1 "CD80"))
                    :op2 ( ENTITY-CD86 / ENTITY
                           :name ( n-5 / name
                                  :op1 "CD86"))
                    :op3 ( ENTITY-10 / mAb
                           :ATTRIBUTE ( ATTRIB-11 / anti-cd28))))
      :ON ( ENTITY-7 / tyrosine))

# ::id 178_nonfiction_GENIA-1999;99115659,8;NE
# ::snt Surprisingly , although stimulation of Jurkat T cells with either CHO-CD80 or anti-CD28 mAb resulted in robust tyrosine phosphorylation of CD28 itself , ligation with CHO-CD86 was unable to induce detectable CD28 tyrosyl phosphorylation over a range of stimulation conditions .
( EVENT-17 / copula
      :MOD ( mod-2 / past)
      :ATTRIBUTE ( ATTRIB-12 / unable
             :TOCOMP ( EVENT-16 / induce
                    :ARG1 ( ENTITY-13 / detectable_CD28_tyrosyl_phosphorylation)
                    :OVER ( ENTITY-14 / range
                           :OF ( GROUP-15 / stimulation_conditions))))
      :ARG0 ( ENTITY-11 / ligation
             :WITH ( ENTITY-CHO-CD86 / ENTITY
                    :name ( n-5 / name
                           :op1 "CHO-CD86")))
      :ALTHOUGH ( EVENT-10 / resulted
             :MOD ( mod-1 / past)
             :ARG0 ( ENTITY-2 / stimulation
                    :OF ( GROUP-3 / Jurkat_T_cells)
                    :WITH ( GROUP-4 / either_or
                           :op1 ( ENTITY-CHO-CD80 / ENTITY
                                  :name ( n-6 / name
                                         :op1 "CHO-CD80"))
                           :op2 ( ENTITY-5 / mAb
                                  :ATTRIBUTE ( ATTRIB-6 / anti-cd28))))
             :IN ( ENTITY-7 / tyrosine_phosphorylation
                    :ATTRIBUTE ( ATTRIB-8 / robust)
                    :OF ( ENTITY-CD28 / ENTITY
                           :name ( n-4 / name
                                  :op1 "CD28")
                           :RFL ( REF1-9 / itself))))
      :MOD ( mod-3 / surprisingly))

# ::id 179_nonfiction_GENIA-1999;99115659,9;NE
# ::snt In addition , the association of phosphoinositide 3-kinase with CD28 and enhanced tyrosine phosphorylation of phospholipase Cgamma were seen after anti-CD28 mAb and CHO-CD80 stimulation but to a much lesser extent after CHO-CD86 stimulation .
( CONJ-16 / but
      :op1 ( EVENT-11 / seen
             :MOD ( mod-17 / past)
             :ARG1 ( ENTITY-2 / association
                    :DEFINITE ( ATTRIB-3 / the)
                    :WITH ( GROUP-4 / AND
                           :op1 ( ENTITY-CD28 / ENTITY
                                  :name ( n-19 / name
                                         :op1 "CD28"))
                           :op2 ( ENTITY-5 / tyrosine_phosphorylation
                                  :ATTRIBUTE ( ATTRIB-6 / enhanced)
                                  :OF ( ENTITY-phospholipase_Cgamma / ENTITY
                                         :name ( n-20 / name
                                                :op1 "phospholipase_Cgamma"))))
                    :OF ( ENTITY-phosphoinositide_3-kinase / ENTITY
                           :name ( n-21 / name
                                  :op1 "phosphoinositide_3-kinase")))
             :AFTER ( ENTITY-10 / stimulation
                    :NAMELY ( GROUP-7 / AND
                           :op1 ( ENTITY-8 / mAb
                                  :ATTRIBUTE ( ATTRIB-9 / anti-cd28))
                           :op2 ( ENTITY-CHO-CD80 / ENTITY
                                  :name ( n-22 / name
                                         :op1 "CHO-CD80"))))
             :IN ( ENTITY-1 / addition))
      :op2 ( EVENT-15 / seen
             :MOD ( mod-18 / past)
             :ARG1 ENTITY-2
             :AFTER ( ENTITY-14 / CHO-CD86_stimulation)
             :TO ( ENTITY-12 / extent
                    :ATTRIBUTE ( ATTRIB-13 / much_lesser))
             :IN ENTITY-1))

# ::id 180_nonfiction_GENIA-1999;99115659,10;NE
# ::snt Thus , ligation of CD28 with either CD80 or CD86 leads to shared early signal transduction events such as the tyrosine phosphorylation of CBL and VAV , to NFAT-mediated transcriptional activation , and to the costimulation of interleukin-2 and granulocyte-macrophage colony-stimulating factor production .
( CONJ-21 / and
      :op1 ( EVENT-18 / leads
             :ARG0 ( ENTITY-1 / ligation
                    :OF ( ENTITY-CD28 / ENTITY
                           :name ( n-23 / name
                                  :op1 "CD28"))
                    :WITH ( GROUP-2 / either_or
                           :op1 ( ENTITY-CD80 / ENTITY
                                  :name ( n-24 / name
                                         :op1 "CD80"))
                           :op2 ( ENTITY-CD86 / ENTITY
                                  :name ( n-25 / name
                                         :op1 "CD86"))))
             :TO ( GROUP-3 / signal_transduction_events
                    :ATTRIBUTE ( ATTRIB-6 / such
                           :AS ( ENTITY-7 / tyrosine_phosphorylation
                                  :DEFINITE ( ATTRIB-8 / the)
                                  :OF ( GROUP-9 / AND
                                         :op1 ( ENTITY-CBL / ENTITY
                                                :name ( n-26 / name
                                                       :op1 "CBL"))
                                         :op2 ( ENTITY-VAV / ENTITY
                                                :name ( n-27 / name
                                                       :op1 "VAV")))))
                    :ATTRIBUTE ( ATTRIB-5 / early)
                    :ATTRIBUTE ( ATTRIB-4 / shared)))
      :op2 ( EVENT-18 / leads
             :ARG0 ENTITY-1
             :TO ( ENTITY-10 / activation
                    :ATTRIBUTE ( ATTRIB-12 / transcriptional)
                    :ATTRIBUTE ( ATTRIB-11 / nfat-mediated)))
      :op3 ( EVENT-18 / leads
             :ARG0 ENTITY-1
             :TO ( ENTITY-13 / costimulation
                    :DEFINITE ( ATTRIB-14 / the)
                    :OF ( ENTITY-15 / factor_production
                           :ATTRIBUTE ( ATTRIB-16 / colony-stimulating
                                  :COMP ( GROUP-17 / AND
                                         :op1 ( ENTITY-interleukin-2 / ENTITY
                                                :name ( n-28 / name
                                                       :op1 "interleukin-2"))
                                         :op2 ( ENTITY-granulocyte-macrophage / ENTITY
                                                :name ( n-29 / name
                                                       :op1 "granulocyte-macrophage")))))))
      :MOD ( mod-22 / thus))

# ::id 181_nonfiction_GENIA-1999;99115659,11;NE
# ::snt However , CD80 and CD86 also induce distinct signal transduction pathways including the tyrosine phosphorylation of CD28 and phospholipase Cgamma1 and the SH2-dependent association of phosphoinositide 3-kinase with CD28 .
( EVENT-13 / induce
      :ARG0 ( GROUP-1 / AND
             :op1 ( ENTITY-CD80 / ENTITY
                    :name ( n-3 / name
                           :op1 "CD80"))
             :op2 ( ENTITY-CD86 / ENTITY
                    :name ( n-4 / name
                           :op1 "CD86")))
      :ARG1 ( GROUP-2 / signal_transduction_pathways
             :ATTRIBUTE ( ATTRIB-3 / distinct)
             :ARG0-of ( EVENT-12 / including
                    :ARG1 ( GROUP-5 / AND
                           :op1 ( ENTITY-6 / tyrosine_phosphorylation
                                  :DEFINITE ( ATTRIB-7 / the)
                                  :OF ( GROUP-8 / AND
                                         :op1 ( ENTITY-CD28 / ENTITY
                                                :name ( n-5 / name
                                                       :op1 "CD28"))
                                         :op2 ( ENTITY-phospholipase_Cgamma1 / ENTITY
                                                :name ( n-6 / name
                                                       :op1 "phospholipase_Cgamma1"))))
                           :op2 ( ENTITY-9 / association
                                  :DEFINITE ( ATTRIB-10 / the)
                                  :ATTRIBUTE ( ATTRIB-11 / sh2-dependent)
                                  :OF ( ENTITY-phosphoinositide_3-kinase / ENTITY
                                         :name ( n-7 / name
                                                :op1 "phosphoinositide_3-kinase"))
                                  :WITH ENTITY-CD28))))
      :MOD ( mod-1 / also)
      :MOD ( mod-2 / however))

# ::id 182_nonfiction_GENIA-1999;99115659,12;NE
# ::snt These quantitative , if not qualitative , differences between signaling initiated by these two ligands for CD28 may contribute to functional differences -LRB- e.g. Th1 or Th2 differentiation -RRB- in T cell responses .
( EVENT-16 / contribute
      :domain-of ( MD-17 / may)
      :ARG0 ( GROUP-1 / differences
             :DETERMINER ( ATTRIB-2 / these)
             :ATTRIBUTE ( ATTRIB-3 / not
                    :MOD ( mod-18 / quantitative
                           :IF ( ATTRIB-4 / qualitative)))
             :BETWEEN ( ENTITY-5 / signaling
                    :ARG1-of ( EVENT-10 / initiated
                           :ARG0 ( GROUP-7 / ligands
                                  :DETERMINER ( ATTRIB-8 / these)
                                  :CARDINAL ( ATTRIB-9 / two))
                           :FOR ( ENTITY-CD28 / ENTITY
                                  :name ( n-19 / name
                                         :op1 "CD28")))))
      :IN ( GROUP-15 / T_cell_responses)
      :TO ( GROUP-11 / differences
             :ATTRIBUTE ( ATTRIB-12 / functional)
             :E_DOT_G_DOT ( ENTITY-14 / differentiation
                    :NAMELY ( GROUP-13 / or
                           :op1 ( ENTITY-Th1 / ENTITY
                                  :name ( n-20 / name
                                         :op1 "Th1"))
                           :op2 ( ENTITY-Th2 / ENTITY
                                  :name ( n-21 / name
                                         :op1 "Th2"))))))

# ::id 183_nonfiction_GENIA-1999;99115672,1;NE
# ::snt Role of Egr-2 in up-regulation of Fas ligand in normal T cells and aberrant double-negative lpr and gld T cells .
( ENTITY-1 / Role
      :IN ( ENTITY-2 / up-regulation
             :IN ( GROUP-4 / AND
                    :op1 ( GROUP-5 / normal_T_cells)
                    :op2 ( GROUP-10 / cells
                           :NAMELY ( GROUP-6 / AND
                                  :op1 ( ENTITY-7 / lpr
                                         :ATTRIBUTE ( ATTRIB-9 / double-negative)
                                         :ATTRIBUTE ( ATTRIB-8 / aberrant))
                                  :op2 ( ENTITY-gld_T / ENTITY
                                         :name ( n-3 / name
                                                :op1 "gld_T")))))
             :OF ( ENTITY-3 / Fas_ligand))
      :OF ( ENTITY-Egr-2 / ENTITY
             :name ( n-4 / name
                    :op1 "Egr-2")))

# ::id 184_nonfiction_GENIA-1999;99115672,2;NE
# ::snt We previously identified a Fas ligand regulatory element -LRB- FLRE -RRB- in the Fas ligand -LRB- fasL -RRB- promoter that binds Egr family proteins and demonstrated that Egr-3 -LRB- PILOT -RRB- but not Egr-1 -LRB- NGFI-A , Krox-24 , Tis-8 , and Zif-268 -RRB- induces transcription of fasL .
( CONJ-19 / and
      :op1 ( EVENT-10 / identified
             :MOD ( mod-270 / past)
             :ARG0 ( REF1-1 / we)
             :ARG1 ( ENTITY-3 / Fas_ligand_regulatory_element
                    :IN ( ENTITY-5 / Fas_ligand_promoter
                           :DEFINITE ( ATTRIB-6 / the)
                           :ARG0-of ( EVENT-9 / binds
                                  :ARG1 ( GROUP-8 / Egr_family_proteins))
                           :NAMELY ( ENTITY-4 / fasL))
                    :NAMELY ( ENTITY-2 / FLRE))
             :TMP ( TIME-269 / previously))
      :op2 ( EVENT-12 / demonstrated
             :MOD ( mod-271 / past)
             :ARG0 REF1-1
             :THAT ( EVENT-18 / induces
                    :ARG0 ( GROUP-13 / but
                           :op1 ( ENTITY-Egr-3 / ENTITY
                                  :name ( n-274 / name
                                         :op1 "PILOT")
                                  :name ( n-272 / name
                                         :op1 "Egr-3"))
                           :op2 ( ENTITY-Egr-1 / AND
                                  :op1 ( ENTITY-NGFI-A / ENTITY
                                         :name ( n-275 / name
                                                :op1 "NGFI-A"))
                                  :op2 ( ENTITY-Krox-24 / ENTITY
                                         :name ( n-276 / name
                                                :op1 "Krox-24"))
                                  :op3 ( ENTITY-Tis-8 / ENTITY
                                         :name ( n-277 / name
                                                :op1 "Tis-8"))
                                  :op4 ( ENTITY-Zif-268 / ENTITY
                                         :name ( n-278 / name
                                                :op1 "Zif-268"))
                                  :name ( n-273 / name
                                         :op1 "Egr-1")
                                  :QUANTIFIER ( ATTRIB-15 / not)))
                    :ARG1 ( ENTITY-16 / transcription
                           :OF ( ENTITY-17 / fasL)))))

# ::id 185_nonfiction_GENIA-1999;99115672,3;NE
# ::snt The aberrant CD4 CD8 T cells from lpr/lpr and gld/gld mice , which have mutations in the genes encoding Fas and FasL , respectively , have an activated phenotype and constitutively express high levels of fasL mRNA , prompting us to ask what role if any the FLRE and Egr family proteins have in this aberrant expression of fasL .
( CONJ-46 / and
      :op1 ( CONJ-41 / and
             :op1 ( EVENT-35 / have
                    :ARG0 ( GROUP-1 / aberrant_CD4_CD8_T_cells
                           :DEFINITE ( ATTRIB-2 / the)
                           :FROM ( GROUP-3 / AND
                                  :op1 ( GROUP-4 / lpr_slash_lpr_mice)
                                  :op2 ( GROUP-5 / gld_slash_gld_mice))
                           :ARG0-of ( EVENT-16 / have
                                  :ARG1 ( GROUP-7 / mutations
                                         :IN ( GROUP-8 / genes
                                                :DEFINITE ( ATTRIB-9 / the)
                                                :ARG0-of ( EVENT-14 / encoding
                                                       :ARG1 ( GROUP-11 / AND
                                                              :op1 ( ENTITY-12 / Fas)
                                                              :op2 ( ENTITY-13 / FasL))
                                                       :MOD ( mod-47 / respectively))))))
                    :ARG1 ( ENTITY-33 / phenotype
                           :ATTRIBUTE ( ATTRIB-34 / activated)))
             :op2 ( EVENT-39 / express
                    :ARG0 GROUP-1
                    :ARG1 ( GROUP-36 / levels
                           :ATTRIBUTE ( ATTRIB-37 / high)
                           :OF ( ENTITY-38 / fasL_mRNA))
                    :MOD ( mod-48 / constitutively)))
      :op2 ( EVENT-18 / prompting
             :ARG0 GROUP-1
             :ARG1 ( REF1-17 / us)
             :TOCOMP ( EVENT-19 / ask
                    :ARG0 REF1-17
                    :THAT ( EVENT-32 / have
                           :domain-of ( QUEST-45 / QUEST)
                           :ARG0 ( ENTITY-23 / AND
                                  :DEFINITE ( ATTRIB-24 / the)
                                  :op1 ( GROUP-26 / FLRE_family_proteins)
                                  :op2 ( GROUP-27 / Egr_family_proteins))
                           :ARG1 ( ENTITY-20 / role
                                  :QUANTIFIER ( ENTITY_UNK-4 / penman-unknown)
                                  :IF ( ENTITY-21 / ENTITY
                                         :QUANTIFIER ( ATTRIB-22 / any)))
                           :IN ( ENTITY-28 / expression
                                  :DETERMINER ( ATTRIB-29 / this)
                                  :ATTRIBUTE ( ATTRIB-30 / aberrant)
                                  :OF ( ENTITY-31 / fasL))))))

# ::id 186_nonfiction_GENIA-1999;99115672,4;NE
# ::snt Unstimulated MRL-lpr/lpr and C3H-gld/gld CD4 CD8 T cells constitutively contained high levels of two proteins that bound to the FLRE .
( EVENT-11 / contained
      :MOD ( mod-2 / past)
      :ARG0 ( GROUP-2 / Unstimulated_CD4_CD8_T_cells
             :NAMELY ( GROUP-1 / AND
                    :op1 ( ENTITY-MRL-lpr_slash_lpr / ENTITY
                           :name ( n-4 / name
                                  :op1 "MRL-lpr_slash_lpr"))
                    :op2 ( ENTITY-C3H-gld_slash_gld / ENTITY
                           :name ( n-5 / name
                                  :op1 "C3H-gld_slash_gld"))))
      :ARG1 ( GROUP-3 / levels
             :ATTRIBUTE ( ATTRIB-4 / high)
             :OF ( GROUP-5 / proteins
                    :CARDINAL ( ATTRIB-6 / two)
                    :ARG0-of ( EVENT-10 / bound
                           :MOD ( mod-1 / past)
                           :TO ( ENTITY-8 / FLRE
                                  :DEFINITE ( ATTRIB-9 / the)))))
      :MOD ( mod-3 / constitutively))

# ::id 187_nonfiction_GENIA-1999;99115672,5;NE
# ::snt Supershift analysis revealed these proteins to be Egr-1 and Egr-2 -LRB- Krox-20 -RRB- ;
( EVENT-4 / revealed
      :MOD ( mod-21 / past)
      :ARG0 ( ENTITY-1 / Supershift_analysis)
      :ARG1 ( GROUP-2 / proteins
             :DETERMINER ( ATTRIB-3 / these))
      :TOCOMP ( EVENT-6 / copula
             :ARG0 GROUP-2
             :ARG1 ( GROUP-5 / AND
                    :op1 ( ENTITY-Egr-1 / ENTITY
                           :name ( n-23 / name
                                  :op1 "Egr-1"))
                    :op2 ( ENTITY-Egr-2 / ENTITY
                           :name ( n-24 / name
                                  :op1 "Krox-20")
                           :name ( n-22 / name
                                  :op1 "Egr-2")))))

# ::id 188_nonfiction_GENIA-1999;99115672,5;NE
# ::snt Egr-3 was not detected .
( EVENT-1 / detected
      :domain-of ( NEG-2 / NEG)
      :MOD ( mod-4 / past)
      :ARG1 ( ENTITY-Egr-3 / ENTITY
             :name ( n-5 / name
                    :op1 "Egr-3")))

# ::id 189_nonfiction_GENIA-1999;99115672,6;NE
# ::snt Activation of normal lymph node cells resulted in increased expression of Egr-1 , -2 , and -3 .
( EVENT-7 / resulted
      :MOD ( mod-4 / past)
      :ARG0 ( ENTITY-1 / Activation
             :OF ( GROUP-2 / lymph_node_cells
                    :ATTRIBUTE ( ATTRIB-3 / normal)))
      :IN ( ENTITY-4 / expression
             :ATTRIBUTE ( ATTRIB-5 / increased)
             :OF ( GROUP-6 / AND
                    :op1 ( ENTITY-Egr-1 / ENTITY
                           :name ( n-5 / name
                                  :op1 "Egr-1"))
                    :op2 ( ENTITY--2 / ENTITY
                           :name ( n-6 / name
                                  :op1 "-2"))
                    :op3 ( ENTITY--3 / ENTITY
                           :name ( n-7 / name
                                  :op1 "-3")))))

# ::id 190_nonfiction_GENIA-1999;99115672,7;NE
# ::snt As with egr-3 , expression of egr-2 was blocked by cyclosporin A .
( EVENT-2 / blocked
      :MOD ( mod-4 / past)
      :ARG0 ( ENTITY-cyclosporin_A / ENTITY
             :name ( n-5 / name
                    :op1 "cyclosporin_A"))
      :ARG1 ( ENTITY-1 / expression
             :OF ( ENTITY-egr-2 / ENTITY
                    :name ( n-6 / name
                           :op1 "egr-2")))
      :AS_WITH ( ENTITY-egr-3 / ENTITY
             :name ( n-7 / name
                    :op1 "egr-3")))

# ::id 191_nonfiction_GENIA-1999;99115672,8;NE
# ::snt Although overexpressed Egr-1 was ineffective , overexpressed Egr-2 was as potent as Egr-3 in inducing fasL promoter-dependent reporter constructs in T cell hybridomas and HeLa cells ,
( EVENT-11 / copula
      :MOD ( mod-5 / past)
      :ATTRIBUTE ( ATTRIB-4 / as_potent
             :AS ( ENTITY-Egr-3 / ENTITY
                    :name ( n-7 / name
                           :op1 "Egr-3")))
      :ARG0 ( ENTITY-overexpressed_Egr-2 / ENTITY
             :name ( n-6 / name
                    :op1 "overexpressed_Egr-2"))
      :IN ( EVENT-10 / inducing
             :ARG0 ENTITY-overexpressed_Egr-2
             :ARG1 ( GROUP-6 / fasL_promoter-dependent_reporter_constructs)
             :IN ( GROUP-7 / AND
                    :op1 ( GROUP-8 / T_cell_hybridomas)
                    :op2 ( GROUP-9 / HeLa_cells)))
      :ALTHOUGH ( EVENT-3 / copula
             :MOD ( mod-4 / past)
             :ATTRIBUTE ( ATTRIB-2 / ineffective)
             :ARG0 ( ENTITY-overexpressed_Egr-1 / ENTITY
                    :name ( n-8 / name
                           :op1 "overexpressed_Egr-1"))))

# ::id 192_nonfiction_GENIA-1999;99115672,8;NE
# ::snt and both up-regulated endogenous fasL mRNA in HeLa cells .
( EVENT-6 / up-regulated
      :MOD ( mod-1 / past)
      :ARG0 ( ENTITY-1 / ENTITY
             :QUANTIFIER ( ATTRIB-2 / both))
      :ARG1 ( ENTITY-3 / fasL_mRNA
             :ATTRIBUTE ( ATTRIB-4 / endogenous))
      :IN ( GROUP-5 / HeLa_cells))

# ::id 193_nonfiction_GENIA-1999;99115672,9;NE
# ::snt FasL-dependent reporter constructs in MRL-lpr/lpr and C3H-gld/gld CD4 CD8 T cells were constitutively active ,
( EVENT-6 / copula
      :MOD ( mod-1 / past)
      :ATTRIBUTE ( ATTRIB-5 / constitutively_active)
      :ARG0 ( GROUP-1 / reporter_constructs
             :ATTRIBUTE ( ATTRIB-2 / fasl-dependent)
             :IN ( GROUP-4 / CD4_CD8_T_cells
                    :NAMELY ( GROUP-3 / AND
                           :op1 ( ENTITY-MRL-lpr_slash_lpr / ENTITY
                                  :name ( n-2 / name
                                         :op1 "MRL-lpr_slash_lpr"))
                           :op2 ( ENTITY-C3H-gld_slash_gld / ENTITY
                                  :name ( n-3 / name
                                         :op1 "C3H-gld_slash_gld"))))))

# ::id 194_nonfiction_GENIA-1999;99115672,9;NE
# ::snt and this activity was largely prevented by mutation of the critical Egr family binding element .
( EVENT-7 / prevented
      :MOD ( mod-2 / past)
      :ARG0 ( ENTITY-3 / mutation
             :OF ( ENTITY-4 / Egr_family_binding_element
                    :DEFINITE ( ATTRIB-5 / the)
                    :ATTRIBUTE ( ATTRIB-6 / critical)))
      :ARG1 ( ENTITY-1 / activity
             :DETERMINER ( ATTRIB-2 / this))
      :MOD ( mod-1 / largely))

# ::id 195_nonfiction_GENIA-1999;99115672,10;NE
# ::snt Thus , Egr-2 , in addition to Egr-3 , regulates FasL expression in activated normal T cells ,
( EVENT-4 / regulates
      :ARG0 ( ENTITY-Egr-2 / ENTITY
             :name ( n-5 / name
                    :op1 "Egr-2"))
      :ARG1 ( ENTITY-2 / FasL_expression
             :IN ( GROUP-3 / activated_normal_T_cells))
      :IN ( ENTITY-1 / addition
             :TO ( ENTITY-Egr-3 / ENTITY
                    :name ( n-6 / name
                           :op1 "Egr-3")))
      :MOD ( mod-4 / thus))

# ::id 196_nonfiction_GENIA-1999;99115672,10;NE
# ::snt and Egr-2 is likely to play a direct role in aberrant fasL up-regulation in lpr/lpr and gld/gld CD4 CD8 T cells .
( EVENT-8 / copula
      :ATTRIBUTE ( ATTRIB-1 / likely
             :TOCOMP ( EVENT-7 / play
                    :ARG1 ( ENTITY-2 / role
                           :ATTRIBUTE ( ATTRIB-3 / direct))
                    :IN ( ENTITY-4 / aberrant_fasL_up-regulation
                           :IN ( GROUP-6 / CD4_CD8_T_cells
                                  :NAMELY ( GROUP-5 / AND
                                         :op1 ( ENTITY-lpr_slash_lpr / ENTITY
                                                :name ( n-4 / name
                                                       :op1 "lpr_slash_lpr"))
                                         :op2 ( ENTITY-gld_slash_gld / ENTITY
                                                :name ( n-5 / name
                                                       :op1 "gld_slash_gld")))))))
      :ARG0 ( ENTITY-Egr-2 / ENTITY
             :name ( n-3 / name
                    :op1 "Egr-2")))

# ::id 197_nonfiction_GENIA-1999;99118181,1;NE
# ::snt Inhibition of NF-kappaB activation in vitro and in vivo : role of 26S proteasome .
( ENTITY-3 / Inhibition
      :OF ( CONJ-8 / and
             :op1 ( ENTITY-4 / NF-kappaB_activation
                    :ATTRIBUTE ( ATTRIB-5 / in_vitro))
             :op2 ( ENTITY-4 / NF-kappaB_activation
                    :ATTRIBUTE ( ATTRIB-6 / in_vivo)))
      :NAMELY ( ENTITY-1 / role
             :OF ( ENTITY-2 / 26S_proteasome)))

# ::id 198_nonfiction_GENIA-1999;99118181,2;NE
# ::snt It is becoming increasingly apparent that NF-kappaB plays a critical role in regulating the inflammatory response .
( EVENT-11 / is_becoming
      :ATTRIBUTE ( ATTRIB-10 / increasingly_apparent)
      :ARG0 ( EVENT-9 / plays
             :ARG0 ( ENTITY-NF-kappaB / ENTITY
                    :name ( n-1 / name
                           :op1 "NF-kappaB"))
             :ARG1 ( ENTITY-2 / role
                    :ATTRIBUTE ( ATTRIB-3 / critical)
                    :IN ( EVENT-8 / regulating
                           :ARG1 ( ENTITY-5 / response
                                  :DEFINITE ( ATTRIB-6 / the)
                                  :ATTRIBUTE ( ATTRIB-7 / inflammatory))))))

# ::id 199_nonfiction_GENIA-1999;99118181,3;NE
# ::snt Data obtained from studies in our laboratories demonstrate that the proteasome plays an important role in the inflammatory cascade by regulating the activation of NF-kappaB .
( EVENT-7 / demonstrate
      :ARG0 ( GROUP-1 / Data
             :ARG1-of ( EVENT-6 / obtained
                    :FROM ( GROUP-3 / studies
                           :IN ( GROUP-4 / laboratories
                                  :POS ( REF1-5 / our)))))
      :THAT ( EVENT-19 / plays
             :ARG0 ( ENTITY-8 / proteasome
                    :DEFINITE ( ATTRIB-9 / the))
             :ARG1 ( ENTITY-10 / role
                    :ATTRIBUTE ( ATTRIB-11 / important)
                    :BY ( EVENT-18 / regulating
                           :ARG1 ( ENTITY-16 / activation
                                  :DEFINITE ( ATTRIB-17 / the)
                                  :OF ( ENTITY-NF-kappaB / ENTITY
                                         :name ( n-1 / name
                                                :op1 "NF-kappaB"))))
                    :IN ( ENTITY-12 / cascade
                           :DEFINITE ( ATTRIB-13 / the)
                           :ATTRIBUTE ( ATTRIB-14 / inflammatory)))))

# ::id 200_nonfiction_GENIA-1999;99118181,4;NE
# ::snt Indeed , the availability of selective and orally active proteasome inhibitors should prove useful in delineating the roles of the proteasome and NF-kappaB in other pathophysiological conditions such as cancer and heart disease .
( EVENT-24 / prove
      :domain-of ( MD-25 / should)
      :ATTRIBUTE ( ATTRIB-9 / useful
             :IN ( EVENT-23 / delineating
                    :ARG1 ( GROUP-11 / roles
                           :DEFINITE ( ATTRIB-12 / the)
                           :IN ( GROUP-16 / conditions
                                  :ATTRIBUTE ( ATTRIB-19 / such
                                         :AS ( GROUP-20 / AND
                                                :op1 ( ENTITY-21 / cancer)
                                                :op2 ( ENTITY-22 / heart_disease)))
                                  :ATTRIBUTE ( ATTRIB-18 / pathophysiological)
                                  :ATTRIBUTE ( ATTRIB-17 / other))
                           :OF ( GROUP-13 / AND
                                  :op1 ( ENTITY-14 / proteasome
                                         :DEFINITE ( ATTRIB-15 / the))
                                  :op2 ( ENTITY-NF-kappaB / ENTITY
                                         :name ( n-26 / name
                                                :op1 "NF-kappaB"))))))
      :ARG0 ( ENTITY-2 / availability
             :DEFINITE ( ATTRIB-3 / the)
             :OF ( GROUP-4 / AND
                    :op1 ( GROUP-5 / proteasome_inhibitors
                           :ATTRIBUTE ( ATTRIB-6 / selective))
                    :op2 ( GROUP-7 / proteasome_inhibitors
                           :ATTRIBUTE ( ATTRIB-8 / orally_active))))
      :IN ( ENTITY-1 / deed))

# ::id 201_nonfiction_GENIA-1999;99119105,1;NE
# ::snt Requirement of GATA-1 and p45 NF-E2 expression in butyric acid -induced erythroid differentiation .
( ENTITY-1 / Requirement
      :OF ( ENTITY-3 / NF-E2_expression
             :IN ( ENTITY-4 / differentiation
                    :ATTRIBUTE ( ATTRIB-7 / erythroid)
                    :ATTRIBUTE ( ATTRIB-5 / -induced
                           :COMP ( ENTITY-6 / butyric_acid)))
             :NAMELY ( GROUP-2 / AND
                    :op1 ( ENTITY-GATA-1 / ENTITY
                           :name ( n-2 / name
                                  :op1 "GATA-1"))
                    :op2 ( ENTITY-p45 / ENTITY
                           :name ( n-3 / name
                                  :op1 "p45")))))

# ::id 202_nonfiction_GENIA-1999;99119105,2;NE
# ::snt Butyric acid -LRB- BA -RRB- is known to induce overexpression of fetal hemoglobin and then erythroid differentiation .
( EVENT-2 / is_known
      :ARG0 ( ENTITY-1 / Butyric_acid
             :NAMELY ( ENTITY-BA / ENTITY
                    :name ( n-1 / name
                           :op1 "BA")))
      :TOCOMP ( EVENT-9 / induce
             :ARG0 ENTITY-1
             :ARG1 ( ENTITY-3 / overexpression
                    :OF ( GROUP-4 / and_then
                           :op1 ( ENTITY-5 / hemoglobin
                                  :ATTRIBUTE ( ATTRIB-6 / fetal))
                           :op2 ( ENTITY-7 / differentiation
                                  :ATTRIBUTE ( ATTRIB-8 / erythroid))))))

# ::id 203_nonfiction_GENIA-1999;99119105,3;NE
# ::snt Therefore , BA is currently under clinical investigation as a potential therapy for the treatment of sickle cell disease and cancer .
( EVENT-11 / copula
      :ARG0 ( ENTITY-BA / ENTITY
             :name ( n-3 / name
                    :op1 "BA"))
      :UNDER ( ENTITY-1 / investigation
             :ATTRIBUTE ( ATTRIB-2 / clinical)
             :AS ( ENTITY-3 / therapy
                    :ATTRIBUTE ( ATTRIB-4 / potential)
                    :FOR ( ENTITY-5 / treatment
                           :DEFINITE ( ATTRIB-6 / the)
                           :OF ( GROUP-7 / AND
                                  :op1 ( ENTITY-8 / cell_disease
                                         :ATTRIBUTE ( ATTRIB-9 / sickle))
                                  :op2 ( ENTITY-10 / cancer)))))
      :MOD ( mod-1 / therefore)
      :TMP ( TIME-2 / currently))

# ::id 204_nonfiction_GENIA-1999;99119105,4;NE
# ::snt Nevertheless , the molecular mechanisms involved in BA-induced differentiation remain largely unknown .
( EVENT-9 / remain
      :ATTRIBUTE ( ATTRIB-8 / largely_unknown)
      :ARG0 ( GROUP-1 / mechanisms
             :DEFINITE ( ATTRIB-2 / the)
             :ATTRIBUTE ( ATTRIB-3 / molecular)
             :ARG1-of ( EVENT-7 / involved
                    :IN ( ENTITY-5 / differentiation
                           :ATTRIBUTE ( ATTRIB-6 / ba-induced))))
      :MOD ( mod-1 / nevertheless))

# ::id 205_nonfiction_GENIA-1999;99119105,5;NE
# ::snt Previous reports have shown that BA-induced overexpression of erythroid genes occurred at the transcriptional level , suggesting the involvement of erythroid transcription factors .
( CONJ-17 / and
      :op1 ( EVENT-8 / have_shown
             :ARG0 ( GROUP-1 / reports
                    :ATTRIBUTE ( ATTRIB-2 / previous))
             :THAT ( EVENT-16 / occurred
                    :MOD ( mod-18 / past)
                    :ARG0 ( ENTITY-9 / overexpression
                           :ATTRIBUTE ( ATTRIB-10 / ba-induced)
                           :OF ( GROUP-11 / genes
                                  :ATTRIBUTE ( ATTRIB-12 / erythroid)))
                    :AT ( ENTITY-13 / level
                           :DEFINITE ( ATTRIB-14 / the)
                           :ATTRIBUTE ( ATTRIB-15 / transcriptional))))
      :op2 ( EVENT-7 / suggesting
             :ARG0 GROUP-1
             :ARG1 ( ENTITY-3 / involvement
                    :DEFINITE ( ATTRIB-4 / the)
                    :OF ( GROUP-5 / transcription_factors
                           :ATTRIBUTE ( ATTRIB-6 / erythroid)))))

# ::id 206_nonfiction_GENIA-1999;99119105,6;NE
# ::snt Here , we intend to demonstrate the requirement of GATA-1 and NF-E2 transcription factors in the BA-induced erythroid differentiation of human leukemic K562 cells .
( EVENT-2 / intend
      :ARG0 ( REF1-1 / we)
      :TOCOMP ( EVENT-14 / demonstrate
             :ARG0 REF1-1
             :ARG1 ( ENTITY-3 / requirement
                    :DEFINITE ( ATTRIB-4 / the)
                    :IN ( ENTITY-9 / differentiation
                           :DEFINITE ( ATTRIB-10 / the)
                           :ATTRIBUTE ( ATTRIB-12 / erythroid)
                           :ATTRIBUTE ( ATTRIB-11 / ba-induced)
                           :OF ( GROUP-13 / human_leukemic_K562_cells))
                    :OF ( GROUP-8 / transcription_factors
                           :NAMELY ( GROUP-5 / AND
                                  :op1 ( ENTITY-6 / GATA-1)
                                  :op2 ( ENTITY-7 / NF-E2)))))
      :LOC ( LOC-2 / here))

# ::id 207_nonfiction_GENIA-1999;99119105,7;NE
# ::snt Time-course experiments showed that nuclear levels of GATA-1 and p45 NF-E2 proteins increased during BA treatment .
( EVENT-3 / showed
      :MOD ( mod-3 / past)
      :ARG0 ( GROUP-1 / experiments
             :ATTRIBUTE ( ATTRIB-2 / time-course))
      :THAT ( EVENT-9 / increased
             :MOD ( mod-2 / past)
             :ARG0 ( GROUP-4 / levels
                    :ATTRIBUTE ( ATTRIB-5 / nuclear)
                    :OF ( GROUP-7 / NF-E2_proteins
                           :NAMELY ( GROUP-6 / AND
                                  :op1 ( ENTITY-GATA-1 / ENTITY
                                         :name ( n-4 / name
                                                :op1 "GATA-1"))
                                  :op2 ( ENTITY-p45 / ENTITY
                                         :name ( n-5 / name
                                                :op1 "p45")))))
             :DURING ( ENTITY-8 / BA_treatment)))

# ::id 208_nonfiction_GENIA-1999;99119105,8;NE
# ::snt Moreover , antisense oligodeoxynucleotides targeting either GATA-1 or p45 NF-E2 proteins inhibited both protein expression and BA-induced differentiation .
( EVENT-13 / inhibited
      :MOD ( mod-2 / past)
      :ARG0 ( GROUP-1 / oligodeoxynucleotides
             :ATTRIBUTE ( ATTRIB-2 / antisense)
             :ARG0-of ( EVENT-6 / targeting
                    :ARG1 ( GROUP-5 / NF-E2_proteins
                           :NAMELY ( GROUP-4 / either_or
                                  :op1 ( ENTITY-GATA-1 / ENTITY
                                         :name ( n-4 / name
                                                :op1 "GATA-1"))
                                  :op2 ( ENTITY-p45 / ENTITY
                                         :name ( n-5 / name
                                                :op1 "p45"))))))
      :ARG1 ( group-7 / AND
             :op1 ( ENTITY-10 / protein_expression)
             :op2 ( ENTITY-11 / differentiation
                    :ATTRIBUTE ( ATTRIB-12 / ba-induced))
             :QUANTIFIER ( ATTRIB-8 / both))
      :MOD ( mod-3 / moreover))

# ::id 209_nonfiction_GENIA-1999;99119105,9;NE
# ::snt In contrast , BA-induced cell growth inhibition was not affected .
( EVENT-4 / affected
      :domain-of ( NEG-5 / NEG)
      :MOD ( mod-6 / past)
      :ARG1 ( ENTITY-2 / cell_growth_inhibition
             :ATTRIBUTE ( ATTRIB-3 / ba-induced))
      :IN ( ENTITY-1 / contrast))

# ::id 210_nonfiction_GENIA-1999;99119105,10;NE
# ::snt These results provide the first direct evidence for the requirement of GATA-1 and NF-E2 in BA-induced differentiation process .
( EVENT-12 / provide
      :ARG0 ( GROUP-1 / results
             :DETERMINER ( ATTRIB-2 / these))
      :ARG1 ( ENTITY-3 / evidence
             :DEFINITE ( ATTRIB-4 / the)
             :ATTRIBUTE ( ATTRIB-6 / direct)
             :ATTRIBUTE ( ATTRIB-5 / first)
             :FOR ( ENTITY-7 / requirement
                    :DEFINITE ( ATTRIB-8 / the)
                    :IN ( ENTITY-10 / differentiation_process
                           :ATTRIBUTE ( ATTRIB-11 / ba-induced))
                    :OF ( GROUP-9 / AND
                           :op1 ( ENTITY-GATA-1 / ENTITY
                                  :name ( n-2 / name
                                         :op1 "GATA-1"))
                           :op2 ( ENTITY-NF-E2 / ENTITY
                                  :name ( n-3 / name
                                         :op1 "NF-E2"))))))

# ::id 211_nonfiction_GENIA-1999;99120322,1;NE
# ::snt A novel growth-factor-dependent myeloid cell line derived from mouse bone marrow cells contains progenitors endowed with high proliferative potential .
( EVENT-13 / contains
      :ARG0 ( ENTITY-1 / cell_line
             :ATTRIBUTE ( ATTRIB-4 / myeloid)
             :ATTRIBUTE ( ATTRIB-3 / growth-factor-dependent)
             :ATTRIBUTE ( ATTRIB-2 / novel)
             :ARG1-of ( EVENT-7 / derived
                    :FROM ( GROUP-6 / mouse_bone_marrow_cells)))
      :ARG1 ( GROUP-8 / progenitors
             :ATTRIBUTE ( ATTRIB-9 / endowed
                    :WITH ( ENTITY-10 / potential
                           :ATTRIBUTE ( ATTRIB-12 / proliferative)
                           :ATTRIBUTE ( ATTRIB-11 / high)))))

# ::id 212_nonfiction_GENIA-1999;99120322,2;NE
# ::snt Constitutive expression of human colony-stimulating factor-1 receptor -LRB- CSF-1R -RRB- confers long-lasting CSF-1-dependent proliferation to mouse myeloid cell lines .
( EVENT-9 / confers
      :ARG0 ( ENTITY-1 / expression
             :ATTRIBUTE ( ATTRIB-2 / constitutive)
             :OF ( ENTITY-4 / human_colony-stimulating_factor-1_receptor
                    :NAMELY ( ENTITY-3 / CSF-1R)))
      :ARG1 ( ENTITY-5 / proliferation
             :ATTRIBUTE ( ATTRIB-7 / csf-1-dependent)
             :ATTRIBUTE ( ATTRIB-6 / long-lasting)
             :TO ( GROUP-8 / mouse_myeloid_cell_lines)))

# ::id 213_nonfiction_GENIA-1999;99120322,3;NE
# ::snt We developed mice transgenic for human CSF-1R because mouse CSF-1 can not activate human CSF-1R .
( CRD-13 / because
      :op1 ( EVENT-9 / activate
             :domain-of ( MD-12 / can)
             :domain-of ( NEG-11 / NEG)
             :ARG0 ( ENTITY-6 / mouse_CSF-1)
             :ARG1 ( ENTITY-7 / CSF-1R
                    :ATTRIBUTE ( ATTRIB-8 / human)))
      :op2 ( EVENT-10 / developed
             :MOD ( mod-14 / past)
             :ARG0 ( REF1-1 / we)
             :ARG1 ( GROUP-2 / mice
                    :ATTRIBUTE ( ATTRIB-3 / transgenic
                           :FOR ( ENTITY-4 / CSF-1R
                                  :ATTRIBUTE ( ATTRIB-5 / human))))))

# ::id 214_nonfiction_GENIA-1999;99120322,4;NE
# ::snt Then bone marrow cells from transgenic mice were plated onto MS-5 stromal cells expressing the membrane form of human CSF-1 -LRB- 2M-1 cells -RRB- in order to combine the hematopoietic supporting properties of stromal cells and the proliferative effects of CSF-1 .
( EVENT-24 / plated
      :MOD ( mod-2 / past)
      :ARG1 ( GROUP-1 / bone_marrow_cells
             :FROM ( GROUP-2 / mice
                    :ATTRIBUTE ( ATTRIB-3 / transgenic)))
      :IN ( ENTITY-12 / order
             :TOCOMP ( EVENT-23 / combine
                    :ARG1 ( GROUP-13 / AND
                           :op1 ( GROUP-14 / supporting_properties
                                  :DEFINITE ( ATTRIB-15 / the)
                                  :ATTRIBUTE ( ATTRIB-16 / hematopoietic)
                                  :OF ( GROUP-17 / cells
                                         :ATTRIBUTE ( ATTRIB-18 / stromal)))
                           :op2 ( GROUP-19 / effects
                                  :DEFINITE ( ATTRIB-20 / the)
                                  :ATTRIBUTE ( ATTRIB-21 / proliferative)
                                  :OF ( ENTITY-22 / CSF-1)))))
      :ONTO ( GROUP-4 / MS-5_stromal_cells
             :ARG0-of ( EVENT-11 / expressing
                    :ARG1 ( ENTITY-6 / membrane_form
                           :DEFINITE ( ATTRIB-7 / the)
                           :OF ( ENTITY-9 / CSF-1
                                  :ATTRIBUTE ( ATTRIB-10 / human)
                                  :NAMELY ( ENTITY-8 / 2M-1_cells)))))
      :TMP ( TIME-3 / then))

# ::id 215_nonfiction_GENIA-1999;99120322,5;NE
# ::snt Thus , we were able to derive a hematopoietic cell line , called 47.10 , that grew indefinitely under these conditions , whereas no cell line could be developed from nontransgenic mice .
( EVENT-19 / copula
      :MOD ( mod-25 / past)
      :ATTRIBUTE ( ATTRIB-2 / able
             :TOCOMP ( EVENT-12 / derive
                    :ARG1 ( ENTITY-3 / cell_line
                           :ATTRIBUTE ( ATTRIB-4 / hematopoietic)
                           :ARG0-of ( EVENT-6 / called
                                  :ARG1 ( ENTITY-47.10 / ENTITY
                                         :name ( n-27 / name
                                                :op1 "47.10")))
                           :ARG0-of ( EVENT-10 / grew
                                  :MOD ( mod-24 / past)
                                  :UNDER ( GROUP-8 / conditions
                                         :DETERMINER ( ATTRIB-9 / these))
                                  :MOD ( mod-23 / indefinitely)))))
      :ARG0 ( REF1-1 / we)
      :WHEREAS ( EVENT-18 / developed
             :domain-of ( MD-22 / could)
             :ARG1 ( ENTITY-14 / cell_line
                    :QUANTIFIER ( ATTRIB-15 / no))
             :FROM ( GROUP-16 / mice
                    :ATTRIBUTE ( ATTRIB-17 / nontransgenic)))
      :MOD ( mod-26 / thus))

# ::id 216_nonfiction_GENIA-1999;99120322,6;NE
# ::snt Proliferation of 47.10 cells is severely affected by neutralizing anti-CSF-1R monoclonal antibodies .
( EVENT-7 / affected
      :ARG0 ( GROUP-3 / antibodies
             :ATTRIBUTE ( ATTRIB-6 / monoclonal)
             :ATTRIBUTE ( ATTRIB-5 / anti-csf-1r)
             :ATTRIBUTE ( ATTRIB-4 / neutralizing))
      :ARG1 ( ENTITY-1 / Proliferation
             :OF ( GROUP-2 / 47.10_cells))
      :MOD ( mod-1 / severely))

# ::id 217_nonfiction_GENIA-1999;99120322,7;NE
# ::snt Morphologic and cytofluorometry analysis established that most 47.10 cells are immature myelomonocytic cells .
( EVENT-4 / established
      :MOD ( mod-12 / past)
      :ARG0 ( CONJ-11 / and
             :op1 ( ENTITY-1 / analysis
                    :ATTRIBUTE ( ATTRIB-2 / morphologic))
             :op2 ( ENTITY-1 / analysis
                    :ATTRIBUTE ( ATTRIB-3 / cytofluorometry)))
      :THAT ( EVENT-10 / copula
             :ARG0 ( GROUP-5 / 47.10_cells
                    :QUANTIFIER ( ATTRIB-6 / most))
             :ARG1 ( GROUP-7 / cells
                    :ATTRIBUTE ( ATTRIB-9 / myelomonocytic)
                    :ATTRIBUTE ( ATTRIB-8 / immature))))

# ::id 218_nonfiction_GENIA-1999;99120322,8;NE
# ::snt Consistent with this phenotype , the myeloid transcription factor PU.1 , but not the erythroid transcription factor GATA-1 , is expressed in 47.10 cells .
( CONJ-14 / and
      :op1 ( EVENT-13 / expressed
             :ARG1 ( GROUP-1 / but_not
                    :op1 ( ENTITY-2 / transcription_factor
                           :DEFINITE ( ATTRIB-3 / the)
                           :ATTRIBUTE ( ATTRIB-4 / myeloid)
                           :NAMELY ( ENTITY-PU.1 / ENTITY
                                  :name ( n-15 / name
                                         :op1 "PU.1")))
                    :op2 ( ENTITY-5 / transcription_factor
                           :DEFINITE ( ATTRIB-6 / the)
                           :ATTRIBUTE ( ATTRIB-7 / erythroid)
                           :NAMELY ( ENTITY-GATA-1 / ENTITY
                                  :name ( n-16 / name
                                         :op1 "GATA-1"))))
             :IN ( GROUP-12 / 47.10_cells))
      :op2 ( EVENT-11 / EVENT
             :ATTRIBUTE ( ATTRIB-8 / consistent
                    :WITH ( ENTITY-9 / phenotype
                           :DETERMINER ( ATTRIB-10 / this)))
             :ARG0 GROUP-1))

# ::id 219_nonfiction_GENIA-1999;99120322,9;NE
# ::snt A few 47.10 cells -LRB- 3-5 % -RRB- do not express lineage specific markers ;
( EVENT-7 / do_express
      :domain-of ( NEG-8 / NEG)
      :ARG0 ( GROUP-1 / 47.10_cells
             :MSR ( DEGREE-3 / percent
                    :CARDINAL ( ATTRIB-4 / 3-5))
             :QUANTIFIER ( ATTRIB-2 / few))
      :ARG1 ( GROUP-5 / markers
             :ATTRIBUTE ( ATTRIB-6 / lineage_specific)))

# ::id 220_nonfiction_GENIA-1999;99120322,9;NE
# ::snt they differentiate spontaneously to lineage-positive cells after replating on 2M-1 cells .
( CRD-9 / after
      :op1 ( EVENT-5 / replating
             :ARG0 ( REF1-1 / they)
             :ON ( GROUP-4 / 2M-1_cells))
      :op2 ( EVENT-6 / differentiate
             :ARG0 REF1-1
             :TO ( GROUP-2 / cells
                    :ATTRIBUTE ( ATTRIB-3 / lineage-positive)))
      :MOD ( mod-10 / spontaneously))

# ::id 221_nonfiction_GENIA-1999;99120322,10;NE
# ::snt In agar cultures , 47.10 cells form 7- and 14 -day colonies in response to a cocktail of granulocyte/macrophage colony-stimulating factor -LRB- 2.5 ng/mL -RRB- , interleukin-3 -LRB- 1 ng/mL -RRB- , and mouse CSF-1 -LRB- 10 ng/mL -RRB- .
( EVENT-17 / form
      :ARG0 ( GROUP-2 / 47.10_cells)
      :ARG1 ( GROUP-3 / colonies
             :TMP ( TIME-4 / -day
                    :CARDINAL ( ATTRIB-5 / 7-and_14)))
      :IN ( ENTITY-6 / response
             :TO ( ENTITY-7 / cocktail
                    :OF ( GROUP-8 / AND
                           :op1 ( ENTITY-9 / granulocyte_slash_macrophage_colony-stimulating_factor
                                  :MSR ( DEGREE-10 / ng_slash_mL
                                         :CARDINAL ( ATTRIB-11 / 2.5)))
                           :op2 ( ENTITY-interleukin-3 / ENTITY
                                  :name ( n-4 / name
                                         :op1 "interleukin-3")
                                  :MSR ( DEGREE-12 / ng_slash_mL
                                         :CARDINAL ( ATTRIB-13 / 1)))
                           :op3 ( ENTITY-14 / mouse_CSF-1
                                  :MSR ( DEGREE-15 / ng_slash_mL
                                         :CARDINAL ( ATTRIB-16 / 10))))))
      :IN ( GROUP-1 / agar_cultures))

# ::id 222_nonfiction_GENIA-1999;99120322,11;NE
# ::snt Under these conditions , about 0.5 % of 47.10 cells formed large 14 -day colonies -LRB- > 1 mm -RRB- composed of mature monocytes and granulocytes , reflecting the presence of progenitors endowed with high proliferative potential -LRB- HPP-47.10 cells -RRB- .
( CONJ-26 / and
      :op1 ( EVENT-25 / formed
             :MOD ( mod-27 / past)
             :ARG0 ( ENTITY-3 / percent
                    :CARDINAL ( ATTRIB-4 / about_0.5)
                    :OF ( GROUP-5 / 47.10_cells))
             :ARG1 ( GROUP-6 / colonies
                    :ATTRIBUTE ( ATTRIB-7 / large)
                    :TMP ( TIME-8 / -day
                           :CARDINAL ( ATTRIB-9 / 14))
                    :ARG1-of ( EVENT-15 / composed
                           :OF ( ENTITY-11 / and_granulocytes
                                  :ATTRIBUTE ( ATTRIB-12 / mature)
                                  :op1 ( GROUP-14 / monocytes))))
             :UNDER ( GROUP-1 / conditions
                    :DETERMINER ( ATTRIB-2 / these)))
      :op2 ( EVENT-24 / reflecting
             :ARG0 GROUP-6
             :ARG1 ( ENTITY-16 / presence
                    :DEFINITE ( ATTRIB-17 / the)
                    :OF ( GROUP-18 / progenitors
                           :ATTRIBUTE ( ATTRIB-19 / endowed
                                  :WITH ( ENTITY-21 / potential
                                         :ATTRIBUTE ( ATTRIB-23 / proliferative)
                                         :ATTRIBUTE ( ATTRIB-22 / high)
                                         :NAMELY ( ENTITY-20 / HPP-47.10_cells)))))))

# ::id 223_nonfiction_GENIA-1999;99120322,12;NE
# ::snt In conclusion , we have characterized a novel continuous myeloid cell line presenting a hierarchical structure similar to that of the bone marrow progenitor cell compartment .
( EVENT-14 / have_characterized
      :ARG0 ( REF1-2 / we)
      :ARG1 ( ENTITY-3 / cell_line
             :ATTRIBUTE ( ATTRIB-4 / novel_continuous_myeloid)
             :ARG0-of ( EVENT-13 / presenting
                    :ARG1 ( ENTITY-6 / structure
                           :ATTRIBUTE ( ATTRIB-8 / similar
                                  :TO ( ENTITY-9 / ENTITY
                                         :DETERMINER ( ATTRIB-10 / that)
                                         :OF ( ENTITY-11 / bone_marrow_progenitor_cell_compartment
                                                :DEFINITE ( ATTRIB-12 / the))))
                           :ATTRIBUTE ( ATTRIB-7 / hierarchical))))
      :IN ( ENTITY-1 / conclusion))

# ::id 224_nonfiction_GENIA-1999;99120900,1;NE
# ::snt Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia .
( ENTITY-1 / expression
      :ATTRIBUTE ( ATTRIB-2 / imbalanced)
      :OF ( GROUP-3 / glucocorticoid_receptor_isoforms
             :DEFINITE ( ATTRIB-4 / the)
             :IN ( GROUP-5 / lymphocytes
                    :ATTRIBUTE ( ATTRIB-6 / cultured)
                    :FROM ( ENTITY-7 / patient
                           :WITH ( GROUP-8 / AND
                                  :op1 ( ENTITY-9 / glucocorticoid_resistance
                                         :ATTRIBUTE ( ATTRIB-10 / systemic))
                                  :op2 ( ENTITY-11 / leukemia
                                         :ATTRIBUTE ( ATTRIB-13 / lymphocytic)
                                         :ATTRIBUTE ( ATTRIB-12 / chronic)))))))

# ::id 225_nonfiction_GENIA-1999;99120900,2;NE
# ::snt The human glucocorticoid receptor -LRB- GR -RRB- is expressed as two alternatively spliced isoforms , GRalpha and GRbeta .
( EVENT-9 / expressed
      :ARG1 ( ENTITY-2 / glucocorticoid_receptor
             :DEFINITE ( ATTRIB-3 / the)
             :ATTRIBUTE ( ATTRIB-4 / human)
             :NAMELY ( ENTITY-1 / GR))
      :AS ( GROUP-6 / isoforms
             :ATTRIBUTE ( ATTRIB-8 / alternatively_spliced)
             :CARDINAL ( ATTRIB-7 / two)
             :NAMELY ( GROUP-5 / AND
                    :op1 ( ENTITY-GRalpha / ENTITY
                           :name ( n-1 / name
                                  :op1 "GRalpha"))
                    :op2 ( ENTITY-GRbeta / ENTITY
                           :name ( n-2 / name
                                  :op1 "GRbeta")))))

# ::id 226_nonfiction_GENIA-1999;99120900,3;NE
# ::snt Whereas GRalpha is a hormone-activated transcription factor , GRbeta does not bind glucocorticoids -LRB- GCs -RRB- , is transcriptionally inactive , and is a potential inhibitor of activated GRalpha .
( CONJ-14 / and
      :op1 ( EVENT-7 / does_bind
             :domain-of ( NEG-13 / NEG)
             :ARG0 ( ENTITY-GRbeta / ENTITY
                    :name ( n-15 / name
                           :op1 "GRbeta"))
             :ARG1 ( GROUP-6 / glucocorticoids
                    :NAMELY ( ENTITY-5 / GCs))
             :WHEREAS ( SITUATION-1 / FACT
                    :THAT ( EVENT-4 / copula
                           :ARG0 ( ENTITY-GRalpha / ENTITY
                                  :name ( n-16 / name
                                         :op1 "GRalpha"))
                           :ARG1 ( ENTITY-2 / transcription_factor
                                  :ATTRIBUTE ( ATTRIB-3 / hormone-activated)))))
      :op2 ( EVENT-9 / copula
             :ATTRIBUTE ( ATTRIB-8 / transcriptionally_inactive)
             :ARG0 ENTITY-GRbeta
             :WHEREAS SITUATION-1)
      :op3 ( EVENT-12 / copula
             :ARG0 ENTITY-GRbeta
             :ARG1 ( ENTITY-10 / inhibitor
                    :ATTRIBUTE ( ATTRIB-11 / potential)
                    :OF ( ENTITY-activated_GRalpha / ENTITY
                           :name ( n-17 / name
                                  :op1 "activated_GRalpha")))
             :WHEREAS SITUATION-1))

# ::id 227_nonfiction_GENIA-1999;99120900,4;NE
# ::snt Differential expression of GR isoforms may play a role in generalized or tissue-specific GC resistance .
( EVENT-10 / play
      :domain-of ( MD-11 / may)
      :ARG0 ( ENTITY-1 / expression
             :ATTRIBUTE ( ATTRIB-2 / differential)
             :OF ( GROUP-3 / GR_isoforms))
      :ARG1 ( ENTITY-4 / role
             :IN ( GROUP-5 / or
                    :op1 ( ENTITY-6 / GC_resistance
                           :ATTRIBUTE ( ATTRIB-7 / generalized))
                    :op2 ( ENTITY-8 / GC_resistance
                           :ATTRIBUTE ( ATTRIB-9 / tissue-specific)))))

# ::id 228_nonfiction_GENIA-1999;99120900,5;NE
# ::snt GCs induce apoptosis in neoplastic lymphoid cells ;
( EVENT-6 / induce
      :ARG0 ( GROUP-1 / GCs)
      :ARG1 ( ENTITY-2 / apoptosis
             :IN ( GROUP-3 / cells
                    :ATTRIBUTE ( ATTRIB-5 / lymphoid)
                    :ATTRIBUTE ( ATTRIB-4 / neoplastic))))

# ::id 229_nonfiction_GENIA-1999;99120900,5;NE
# ::snt and , defective apoptosis is implicated in the genesis of chronic lymphocytic leukemia -LRB- CLL -RRB- .
( EVENT-8 / implicated
      :ARG1 ( ENTITY-1 / apoptosis
             :ATTRIBUTE ( ATTRIB-2 / defective))
      :IN ( ENTITY-3 / genesis
             :DEFINITE ( ATTRIB-4 / the)
             :OF ( ENTITY-5 / leukemia
                    :ATTRIBUTE ( ATTRIB-7 / lymphocytic)
                    :ATTRIBUTE ( ATTRIB-6 / chronic)
                    :NAMELY ( ENTITY-CLL / ENTITY
                           :name ( n-1 / name
                                  :op1 "CLL")))))

# ::id 230_nonfiction_GENIA-1999;99120900,6;NE
# ::snt We studied a patient with generalized GC resistance and CLL .
( EVENT-6 / studied
      :MOD ( mod-1 / past)
      :ARG0 ( REF1-1 / we)
      :ARG1 ( ENTITY-2 / patient
             :WITH ( GROUP-3 / AND
                    :op1 ( ENTITY-4 / GC_resistance
                           :ATTRIBUTE ( ATTRIB-5 / generalized))
                    :op2 ( ENTITY-CLL / ENTITY
                           :name ( n-2 / name
                                  :op1 "CLL")))))

# ::id 231_nonfiction_GENIA-1999;99120900,7;NE
# ::snt GR number in the patient 's transformed lymphocytes was approximately one half that of control cells with a approximately 10-fold reduction in binding affinity for dexamethasone .
( EVENT-14 / copula
      :MOD ( mod-1 / past)
      :ARG0 ( ENTITY-1 / GR_number
             :IN ( GROUP-2 / lymphocytes
                    :ATTRIBUTE ( ATTRIB-5 / transformed)
                    :POS ( ENTITY-3 / patient
                           :DEFINITE ( ATTRIB-4 / the))))
      :ARG1 ( ENTITY-6 / ENTITY
             :DETERMINER ( ATTRIB-8 / that)
             :OF ( GROUP-9 / cells
                    :ATTRIBUTE ( ATTRIB-10 / control))
             :CARDINAL ( ATTRIB-7 / approximately_one_half))
      :WITH ( ENTITY-11 / reduction
             :ATTRIBUTE ( ATTRIB-12 / approximately_10-fold)
             :IN ( ENTITY-13 / binding_affinity
                    :FOR ( ENTITY-dexamethasone / ENTITY
                           :name ( n-2 / name
                                  :op1 "dexamethasone")))))

# ::id 232_nonfiction_GENIA-1999;99120900,8;NE
# ::snt In vitro apoptosis induction in CLL cells was delayed in response to GCs , but not to other apoptosis inducers .
( CONJ-9 / but
      :op1 ( EVENT-8 / delayed
             :MOD ( mod-10 / past)
             :ARG1 ( ENTITY-1 / apoptosis_induction
                    :ATTRIBUTE ( ATTRIB-2 / in_vitro)
                    :IN ( GROUP-3 / CLL_cells))
             :IN ( ENTITY-4 / response
                    :TO ( GROUP-5 / GCs)))
      :op2 ( EVENT-8 / delayed
             :ARG1 ENTITY-1
             :TO ( GROUP-6 / apoptosis_inducers
                    :ATTRIBUTE ( ATTRIB-7 / other))))

# ::id 233_nonfiction_GENIA-1999;99120900,9;NE
# ::snt Sequencing of the GR cDNA and gene including the 2.3-kb coding region , the intron/exon junctions , the known 5'-regulatory region , and approximately 300 bp of the 3'-region revealed no alterations .
( EVENT-25 / revealed
      :MOD ( mod-1 / past)
      :ARG0 ( ENTITY-1 / Sequencing
             :OF ( ENTITY-2 / AND
                    :op1 ( ENTITY-4 / GR_cDNA
                           :DEFINITE ( ATTRIB-5 / the))
                    :op2 ( ENTITY-6 / gene)
                    :ARG0-of ( EVENT-22 / including
                           :ARG1 ( GROUP-8 / AND
                                  :op1 ( ENTITY-9 / coding_region
                                         :DEFINITE ( ATTRIB-10 / the)
                                         :ATTRIBUTE ( ATTRIB-11 / 2.3-kb))
                                  :op2 ( GROUP-12 / intron_slash_exon_junctions
                                         :DEFINITE ( ATTRIB-13 / the))
                                  :op3 ( ENTITY-14 / region
                                         :DEFINITE ( ATTRIB-15 / the)
                                         :ATTRIBUTE ( ATTRIB-17 / 5 ' -regulatory)
                                         :ATTRIBUTE ( ATTRIB-16 / known))
                                  :op4 ( ENTITY-18 / bp
                                         :OF ( ENTITY-20 / 3 ' -region
                                                :DEFINITE ( ATTRIB-21 / the))
                                         :CARDINAL ( ATTRIB-19 / approximately_300))))))
      :ARG1 ( GROUP-23 / alterations
             :QUANTIFIER ( ATTRIB-24 / no)))

# ::id 234_nonfiction_GENIA-1999;99120900,10;NE
# ::snt Western blot with an N-terminal antibody showed normal levels of immunoreactive GR ,
( EVENT-8 / showed
      :MOD ( mod-1 / past)
      :ARG0 ( ENTITY-1 / Western_blot
             :WITH ( ENTITY-2 / antibody
                    :ATTRIBUTE ( ATTRIB-3 / n-terminal)))
      :ARG1 ( GROUP-4 / levels
             :ATTRIBUTE ( ATTRIB-5 / normal)
             :OF ( ENTITY-6 / GR
                    :ATTRIBUTE ( ATTRIB-7 / immunoreactive))))

# ::id 235_nonfiction_GENIA-1999;99120900,10;NE
# ::snt but quantitative analysis with isoform-specific C-terminal antibodies revealed a markedly reduced GRalpha expression , and high GRbeta expression .
( EVENT-10 / revealed
      :MOD ( mod-1 / past)
      :ARG0 ( ENTITY-1 / analysis
             :ATTRIBUTE ( ATTRIB-2 / quantitative)
             :WITH ( GROUP-3 / antibodies
                    :ATTRIBUTE ( ATTRIB-5 / c-terminal)
                    :ATTRIBUTE ( ATTRIB-4 / isoform-specific)))
      :ARG1 ( GROUP-6 / AND
             :op1 ( ENTITY-7 / GRalpha_expression
                    :ATTRIBUTE ( ATTRIB-8 / markedly_reduced))
             :op2 ( ENTITY-9 / high_GRbeta_expression)))

# ::id 236_nonfiction_GENIA-1999;99120900,11;NE
# ::snt These findings indicate that imbalanced expression of the GR isoforms may be a mechanism of GC resistance , and may have implications for tumorigenesis by enhancing cell survival .
( EVENT-3 / indicate
      :ARG0 ( GROUP-1 / findings
             :DETERMINER ( ATTRIB-2 / these))
      :THAT ( CONJ-23 / and
             :op1 ( EVENT-10 / copula
                    :domain-of ( MD-20 / may)
                    :ARG0 ( ENTITY-4 / expression
                           :ATTRIBUTE ( ATTRIB-5 / imbalanced)
                           :OF ( GROUP-6 / GR_isoforms
                                  :DEFINITE ( ATTRIB-7 / the)))
                    :ARG1 ( ENTITY-8 / mechanism
                           :OF ( ENTITY-9 / GC_resistance)))
             :op2 ( CRD-21 / by
                    :domain-of ( MD-22 / may)
                    :op1 ( EVENT-14 / enhancing
                           :ARG0 ( GROUP-11 / implications
                                  :FOR ( ENTITY-12 / tumorigenesis))
                           :ARG1 ( ENTITY-13 / cell_survival))
                    :op2 ( EVENT-15 / have
                           :ARG0 ENTITY-4
                           :ARG1 GROUP-11))))

# ::id 237_nonfiction_GENIA-1999;99120900,12;NE
# ::snt Copyright 1999 Academic Press .
( EVENT-1 / EVENT
      :LINK ( ENTITY-Copyright_1999 / ENTITY
             :name ( n-1 / name
                    :op1 "Copyright_1999"))
      :LINK ( ENTITY-Academic_Press / ENTITY
             :name ( n-2 / name
                    :op1 "Academic_Press")))
